KOL | Charles L LoprinziMayo Clinic, Rochester, MN; | Division of Medical Oncology, Mayo Clinic, Rochester, MN 55902, USA;, cloprinzi@mayo.edu | Department of Oncology, Mayo Clinic, Rochester, MN ... |
KOL Resume for Charles L Loprinzi
| Year | |
|---|---|
| 2022 | Mayo Clinic, Rochester, MN; |
| 2021 | Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States. Electronic address: Mayo Clinic, Rochester, MN, USA |
| 2020 | Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, United States of America Division of Medical Oncology, Mayo Clinic, Rochester, USA North Central Cancer Treatment Group, Mayo Clinic, Rochester, Minnesota Mayo Clinic, Rochester, MN, United States. |
| 2019 | Department of Oncology; Mayo Clinic; Rochester, Minnesota Mayo Clinic Rochester, Florida, USA Medical Oncology |
| 2018 | Department of Medical Oncology, Mayo Clinic, 200 First St SW, 55905, Rochester, MN, USA Division of Medical Oncology, Mayo Clinic, Rochester, MN |
| 2017 | Division of Medical Oncology, Mayo Clinic, Rochester, MN. Timothy Gilligan, Cleveland Clinic, Cleveland, OH ; Nessa Coyle, Memorial Sloan Kettering Cancer Center, New York; Ronald M. Epstein, University of Rochester School of Medicine, Rochester, NY; Richard M. Frankel, Regenstrief Institute, Indiana University School of Medicine, Indianapolis, IN; Donna L. Berry and Christopher S. Lathan, Dana-Farber Cancer Institute, Harvard Medical School; Vicki A. Jackson, Massachusetts General Hospital, Harvard Medical School, Boston; Carole Seigel, Patient/Advocacy Representative, Brookline, MA; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Esme Finlay, University of New Mexico School of Medicine, Albuquerque, NM; Charles L. Loprinzi, Mayo Clinic, Rochester, MN; and Lynne H. Nguyen and Walter F. Baile, The University of Texas MD Anderson Cancer Center, Houston, TX. Mayo Clinic Minnesota Department of Oncology Rochester Minnesota The Cancer Center |
| 2016 | Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN Mayo Clinic Cancer Center, Rochester, Minnesota |
| 2015 | Departments of Neurology, Oncology, Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN, USA Mayo Clinic Division of Medical Oncology Rochester Minnesota |
| 2014 | Mayo Clinic Cancer Center Rochester MN |
| 2013 | From the Department of Oncology and Cancer Center Statistics, Mayo Clinic, Rochester, MN. Mayo Clinic Rochester, 200 First Street, SW, 55905, Rochester, MN, USA |
| 2012 | Department of Oncology, Mayo Clinic, 55905, Rochester, MN, USA Mayo Clinic, Rochester, MN, United States |
Charles L Loprinzi: Influence Statistics
Open the FULL List in Excel
| Concept | World rank |
|---|---|
| fluorouracilinduced stomatitis | #1 |
| ru221408i | #1 |
| treating institution intervention | #1 |
| hot flashes treatment | #1 |
| treatments modalities | #1 |
| hfs ulabtka | #1 |
| dfs 5fu | #1 |
| 1 month appetite | #1 |
| sae δ − | #1 |
| dmc assay | #1 |
| cyclohexanols female | #1 |
| drug humans interferons | #1 |
| prevent oxaliplatin | #1 |
| flashes pilot | #1 |
| bridging editorial | #1 |
| topic peripheral neuropathy | #1 |
| nonhormonal agent | #1 |
| impaired postural control | #1 |
| positive indication prognosis | #1 |
| hot flashes quality | #1 |
| evidence cipn | #1 |
| vitamin cipn | #1 |
| patients paclitaxel polyneuropathy | #1 |
| diphenhydraminelidocaineantacid | #1 |
| patient followup studies | #1 |
| cryotherapy mucositis | #1 |
| therapeutic targets cipn | #1 |
| oral cryotherapy | #1 |
| duloxetine response patients | #1 |
| metastatic disease initiation | #1 |
| relatedness treatment | #1 |
| purposehot | #1 |
| uncertain gbu gbu | #1 |
| 2 study arms | #1 |
| neuropathy randomized | #1 |
| ncctg n08c1 | #1 |
| oral cryotherapy patients | #1 |
| alopecia ocular toxicity | #1 |
| cancer hot | #1 |
| leap 12 months | #1 |
| anecdotal observations gabapentin | #1 |
| fsfi udi | #1 |
| cancerrelated fatigue interventions | #1 |
| suggestion oral cryotherapy | #1 |
| motor subscales | #1 |
| underdescribers | #1 |
| management genital symptoms | #1 |
| symptom intervention | #1 |
| deprivation symptoms | #1 |
| magnesium camg | #1 |
| differences neuropathy syndromes | #1 |
| 81 patients patients | #1 |
| women 65 day | #1 |
| data hot | #1 |
| pregabalin paps | #1 |
| underdescribers weeks | #1 |
| trust oncologists competence | #1 |
| topical cannabinoids patients | #1 |
| slight appetite stimulation | #1 |
| safety progestational agents | #1 |
| reducing hot | #1 |
| lidocaine antacid | #1 |
| patients dosing guidelines | #1 |
| painful oxaliplatininduced cipn | #1 |
| n08cb alliance | #1 |
| antiemetic prescribing | #1 |
| alliance n08c1 | #1 |
| 8week observation period | #1 |
| purposehot flashes | #1 |
| patients 10 range | #1 |
| rest psychostimulants | #1 |
| flash score | #1 |
| patients underdescribers | #1 |
| association arhgef10 | #1 |
| preceding 2 months | #1 |
| paps fatigue | #1 |
| arhgef10 cipn | #1 |
| suggestion toxicity | #1 |
| 22 nonestrogenic management | #1 |
| prevention cipn | #1 |
| n08c3 | #1 |
| randomized study lymphedema | #1 |
| cipnsummarythere | #1 |
| initiation tpn | #1 |
| patients dfs predictions | #1 |
| oncologists competence | #1 |
| flaxseed bar | #1 |
| hot flash frequency | #1 |
| darbepoetin alfa head | #1 |
| patients gabapentin | #1 |
| attribution clinical trials | #1 |
| anecdotal observations | #1 |
| weeks hot | #1 |
| accru study | #1 |
| duloxetine response | #1 |
| infliximab cancer | #1 |
| patientreported outcomes balance | #1 |
| survivors genitourinary syndrome | #1 |
| gabapentin hot flashes | #1 |
| hot flashes day | #1 |
| cipn paps | #1 |
| safety oestrogen | #1 |
| pilot trial hands | #1 |
| baseline week gabapentin | #1 |
| megestrol acetate nausea | #1 |
| iii double | #1 |
| neoplasms placebos | #1 |
| cipn development severity | #1 |
| anorexia appetite | #1 |
| leucovorin breast cancer | #1 |
| subsequent chemotherapy cycles | #1 |
| 2007 guidelines guideline | #1 |
| lignans 6 weeks | #1 |
| inadequate control antidepressant | #1 |
| lymphedemafree rates | #1 |
| flashes venlafaxine | #1 |
| acetate anorexia | #1 |
| flaxseed bar lignans | #1 |
| cyproheptadine appetite | #1 |
| nonfluid | #1 |
| vaginal dehydroepiandrosterone dhea | #1 |
| paresthesia peripheral | #1 |
| hormone deprivation symptoms | #1 |
| difference cipn20 scores | #1 |
| antiemetic prescribing practices | #1 |
| nonestrogenic management | #1 |
| isae data | #1 |
| deprivation therapy patients | #1 |
| newer antidepressants | #1 |
| prominent clinical problem | #1 |
| peripheral neuropathy | #1 |
| patients 25 micrograms | #1 |
| therapy numbness | #1 |
| agents antihypertensive agents | #1 |
| uncertain gbu | #1 |
| gsm fsfi | #1 |
| minocycline cipn | #1 |
| numeracy adjuvant | #1 |
| hot flash score | #1 |
| ncctg trial n06ca | #1 |
| placebos pregabalin quality | #1 |
| improvements hot flashes | #1 |
| n01c9 | #1 |
| digital melt curve | #1 |
| alliance study a221102 | #1 |
| vaginal dehydroepiandrosterone | #1 |
| cachexia megestrol | #1 |
| weight megestrol acetate | #1 |
| rs9657362 | #1 |
| 30 points 95 | #1 |
| nonfluid weight gain | #1 |
| underdescribing | #1 |
| agents humans clinicians | #1 |
| prestudy hypothesis | #1 |
| altered sensory organization | #1 |
| paclitaxel coasting phenomenon | #1 |
| supportive cryotherapy | #1 |
| bakplo symptoms | #1 |
| overview crci | #1 |
| toxicity anecdotal observations | #1 |
| doubleblinded manner | #1 |
| n08c1 | #1 |
| treatment alteration | #1 |
| centrally active agent | #1 |
| compliance institutional guidelines | #1 |
| stellate ganglion block | #1 |
| bellergal | #1 |
| postural instability chemotherapy | #1 |
| recurrences clinical histories | #1 |
| mouthwash diphenhydramine | #1 |
| cinv day | #1 |
| appetite stimulation patients | #1 |
| cipn methods | #1 |
| compassionate honesty | #1 |
| week tamoxifen | #1 |
| women megestrol acetate | #1 |
| vaginal cytology women | #1 |
| tools oncologists | #1 |
| auc cryotherapy | #1 |
| feet oxaliplatin | #1 |
| aimss life | #1 |
| supportive cytotoxic chemotherapy | #1 |
| cipn function | #1 |
| neuropathy 20 | #1 |
| placebo 30 points | #1 |
| prevention paps | #1 |
| chemotherapy response rates | #1 |
| megestrol acetate weeks | #1 |
| increased difficulty patients | #1 |
| flashes patients | #1 |
| leap lymphedema | #1 |
| eortc cipn20 | #1 |
| flashes breast | #1 |
| purposepaclitaxel | #1 |
| authors 30 minutes | #1 |
| adt cyclohexanecarboxylic acids | #1 |
| tpn initiation death | #1 |
| neuronal uptake transporters | #1 |
| adjuvant numeracy | #1 |
| lenolidamide | #1 |
| aminobutyric acid adt | #1 |
| cancer anorexia cachexia | #1 |
| points doxepin | #1 |
| rom leap | #1 |
| ulabtka arm | #1 |
| prevention oral cryotherapy | #1 |
| natural postural instability | #1 |
| lymphedema hrqol outcomes | #1 |
| rose geranium | #1 |
| pilot study minocycline | #1 |
| induced neurotoxicity oct2 | #1 |
| flaxseed hot flashes | #1 |
| nonhormonal agents | #1 |
| toxicities opioids | #1 |
| flashes stellate | #1 |
| median δ qs | #1 |
| flashes objective | #1 |
| qlq cipn20 | #1 |
| flashes women | #1 |
| cinv neoplasms vomiting | #1 |
| fractures infertility | #1 |
| life qlqcipn20 | #1 |
| attribution treatment | #1 |
| relatedness treatment arms | #1 |
| oxybutynin doses | #1 |
| intervention leap | #1 |
| flashes week | #1 |
| hormone deprivation cancer | #1 |
| oral cryotherapy management | #1 |
| bortezomib alters | #1 |
| premenopause radiotherapy | #1 |
| a151408 | #1 |
| taxane treatment development | #1 |
| antacid mouthwash | #1 |
| rs17683288 | #1 |
| paclitaxel weekly cryotherapy | #1 |
| oral cryotherapy prevention | #1 |
| middle aged minocycline | #1 |
| cytotoxic chemotherapy supportive | #1 |
| neuropathy prevention | #1 |
| aps paclitaxel | #1 |
| time publication attitude | #1 |
| management hot flashes | #1 |
| anthracycline data | #1 |
| neuropathy data | #1 |
| tingling | #1 |
| purpose hot | #1 |
| resected cutaneous melanomas | #1 |
| qol reported difficulty | #1 |
| phase iii evaluation | #1 |
| hormone deprivation | #1 |
| antidepressant gabapentin | #1 |
| acute pain syndrome | #1 |
| patients nasal vestibulitis | #1 |
| pilot evaluation | #1 |
| postsurgical neuropathic pain | #1 |
| or1 year patients | #1 |
| joints syndrome | #1 |
| baseline prognosis | #1 |
| antibiotic lozenge placebo | #1 |
| megestrol acetate patients | #1 |
| qolconclusionsthe | #1 |
| estimated benefit dfs | #1 |
| cipn common | #1 |
| shooting burning | #1 |
| placebo oral mucositis | #1 |
| phytotherapy vitamin | #1 |
| gabapentin hot | #1 |
| cachexia trial | #1 |
| prognosis items | #1 |
| management hot | #1 |
| paclitaxel favor | #1 |
| doxepin mouthwash placebo | #1 |
| cipn phase iii | #1 |
| flashes treatment | #1 |
| placebo 15 points | #1 |
| pregabalin paclitaxel | #1 |
| sensory neuropathy symptoms | #1 |
| isaes | #1 |
| preliminary evidence improvement | #1 |
| alliance trial | #1 |
| paclitaxel study arms | #1 |
| chamomile mouthwash toxicity | #1 |
| ambulatory patients opioids | #1 |
| ulabtka hfs | #1 |
| tested interventions lymphedema | #1 |
| oncologists prognostic | #1 |
| fluoxetine hot | #1 |
| toxicity prospective trial | #1 |
| fsfi 95 | #1 |
| cancers prevalence | #1 |
| placebo pilot trials | #1 |
| pregenplus | #1 |
| difficulty neuropathic pain | #1 |
| life megestrol acetate | #1 |
| grade peripheral neuropathy | #1 |
| nociceptors putative mechanism | #1 |
| n06ca | #1 |
| stomatitis scores | #1 |
| hot flash relief | #1 |
| magnesium oxaliplatininduced neurotoxicity | #1 |
| balance patientreported outcomes | #1 |
| antidepressants gabapentin | #1 |
| hec cisplatin therapy | #1 |
| chemotherapy regimen type | #1 |
| adam vte trial | #1 |
| 5fuinduced stomatitis | #1 |
| symptoms hands | #1 |
| judicious tpn | #1 |
| cachexia dexamethasone | #1 |
| patients physical examinations | #1 |
| control hot flashes | #1 |
| gabapentin arm | #1 |
| benefit fluoxetine | #1 |
| prtmethodsdata | #1 |
| discrepancies women | #1 |
| placebo anecdotal observations | #1 |
| cryotherapy hands | #1 |
| acetate doses | #1 |
| baseline neuropathic pain | #1 |
| lymphedema prevention education | #1 |
| udi scores baseline | #1 |
| numbness tingling | #1 |
| suggested gabapentin | #1 |
| cryotherapy auc | #1 |
| highdose melphalan intervention | #1 |
| flashes prospective | #1 |
| newer antidepressants gabapentin | #1 |
| dfs predictions adjuvant | #1 |
| overview oncology providers | #1 |
| neoplasm recurrence apixaban | #1 |
| patients subcutaneous testosterone | #1 |
| decrease hot | #1 |
| 95 neuropathic pain | #1 |
| drowsiness unpleasant taste | #1 |
| baseline prognosis values | #1 |
| placebo arm gabapentin | #1 |
| myalgias arthralgias | #1 |
| flash scores | #1 |
| individual patients understanding | #1 |
| flash therapies | #1 |
| cyclohexanecarboxylic acids gamma | #1 |
| vte recurrence enoxaparin | #1 |
| ulabtka | #1 |
| oral mucositisrelated pain | #1 |
| hot flashes | #1 |
| oestrogen hot flashes | #1 |
| cipn20 data | #1 |
| device 5 weeks | #1 |
| qolresultsfrom | #1 |
| hfs trial | #1 |
| residual hot flashes | #1 |
| placebo arms percentage | #1 |
| historical placebo response | #1 |
| glutamine toxicity | #1 |
| trial n00cb | #1 |
| oncologists competence 95ci | #1 |
| induced cipn | #1 |
| polyneuropathy allelic variability | #1 |
| aes relatedness | #1 |
| nonhormonal therapies paroxetine | #1 |
| alleviate hot | #1 |
| ocular ice packs | #1 |
| cipn clinical trial | #1 |
| topic rectum surveys | #1 |
| neoplasms climacteric | #1 |
| coasting phenomenon | #1 |
| baseline fsfi score | #1 |
| fosaprepitant isae | #1 |
| life study arms | #1 |
| bothersome hot | #1 |
| chemotherapy neuropathy | #1 |
| symptoms cipn | #1 |
| life leap | #1 |
| recommended colorectal | #1 |
| hot flash | #1 |
| ganglion surveys humans | #1 |
| gabapentin aminobutyric acid | #1 |
| methylphenidate cancer patients | #1 |
| pharmacologic therapeutics | #1 |
| rs9657362 previous study | #1 |
| extensive animal data | #1 |
| flashes common | #1 |
| breakthrough nausea patients | #1 |
| active nonhormonal | #1 |
| udi δ − | #1 |
| hot flash control | #1 |
| acetate hot | #1 |
| diseases pilot | #1 |
| nonfluid bodyweights | #1 |
| olanzapine projects vomiting | #1 |
| arthralgia breast life | #1 |
| cipn20 | #1 |
| pharmacological targeting oct2 | #1 |
| cipn data | #1 |
| data clinical histories | #1 |
| gait testing patients | #1 |
| accru trial | #1 |
| symptoms hormone deprivation | #1 |
| developed mucositis | #1 |
| alliance n08ca | #1 |
| 1year survival trials | #1 |
| accru study ru221408i | #1 |
| 95 increased difficulty | #1 |
| male megestrol life | #1 |
| isae anthracycline | #1 |
| cachexia studies | #1 |
| n08ca association | #1 |
| patients hot flashes | #1 |
| anorexia antineoplastic agents | #1 |
| lymphedema incidence intervention | #1 |
| daily questionnaires | #1 |
| ctcae grade | #1 |
| education lymphedema prevention | #1 |
| physical consequences cipn | #1 |
| 20 data patients | #1 |
| recommendation prevention | #1 |
| symptoms feet | #1 |
| oral mucosa study | #1 |
| items uncertain gbu | #1 |
| fourth treatment week | #1 |
| antineoplastic agents nrs | #1 |
| bothersome hot flashes | #1 |
| dronabinol megestrol acetate | #1 |
| routine feces sensitivity | #1 |
| education lymphedema education | #1 |
| women male megestrol | #1 |
| tingling numbness | #1 |
| 5fu adjuvant | #1 |
| infliximab lung | #1 |
| treatment hot flashes | #1 |
| crc patients 95 | #1 |
| cachexia carcinoma life | #1 |
| taxane infusion | #1 |
| nonhormonal agents treatment | #1 |
| peripheral neuropathy paclitaxel | #1 |
| lymphedemafree rates groups | #1 |
| efficacy gabapentin | #1 |
| 5fuinduced ocular toxicity | #1 |
| balance impairments patients | #1 |
| toxicity gabapentin | #1 |
| nonhormonal hot | #1 |
| patients cancer anorexia | #1 |
| female services tpn | #1 |
| illness neuropathic symptoms | #1 |
| bakplo placebo | #1 |
| longitudinal continuation | #1 |
| antiserotonergic drug | #1 |
| efficacy agent | #1 |
| cisplatin therapy cinv | #1 |
| patients spray product | #1 |
| hot flash mechanism | #1 |
| doxepin mouthwash | #1 |
| stomatitis administration | #1 |
| mouthwash placebo | #1 |
| burning pain | #1 |
| cipn postural control | #1 |
| snv rs9657362 | #1 |
| flashes gabapentin | #1 |
| treatment attribution | #1 |
| regional hypothermia burden | #1 |
| cachexia cyproheptadine | #1 |
| acetate dexamethasone | #1 |
| treatment symptom intervention | #1 |
| compliance institutional guideline | #1 |
| incurable cancer records | #1 |
| ulabtka placebo cream | #1 |
| cipnmethodspatients | #1 |
| doxepin mouthwash patients | #1 |
| hot flashes weeks | #1 |
| survival tpn initiation | #1 |
| leap rom | #1 |
| therapy hot | #1 |
| flashes quality | #1 |
| leucovorin breast | #1 |
| rs2294039 | #1 |
| amines antidepressive | #1 |
| topical cannabinoids | #1 |
| patients ulabtka | #1 |
| eortc cipn | #1 |
| hot flashes patients | #1 |
| hot flash activity | #1 |
| supportive nsclc | #1 |
| mascc isoo guidelines | #1 |
| individuals cipn | #1 |
| progestational agents patients | #1 |
| uniscale qol baseline | #1 |
| n00cb | #1 |
| women inadequate control | #1 |
| pilot trials venlafaxine | #1 |
| gene arhgef10 | #1 |
| flashes prostate | #1 |
| treating hot | #1 |
| reduction hot | #1 |
| managing hot | #1 |
| cipn agents | #1 |
| mascc isoo evidence | #1 |
| tpn death | #1 |
| hot flashes acceptability | #1 |
| balance gait testing | #1 |
| attribution percentage | #1 |
| δ − 95 | #1 |
| alleviating hot | #1 |
| male megestrol megestrol | #1 |
| conducted studies hrt | #1 |
| aes placebo arm | #1 |
| agents cyclohexanecarboxylic | #1 |
| managing hot flashes | #1 |
| dronabinol combination | #1 |
| antibiotic lozenge | #1 |
| papsmethodspatients | #1 |
| acetate versus | #1 |
| aminobutyric acid hec | #1 |
| subcutaneous testosterone improvements | #1 |
| outcomes study points | #1 |
| 5 methylphenidate | #1 |
| single snv rs9657362 | #1 |
| cachexia cancer anorexia | #1 |
| topical keratolytic | #1 |
| points diphenhydramine | #1 |
| enoxaparin cvte | #1 |
| antidepressive agents gamma | #1 |
| sensory subscale | #1 |
| agents cipn | #1 |
| hot flash scores | #1 |
| acetate appetite | #1 |
| nonhormonal | #1 |
| replacement testosterone andropause | #1 |
| effects limited efficacy | #1 |
| placebo 15 glutathione | #1 |
| megestrol acetate | #1 |
| benefit 5fu | #1 |
| ganglion surveys | #1 |
| numbness scores | #1 |
| burden alopecia | #1 |
| ocular ice | #1 |
| institutional guidelines patients | #1 |
| preliminary promising data | #1 |
| ssc device prototype | #1 |
| studies cyproheptadine | #1 |
| numbness hands | #1 |
| established cipn | #1 |
| numeracy benefit | #1 |
| isae | #1 |
| testosterone improvements | #1 |
| cipn20 questionnaire | #1 |
| numerical analogue scale | #1 |
| sham acupuncture participants | #1 |
| cipn topical gel | #1 |
| humans ganglion surveys | #1 |
| paclitaxel acute | #1 |
| ncctg n08c3 | #1 |
| head therapeutic equivalency | #1 |
| chamomile mouthwash | #1 |
| flashes androgen | #1 |
| dmc samples | #1 |
| compounded topical gel | #1 |
| tpn longterm survival | #1 |
| cipn20 sensory | #1 |
| gas menopause patient | #1 |
| oxybutynin hot flashes | #1 |
| life cipn | #1 |
| oral mucositis alopecia | #1 |
| glutathione cipn | #1 |
| gabapentin antidepressant | #1 |
| bupropion nicotine dependence | #1 |
| patientcompleted questionnaires | #1 |
| based chemotherapy isae | #1 |
| cancerassociated anorexia cachexia | #1 |
| 43 oral complications | #1 |
| oestrogen survivors | #1 |
| 12 months anticoagulation | #1 |
| 5 weeks device | #1 |
| patients placebo pellet | #1 |
| eortc qlqcipn20 instrument | #1 |
| disease patient factors | #1 |
| loe prevention | #1 |
| treatment hot | #1 |
| placebo mouthwash | #1 |
| items positive indication | #1 |
| authors 115 patients | #1 |
| creatine placebo groups | #1 |
| suggestion pregabalin | #1 |
| − fsfi | #1 |
| nonfluid weight | #1 |
| effects hot flashes | #1 |
| combination chemotherapy hec | #1 |
| isae patients | #1 |
| skin dermatitis trials | #1 |
| adjuvant numeracy calculators | #1 |
| a151408 study data | #1 |
| acceptability ssc device | #1 |
| populations neurologic humans | #1 |
| oil nasal | #1 |
| toxicity ocular | #1 |
| neuropathic pain difficulty | #1 |
| tpn female services | #1 |
| n08cb | #1 |
| extreme phenotyping | #1 |
| adam vte | #1 |
| hot flash data | #1 |
| score baseline values | #1 |
| nsclc response rate | #1 |
| nasal vestibulitis | #1 |
| discrepancies clinicians assessment | #1 |
| paclitaxel polyneuropathy | #1 |
| pain chemotherapy | #1 |
| complete response authors | #1 |
| modalities cancer patients | #1 |
| records adult patients | #1 |
| gabapentin baseline week | #1 |
| baseline week followup | #1 |
| patientreported nasal symptoms | #1 |
| understanding potential benefits | #1 |
| 137 patients cycle | #1 |
| hot flashes gabapentin | #1 |
| dmc mutations | #1 |
| day cisplatin therapy | #1 |
| patients highdose interferon | #1 |
| n08ca patients | #1 |
| cipn adult | #1 |
| background hot | #1 |
| small cell continuity | #1 |
| neuropathic symptoms breast | #1 |
| week hot | #1 |
| pilot trials citalopram | #1 |
| olanzapine arm emesis | #1 |
| cvte rivaroxaban | #1 |
| venous toxicity fosaprepitant | #1 |
| study stool samples | #1 |
| tools hypothetical scenarios | #1 |
| bakplo | #1 |
| hot flashes women | #1 |
| n08ca | #1 |
| hfs symptoms patients | #1 |
| drowsiness doxepin mouthwash | #1 |
| prevention induced cipn | #1 |
| inadequate hot | #1 |
| acute symptoms cycle | #1 |
| effects cipn | #1 |
| severe stomatitis | #1 |
| cipn nervous diseases | #1 |
| baseline assessment week | #1 |
| alliance a151724 | #1 |
| daily hot | #1 |
| guidelineendorsed treatment | #1 |
| backgrounddehydroepiandrosterone | #1 |
| treatment cipn | #1 |
| 65 day | #1 |
| cipn trials | #1 |
| pilot trials efficacy | #1 |
| weight loss investigation | #1 |
| oncology providers crci | #1 |
| prominent toxicity | #1 |
| hormonal ablation andropause | #1 |
| 95 doxepin mouthwash | #1 |
| weeks hot flashes | #1 |
| patients megestrol acetate | #1 |
| receiving fluorouracil | #1 |
| current trial | #1 |
| toxicity agent | #1 |
| revisitation doc | #1 |
| 2007 guidelines suggestion | #1 |
| chemotherapy treatment chemotherapy | #1 |
| individuals impaired balance | #1 |
| placebo drowsiness | #1 |
| hours nighttime sleep | #1 |
| favor placebo | #1 |
| study dmc assay | #1 |
| response relationship odc | #1 |
| patients olanzapine arm | #2 |
| tamoxifen metabolism evidence | #2 |
| hot flashes pregabalin | #2 |
| 979254 | #2 |
| neuropathy paclitaxel | #2 |
| inadequate benefit | #2 |
| ecog nutrition score | #2 |
| vitamin hot flashes | #2 |
| randomized study mometasone | #2 |
| cipn cases | #2 |
| conclusions original report | #2 |
| colonoscopically normal patients | #2 |
| scrambler therapy management | #2 |
| sunscreen arms | #2 |
| pa outcomes pros | #2 |
| day average pain | #2 |
| patients black cohosh | #2 |
| 120000 epoetin alfa | #2 |
| study n08cb alliance | #2 |
| methylphenidate cancer | #2 |
| provider assessed | #2 |
| lamotrigine neuropathic symptoms | #2 |
| trial suggestion | #2 |
| anthrapyrazoles piroxantrone | #2 |
| cipn primary outcomes | #2 |
| treatment baseline week | #2 |
| stage disease 5fu | #2 |
| control arms rate | #2 |
| n01c4 | #2 |
| time randomized study | #2 |
| cipn antineoplastic agents | #2 |
| aprepitan | #2 |
| trials suggested | #2 |
| anthraquinones agents breast | #2 |
| pilot citalopram | #2 |
| randomized receive | #2 |
| hot flash trials | #2 |
| neoplasms double | #2 |
| venlafaxine control | #2 |
| dronabinol combination therapy | #2 |
| historic controls npy | #2 |
| singleagent megestrol acetate | #2 |
| dhea 4 weeks | #2 |
| sensitivity screenrelevant neoplasms | #2 |
| 95 indirect estimates | #2 |
| cachexia decision | #2 |
| life treatment weeks | #2 |
| hot flash management | #2 |
| original report mometasone | #2 |
| magnesium oxaliplatin | #2 |
| sdt2 sdt1 | #2 |
| guaninemethyltransferase | #2 |
| differences mometasone | #2 |
| placebo situ carcinoma | #2 |
| feet 18 months | #2 |
| oxybutynin women | #2 |
| appetite improvement | #2 |
| fsfi score baseline | #2 |
| ncctg trial | #2 |
| infliximab docetaxel | #2 |
| reduce hot | #2 |
| placebo bar | #2 |
| study arms | #2 |
| patients shark cartilage | #2 |
| study arms quality | #2 |
| dronabinol versus | #2 |
| placebo combination therapy | #2 |
| daily mmf radiotherapy | #2 |
| life 4week intervention | #2 |
| life cipn20 | #2 |
| cipn cancer survivors | #2 |
| sdt2 hemoccult | #2 |
| doses megestrol | #2 |
| 432 smokers treatment | #2 |
| citalopram cyclohexanols humans | #2 |
| nutrition scores physicians | #2 |
| vitamin hot | #2 |
| cipn20 factor analysis | #2 |
| toxicity profiles time | #2 |
| gabapentin symptoms | #2 |
| hot flash studies | #2 |
| docetaxel serum concentrations | #2 |
| study treatment citalopram | #2 |
| 16 hemoccult | #2 |
| cdf score | #2 |
| dermatitis symptom evolution | #2 |
| illness tetracycline egfr | #2 |
| weight concerns 26 | #2 |
| levetiracetam 4 weeks | #2 |
| cohosh treatment | #2 |
| nonestrogenic hot | #2 |
| placebo breast radiotherapy | #2 |
| mometasone time | #2 |
| receiving megestrol | #2 |
| breast cancer venlafaxine | #2 |
| intermediate term efficacy | #2 |
| starting tamoxifen | #2 |
| trial acetate doses | #2 |
| postchemotherapy rheumatism | #2 |
| piroxantrone women | #2 |
| qol hb increment | #2 |
| real patients treatment | #2 |
| anorexia antineoplastic | #2 |
| oxaliplatin induced neurotoxicity | #2 |
| pain ≥4 10 | #2 |
| patients 40k arm | #2 |
| n03cb | #2 |
| evaluating venlafaxine | #2 |
| central cancer | #2 |
| adjuvant 5fu models | #2 |
| appetite dissent disputes | #2 |
| 95 oral placebo | #2 |
| irox folfox auc | #2 |
| “use vitamin | #2 |
| locoregional event | #2 |
| aprepitant 4 weeks | #2 |
| flashes citalopram | #2 |
| vte recurrence dalteparin | #2 |
| thiophenes treatment life | #2 |
| longitudinal studies postmenopause | #2 |
| oxaliplatin doses trends | #2 |
| prevent radiation | #2 |
| duloxetine hydrochloride humans | #2 |
| cycle chronic neurotoxicity | #2 |
| pilocarpine vaginal | #2 |
| treatment target doses | #2 |
| suggested agents | #2 |
| pilocarpine vaginal dryness | #2 |
| flashes placebo | #2 |
| women rom | #2 |
| placebo arms women | #2 |
| symptoms surveys | #2 |
| guidelines recommendation | #2 |
| patients treating institution | #2 |
| flash studies | #2 |
| epoetin alfa 40000 | #2 |
| 01 mmf | #2 |
| cipn clinical | #2 |
| hot flashes data | #2 |
| ctcae pruritus | #2 |
| anorexia severity | #2 |
| ferric gluconate darbepoetin | #2 |
| cipn cancer treatment | #2 |
| study arms conclusions | #2 |
| cycle folfox | #2 |
| bupropion nicotine inhaler | #2 |
| hot flashes dehydroepiandrosterone | #2 |
| numeracy prognosis | #2 |
| lvef 1000 | #2 |
| treating chemotherapy | #2 |
| placebo vaginal dryness | #2 |
| day baseline week | #2 |
| nutrition scores 95 | #2 |
| placebo oxybutynin doses | #2 |
| 14 hot flashes | #2 |
| conceppt | #2 |
| antidepressants hot | #2 |
| dosing zoledronic | #2 |
| clinically deficient fatigue | #2 |
| folfox symptoms | #2 |
| symptomatic cipn | #2 |
| therapy hot flashes | #2 |
| week black cohosh | #2 |
| time ncctg alliance | #2 |
| 40000 40k arm | #2 |
| 16 sdt2 | #2 |
| life aimss | #2 |
| iii randomized | #2 |
| hemoccultsensa detection | #2 |
| stat erythema | #2 |
| scrambler | #2 |
| antidepressant hot flashes | #2 |
| pruritus pros | #2 |
| established chemotherapy | #2 |
| chemotherapy peripheral neuropathy | #2 |
| palliative communications | #2 |
| skindex16 ctcae | #2 |
| tens global impression | #2 |
| positive doseresponse | #2 |
| coriat | #2 |
| hot flashes citalopram | #2 |
| treatment smoking abstinence | #2 |
| treatment breakthrough cinv | #2 |
| failure prior chemotherapy | #2 |
| breakthrough cinv | #2 |
| oxybutynin doses placebo | #2 |
| sensitivity cold items | #2 |
| egfr inhibitor tetracycline | #2 |
| npy levels groups | #2 |
| folfox auc p0·0001 | #2 |
| scrambler therapy | #2 |
| life illness tetracycline | #2 |
| pregabalin arms | #2 |
| pilocarpine arms | #2 |
| induced peripheral | #2 |
| baseline week day | #2 |
| hemoccultsensa sensitivity | #2 |
| megestrol acetate dexamethasone | #2 |
| infliximab 5 day | #2 |
| dhea vaginal symptoms | #2 |
| woman quality | #2 |
| 80 anorexia | #2 |
| participants 3 stools | #2 |
| smokers nicotine inhaler | #2 |
| 3 months bupropion | #2 |
| tetracycline rash incidence | #2 |
| disagreement patients | #2 |
| management genitourinary symptoms | #2 |
| neuropathy caused | #2 |
| cipn paclitaxel | #2 |
| tamoxifen medications | #2 |
| patients adjuvant 5fu | #2 |
| acttionconsortium | #2 |
| screenrelevant neoplasms 16 | #2 |
| shark cartilage product | #2 |
| supplementary n03cb | #2 |
| paclitaxel induced | #2 |
| subsequent mucositis | #2 |
| appearing pilot data | #2 |
| average stomatitis sex | #2 |
| injections hot flashes | #2 |
| postural instability individuals | #2 |
| target doses placebo | #2 |
| pregabalin treatments placebo | #2 |
| cachexia acetate | #2 |
| clinical trials n9741 | #2 |
| ≤ moderate correlations | #2 |
| oral iron 46 | #2 |
| women hot flashes | #2 |
| hot flashes aprepitant | #2 |
| descriptive manner | #2 |
| eortc qlqcipn20 | #2 |
| hemoccultsensa hemoccult | #2 |
| tingling shooting | #2 |
| hot flash quality | #2 |
| kps nutrition scores | #2 |
| cipn interventions | #2 |
| starting tamoxifen women | #2 |
| global impression life | #2 |
| moderate correlations ≤ | #2 |
| qol crc | #2 |
| treatment aprepitant | #2 |
| time toxt approach | #2 |
| gabapentin venlafaxine hydrochloride | #2 |
| 5fuinduced mucositis | #2 |
| peripheral neuropathy cipn | #2 |
| neuropathy cipn | #2 |
| 150 groups patients | #2 |
| questionnaires antineoplastic agents | #2 |
| stat itching | #2 |
| fluoxymesterone treatment | #2 |
| 108±11 | #2 |
| efficacy scrambler therapy | #2 |
| weekly epoetin | #2 |
| treatment arm mmf | #2 |
| venlafaxine oxaliplatin neurotoxicity | #2 |
| mucositis 5fubased chemotherapy | #2 |
| hot flashes humans | #2 |
| detection dna markers | #2 |
| cipn cohort | #2 |
| desipramine hot flashes | #2 |
| infertility ovarian failure | #2 |
| gabapentin 4 weeks | #2 |
| skindex16 itching | #2 |
| evaluating gabapentin | #2 |
| improvement hot flashes | #2 |
| patient‐physician disagreement | #2 |
| trial baseline week | #2 |
| topic estrogen | #2 |
| dronabinoltreated patients | #2 |
| glutamine placebo preparation | #2 |
| arms conclusions | #2 |
| cipn peripheral neuropathy | #2 |
| natural paps | #2 |
| prevent paclitaxel | #2 |
| appetite dissent | #2 |
| lessons cipn | #2 |
| middle aged survivors | #2 |
| 40k arm | #2 |
| venlafaxine treatment 75 | #2 |
| versus megestrol | #2 |
| tingling patients | #2 |
| folfox auc analysis | #2 |
| 120k arm patients | #2 |
| week breast cancer | #2 |
| detection screenrelevant neoplasms | #2 |
| cipn20 scores | #2 |
| patients receiving fluorouracil | #2 |
| humans postmenopause pregabalin | #2 |
| manuscript “use | #2 |
| coumarin placebo | #2 |
| anabolic corticosteroid appetite | #2 |
| ncctg n10c1 | #2 |
| sdt1 hemoccult | #2 |
| surveys repeated measures | #2 |
| data gabapentin | #2 |
| cisplatin polymerase inhibitors | #2 |
| treatment cycles cycle | #2 |
| alternative treatment regimen | #2 |
| 7 control arms | #2 |
| autonomic scales | #2 |
| topical aged antimetabolites | #2 |
| 120k arm | #2 |
| hot flashes efficacy | #2 |
| decreasing stomatitis | #2 |
| months randomized | #2 |
| lmwh arms 7 | #2 |
| patients cipn | #2 |
| ctcae differences | #2 |
| symptoms skin toxicity | #2 |
| tamoxifenassociated hot flashes | #2 |
| receive parenteral | #2 |
| outcome measures ctcae | #2 |
| n0993 | #2 |
| circulating concentrations npy | #2 |
| anemia caa | #2 |
| kps nutrition score | #2 |
| local antineoplastic agents | #2 |
| npy anorexia cholecystokinin | #2 |
| type chemotherapy drug | #2 |
| survival 3915 patients | #2 |
| hot flash diary | #2 |
| single snv | #2 |
| stomatitis women | #2 |
| patients monthly intervals | #2 |
| treatment week placebo | #2 |
| 5fubased chemotherapy mucositis | #2 |
| 34—vitamin | #2 |
| cachexia pentoxifylline | #2 |
| evaluate weight | #2 |
| patients chemotherapyassociated anemia | #2 |
| day study week | #2 |
| study arms tetracycline | #2 |
| patients difluoromethylornithine | #2 |
| glutathione prevention | #2 |
| prevalence weight concerns | #2 |
| standard arm rate | #2 |
| improvement hot | #2 |
| ductal mometasone furoate | #2 |
| subject global impression | #2 |
| 49 venlafaxine | #2 |
| shark cartilage patients | #2 |
| 40k arm 120000 | #2 |
| oral megestrol | #2 |
| stomatitis sex | #2 |
| 46 screenrelevant neoplasms | #2 |
| leucovorin women | #2 |
| older age bupropion | #2 |
| chemotherapyassociated anemia caa | #2 |
| treatment alterations | #2 |
| usual breathing | #2 |
| nutrition score disagreement | #2 |
| indirect comparison apixaban | #2 |
| rcts preventive therapies | #2 |
| real real patients | #2 |
| 1 oral megestrol | #2 |
| reducing chemotherapy | #2 |
| nonhormonal management | #2 |
| disagreement increased risk | #2 |
| predictors disagreement | #2 |
| product hot flashes | #2 |
| anabolic corticosteroid treatment | #2 |
| phytogenic female humans | #2 |
| tamoxifen percentage reduction | #2 |
| cck8 anorexia severity | #2 |
| time toxt analysis | #2 |
| cipn | #2 |
| women stomatitis | #2 |
| worse survivorship | #2 |
| dalteparin lowest risk | #2 |
| sulfate prevent | #2 |
| citalopram hot flashes | #2 |
| substantial hot flashes | #2 |
| 4 treatment weeks | #2 |
| intervention 18 months | #2 |
| oxaliplatin hands | #2 |
| paclitaxel chronic neuropathy | #2 |
| dexamethasone fluoxymesterone | #2 |
| anabolic corticosteroid | #2 |
| hemoccultsensa sdt2 | #2 |
| advancedstage cancer | #2 |
| cipn prevention trials | #2 |
| week baseline week | #2 |
| scrambler therapy tens | #2 |
| trials newer antidepressants | #2 |
| females cessation treatment | #2 |
| experience hot flashes | #2 |
| previous hot flashes | #2 |
| life cancerrelated fatigue | #2 |
| physicians kps | #2 |
| mometasone cream | #2 |
| patients oxybutynin doses | #2 |
| 135±19 | #2 |
| hf frequency placebo | #2 |
| lmwh arms | #2 |
| hemoccultsensa sdt1 | #2 |
| newer antidepressants trials | #2 |
| weekly hf score | #2 |
| venlafaxine gabapentin | #2 |
| cpmp scrambler therapy | #2 |
| advanced cancer anorexia | #2 |
| nicotine inhaler bupropion | #2 |
| 800 liquid suspension | #2 |
| placebo pregabalin treatments | #2 |
| scrambler therapy treatment | #2 |
| humans citalopram cyclohexanols | #2 |
| nonestrogenic therapies | #2 |
| patients 120k arm | #2 |
| sdt2 | #2 |
| allopurinol mouthwash | #2 |
| induced peripheral neuropathy | #2 |
| conclusions sunscreen | #2 |
| fatigue improvement methylphenidate | #2 |
| cancerassociated anorexia | #2 |
| fosaprepitant patients | #2 |
| life venlafaxine | #2 |
| design considerations recommendations | #2 |
| induced arthralgias | #2 |
| pregabalin hot flashes | #2 |
| acknowledged loss | #2 |
| chronic chemotherapy | #2 |
| hot flashes bupropion | #2 |
| hot flash frequencies | #2 |
| cancerassociated wasting | #2 |
| incidence severity stomatitis | #2 |
| poor qol 95 | #2 |
| postmenopausal women previous | #2 |
| mometasone surveys | #2 |
| 75 49 venlafaxine | #2 |
| original report time | #2 |
| cold items 71 | #2 |
| dna markers participants | #2 |
| life venlafaxine hydrochloride | #2 |
| life scrambler therapy | #2 |
| folfox alliance | #2 |
| tens 2 weeks | #2 |
| data relative benefits | #2 |
| increased risk cipn | #2 |
| preventive therapies cipn | #2 |
| 46 adenomas 1 | #2 |
| flash diary | #2 |
| rash incidence severity | #2 |
| shark cartilage placebo | #2 |
| monthly intervals appetite | #2 |
| vte recurrence doacs | #2 |
| treatment minority smokers | #2 |
| placebo hf frequency | #2 |
| depomedroxyprogesterone | #2 |
| screenrelevant neoplasms | #2 |
| mmf itching | #2 |
| 15 points 95 | #2 |
| 120 arm | #2 |
| n06c4 | #2 |
| appetite cachexia | #2 |
| alliance folfox | #2 |
| declining qol | #2 |
| patients daily mmf | #2 |
| frequency hot | #3 |
| etanercept current trial | #3 |
| weekly arm differences | #3 |
| 40000 units | #3 |
| epa combinationtreated arms | #3 |
| treatment bother | #3 |
| cancer patients drugs | #3 |
| median δ | #3 |
| prevent epidermal | #3 |
| dalteparin vte | #3 |
| combinationtreated arms | #3 |
| study antidepressive agents | #3 |
| cartilage shark | #3 |
| longitudinal adverse | #3 |
| methylphenidate patients | #3 |
| epoetintreated patients | #3 |
| baseline hot | #3 |
| mcbdr | #3 |
| inhibitorinduced rash | #3 |
| patients cancerassociated wasting | #3 |
| rash conclusions | #3 |
| rash symptoms | #3 |
| 3 weeks 80k | #3 |
| mcbdr primary endpoint | #3 |
| traditional ctcae | #3 |
| hands burning pain | #3 |
| reported rash | #3 |
| pros differences | #3 |
| egfr inhibitor patients | #3 |
| tingling burning pain | #3 |
| cmtassociated genes | #3 |
| blind trial | #3 |
| cipn cmtassociated genes | #3 |
| pts stage iii | #3 |
| asco surveillance | #3 |
| hormonal ablation | #3 |
| n08ca n08cb study | #3 |
| hgb rbc transfusions | #3 |
| upfront arm | #3 |
| osteoporosis osteopenia letrozole | #3 |
| questionnaires syndrome paclitaxel | #3 |
| acetate treated | #3 |
| real day | #3 |
| mucositis scores | #3 |
| rash study arms | #3 |
| vaginal dhea | #3 |
| female gabapentin | #3 |
| hot flashes placebo | #3 |
| centric decision | #3 |
| sham acupuncture week | #3 |
| topical ceramides | #3 |
| fasting chemotherapy | #3 |
| flutamide hgpin | #3 |
| hgpin chemoprevention trial | #3 |
| stomatitis sucralfate | #3 |
| 20 calories | #3 |
| advanced cancer standard | #3 |
| burning pain patients | #3 |
| patients baseline week | #3 |
| ctcae grading arms | #3 |
| mouthwash patients | #3 |
| receive placebo | #3 |
| dhea hot flashes | #3 |
| evidence prostate adenocarcinoma | #3 |
| gabapentin management | #3 |
| intravenous calcium magnesium | #3 |
| middle aged pilot | #3 |
| drug toxicity patients | #3 |
| pilot trial pregabalin | #3 |
| n05c4 | #3 |
| gwas mayo clinic | #3 |
| eightyone randomized women | #3 |
| patients scrambler therapy | #3 |
| primary endpoint gwas | #3 |
| interventions cancerrelated fatigue | #3 |
| canada collaborative effort | #3 |
| ctpm experts | #3 |
| cmt gene | #3 |
| clonidine randomized trials | #3 |
| crossover methodology | #3 |
| cipn ctpm | #3 |
| fluoxetine arm | #3 |
| shooting burning pain | #3 |
| placebo prostate adenocarcinoma | #3 |
| hemoccultsensa | #3 |
| patient completed | #3 |
| cipn evidence | #3 |
| patients upfront arm | #3 |
| oral megestrol acetate | #3 |
| months bupropion | #3 |
| qlqcipn20 traditional ctcae | #3 |
| 1 month cytokines | #3 |
| 10 weeks therapy | #3 |
| trial bmd | #3 |
| hot flashes trial | #3 |
| ginseng arm | #3 |
| hemoccult hemoccultsensa | #3 |
| study population mcbdr | #3 |
| eventual sensory patients | #3 |
| chemotherapy increases | #3 |
| cipn snv | #3 |
| survival epa | #3 |
| 51 female age | #3 |
| baseline treatment day | #3 |
| egfr inhibitorinduced rash | #3 |
| average severity | #3 |
| patients cyproheptadine | #3 |
| neuropathy chemotherapy | #3 |
| chemotherapyassociated anemia | #3 |
| life dronabinol | #3 |
| ≤−20 | #3 |
| snv cmtassociated genes | #3 |
| 95 udi | #3 |
| qol hgb | #3 |
| acute neuropathy | #3 |
| cachexia decision humans | #3 |
| oxaliplatin cipn | #3 |
| rash prevention | #3 |
| bacterial agents life | #3 |
| carboplatin gwas | #3 |
| subcutaneous weekly | #3 |
| experience greater | #3 |
| cyclohexanecarboxylic acids | #3 |
| cmt genes oxaliplatin | #3 |
| ctcae grades patients | #3 |
| purposefosaprepitant | #3 |
| delayed zoledronic | #3 |
| life antineoplastic agents | #3 |
| placebo breast | #3 |
| data pilot trials | #3 |
| ginseng crf | #3 |
| completed diaries | #3 |
| chemotherapy‐associated anemia | #3 |
| oxaliplatininduced neuropathy | #3 |
| 95 40 points | #3 |
| centrally active agents | #3 |
| controls singleton snv | #3 |
| combinationtreated arms survival | #3 |
| life hospice patients | #3 |
| epoetintreated patients incidence | #3 |
| experts cipn | #3 |
| repeated measures analyses | #3 |
| patients antiemetic | #3 |
| pilot evaluation gabapentin | #3 |
| patients lidocaine patch | #3 |
| vitamin prevention | #3 |
| tamoxifen fluoxetine | #3 |
| paps scores | #3 |
| epoetintreated patients study | #3 |
| week chemotherapy dose | #3 |
| mpa single dose | #3 |
| n03cc | #3 |
| cold items | #3 |
| survivors gsm | #3 |
| n08ca paclitaxel | #3 |
| minocycline prevention | #3 |
| patients paps scores | #3 |
| life eortc qlq | #3 |
| toxicities selfreport | #3 |
| methodologic lessons | #3 |
| toxicity agents | #3 |
| recommendations dietary counseling | #3 |
| thromboembolism secondary | #3 |
| radiation‐induced mucositis | #3 |
| iii evaluation | #3 |
| neurotoxic chemotherapy cipn | #3 |
| ” numbness | #3 |
| qlqcipn20 | #3 |
| paps scores dose | #3 |
| genetic predictors paclitaxel | #3 |
| relationship numbness | #3 |
| chemotherapy gabapentin | #3 |
| qlqcipn20 scores | #3 |
| baseline general subscale | #3 |
| alfa compared | #3 |
| survival cancerassociated wasting | #3 |
| relationship response rate | #3 |
| data ginseng | #3 |
| mfsisf 4 weeks | #3 |
| feet 15 | #3 |
| oxaliplatin primary endpoint | #3 |
| bivariate construct | #3 |
| additional 4 weeks | #3 |
| physiologic pilot | #3 |
| oncology colorectal | #3 |
| follow fsfi | #3 |
| genetic factors patients | #3 |
| preventing peripheral | #3 |
| male megestrol | #3 |
| prophylactic tetracycline | #3 |
| numeracy patients | #3 |
| upfront treatment arm | #3 |
| depression somnolence | #3 |
| mastectomy rates | #3 |
| patients chemotherapy cycle | #3 |
| apixaban lowest risk | #3 |
| selfreport ctcae grading | #3 |
| neuropathy trials | #3 |
| management cancer cachexia | #3 |
| starting letrozole | #3 |
| chlorhexidine mouthwash | #3 |
| qol placebotreated patients | #3 |
| purposeoxaliplatin | #3 |
| ssc device | #3 |
| iii controlled | #3 |
| incurable cancers | #3 |
| projects prospective | #3 |
| ctcae pros | #3 |
| chronic neuropathy patients | #3 |
| epoetin alfa hgb | #3 |
| cyproheptadine patients | #3 |
| topic mayo clinic | #3 |
| cvte | #3 |
| thirdline hormonal therapy | #3 |
| oxaliplatinbased therapy | #3 |
| anorexia anorexia appetite | #3 |
| n08cx | #3 |
| “use | #3 |
| aminobutyric acid gabapentin | #3 |
| week venlafaxine therapy | #3 |
| cipn n08cx population | #3 |
| cipn mcbdr population | #3 |
| bit hands | #3 |
| chemotherapy induced | #3 |
| undergoing androgen ablation | #3 |
| neoplasms vomiting | #3 |
| cumulative neurotoxicity oxaliplatin | #3 |
| trials newer | #3 |
| neurotoxic chemotherapies | #3 |
| placebo preparation | #3 |
| snv charcotmarietooth disease | #3 |
| trials n9741 | #3 |
| general subscale mfsisf | #3 |
| paps dose | #3 |
| cipn biological targets | #3 |
| measures peripheral | #3 |
| genetic predictors cipn | #3 |
| asco guideline management | #3 |
| delayed treatment arm | #3 |
| classic sums | #3 |
| corticosteroid medications | #3 |
| controlled double | #3 |
| achievements ncctg | #4 |
| oxybutynin placebo | #4 |
| cipn20 ctcae | #4 |
| anorexia cholecystokinin | #4 |
| tpn initiation | #4 |
| receive oral | #4 |
| treatment ncctg | #4 |
| nonabsorbable antibiotic | #4 |
| colorectal cancer asco | #4 |
| general subscale | #4 |
| recommended endorsement | #4 |
| toxt analysis | #4 |
| iron arm | #4 |
| ais biomarkers | #4 |
| loss syndrome | #4 |
| odx ctx | #4 |
| prominent problem | #4 |
| vaginal assessment scale | #4 |
| severity sexes | #4 |
| 6 months bupropion | #4 |
| apr dex | #4 |
| mastectomy rates patients | #4 |
| appetite stimulation | #4 |
| anorectic cancer patients | #4 |
| numbness toes | #4 |
| cachexia purpose | #4 |
| therapy aimss | #4 |
| odc activity mice | #4 |
| flash frequency | #4 |
| rash incidence | #4 |
| appetite quality | #4 |
| 900 dose | #4 |
| backgroundhistorically | #4 |
| aged mouthwashes | #4 |
| chemotherapy‐induced peripheral | #4 |
| trpa1 cisplatin | #4 |
| topic survivors | #4 |
| intrapatient difference | #4 |
| hfs quality | #4 |
| or1 year | #4 |
| benefits adjuvant | #4 |
| hec cisplatin | #4 |
| guidelines oral | #4 |
| hot flashes week | #4 |
| suggested efficacy | #4 |
| based chemotherapy severity | #4 |
| breast medical oncologists | #4 |
| weekly toxicity | #4 |
| placebo hot | #4 |
| addition letrozole | #4 |
| to100 | #4 |
| paced breathing | #4 |
| doxepin female head | #4 |
| cancer acute vte | #4 |
| predictors duloxetine response | #4 |
| gabapentin day | #4 |
| major doselimiting toxicity | #4 |
| day paroxetine | #4 |
| qol performance score | #4 |
| treatment cancer anorexia | #4 |
| dietician | #4 |
| control hot | #4 |
| followup surveillance protocol | #4 |
| measurable metastatic disease | #4 |
| hemoccult | #4 |
| survivors hot | #4 |
| bupropion 3 | #4 |
| secondary vte prevention | #4 |
| ctx odx | #4 |
| symptoms individual patients | #4 |
| severe stomatitis leukopenia | #4 |
| additional meta analysis | #4 |
| surgery lymphedema | #4 |
| 40000 | #4 |
| endorsed treatment | #4 |
| nonestrogenic | #4 |
| recommendation ctx | #4 |
| based chemotherapy women | #4 |
| cutaneous electrostimulation | #4 |
| placebo arms | #4 |
| oral cavity mucosa | #4 |
| logistic regression incidence | #4 |
| publication antiemetics humans | #4 |
| fluorouracilbased chemotherapy | #4 |
| doac dalteparin | #4 |
| flaxseed placebo | #4 |
| baseline fatigue survival | #4 |
| aimss | #4 |
| administration parp inhibitor | #4 |
| odc odc activity | #4 |
| cco guideline followup | #4 |
| weight loss syndrome | #4 |
| qol baseline fatigue | #4 |
| oral cryotherapy mucositis | #4 |
| outcomes olanzapine | #4 |
| chronic neuropathy | #4 |
| hot flashes therapy | #4 |
| doubleblind manner | #4 |
| parenteral iron | #4 |
| hgpin antineoplastic agents | #4 |
| 95 oral iron | #4 |
| bupropion 3 months | #4 |
| 3915 patients | #4 |
| women greater toxicity | #4 |
| controls imbalance | #4 |
| risk reduction therapy | #4 |
| rash study | #4 |
| nsclc trials | #4 |
| single dose venlafaxine | #4 |
| therapy oncologists | #4 |
| arm breast neoplasms | #4 |
| calgb 70305 | #4 |
| daily baseline | #4 |
| inhibitor induced | #4 |
| 1093 women | #4 |
| egfr inhibitor rash | #4 |
| anorexia weight | #4 |
| neuropeptide leptin | #5 |
| trial developed | #5 |
| fiftynine percent | #5 |
| physicians predictive ttr | #5 |
| genetic quality life | #5 |
| acetate neoplasms quality | #5 |
| placebo exposed | #5 |
| cumulative neurotoxicity | #5 |
| neuropathic pain qol | #5 |
| trials lessons | #5 |
| current trial patients | #5 |
| cancerrelated fatigue patients | #5 |
| patient outcomes numeracy | #5 |
| trial hot | #5 |
| odx | #5 |
| difference control arm | #5 |
| additional 8 weeks | #5 |
| discontinuation aimss | #5 |
| treating postmenopausal | #5 |
| progestational agent | #5 |
| tools numeracy | #5 |
| cyclohexanecarboxylic | #5 |
| gabapentin patients | #5 |
| treatment benefits sex | #5 |
| ajcc external validation | #5 |
| intravenous calcium | #5 |
| cachexia anorexia | #5 |
| neuropathy acute | #5 |
| cancer anorexia | #5 |
| cipn numbness | #5 |
| reported hot | #5 |
| 3 stools | #5 |
| ttr cindices | #5 |
| acetate neoplasms | #5 |
| nodal status stage | #5 |
| numeracy online clinical | #5 |
| major outcome measure | #5 |
| ajcc tools | #5 |
| cancer survivors symptoms | #5 |
| study dmc | #5 |
| vasomotor hot flashes | #5 |
| mucositis allopurinol | #5 |
| cisplatin ganglia | #5 |
| flashes data | #5 |
| pain scores dose | #5 |
| bone loss osteopenia | #5 |
| questionnaires pregabalin | #5 |
| life epa | #5 |
| ajcc version staging | #5 |
| life lmwh | #5 |
| patients lmwh injections | #5 |
| higher drug doses | #5 |
| digital melt | #5 |
| groups leptin concentrations | #5 |
| trial gabapentin | #5 |
| crc cancers | #5 |
| acetate placebo | #5 |
| libido | #5 |
| postsurgical neuropathic | #5 |
| crc cancer types | #5 |
| cipn participants | #5 |
| gabapentin trial | #5 |
| disputes female humans | #5 |
| hb increment | #5 |
| neoplasms compared | #5 |
| medical oncology outpatients | #5 |
| editor manuscript | #5 |
| nodal status grade | #5 |
| nutrition scores | #5 |
| 3 patients 4 | #5 |
| mucositis caused | #5 |
| induced stomatitis | #5 |
| death communication humans | #5 |
| oxantrazole | #5 |
| physicianreported | #5 |
| subsets treatment benefits | #5 |
| fluoxymesterone patients | #5 |
| ttr variables | #5 |
| women 5fu | #5 |
| trials cytotoxic chemotherapy | #5 |
| neoplasm diagnostic tests | #5 |
| cipn effects | #5 |
| cipnrelated symptoms | #5 |
| aapro | #5 |
| centrally active | #5 |
| models ttr | #5 |
| appetite enhancement | #5 |
| fosaprepitant prevention | #5 |
| iron oral | #5 |
| ongoing clinical trial | #5 |
| kps ecog | #5 |
| sham real | #5 |
| combination electroacupuncture | #5 |
| race ttr | #5 |
| colorectal cancer surveillance | #5 |
| colorectal cancer society | #5 |
| rectal cancer surveillance | #5 |
| epa supplement | #5 |
| olanzapine arm | #5 |
| grade model estimates | #5 |
| receiving paclitaxel | #5 |
| reduce chemotherapy | #5 |
| numeracy tools | #5 |
| cindices ajcc | #5 |
| impaired postural | #5 |
| ttr ajcc | #5 |
| 5fu trials | #5 |
| agents basis | #5 |
| flashes humans | #6 |
| methylo | #6 |
| depomedroxyprogesterone acetate | #6 |
| neurological safety | #6 |
| therapy 10 weeks | #6 |
| studies vomiting | #6 |
| life toxicity | #6 |
| placebo hfs | #6 |
| megestrol | #6 |
| mri trends | #6 |
| predictive illness surveys | #6 |
| inhaler bupropion | #6 |
| agents breast | #6 |
| 71 sensitivity | #6 |
| death kps | #6 |
| 4week intervention | #6 |
| nicotine inhaler | #6 |
| wisconsin ginseng | #6 |
| proportion aes | #6 |
| severity neuropathic symptoms | #6 |
| 500 mcg | #6 |
| daily diary questionnaires | #6 |
| hospitalized oncology patients | #6 |
| her2directed therapy | #6 |
| apixaban cancer patients | #6 |
| staging patient outcomes | #6 |
| breakthrough nausea | #6 |
| data supporting | #6 |
| north central | #6 |
| rs11572080 | #6 |
| loe guidelines | #6 |
| pharmaceutic aged aged | #6 |
| nci ctcae | #6 |
| cipn treatment | #6 |
| medical acupuncture | #6 |
| hrqol breast neoplasms | #6 |
| longacting methylphenidate | #6 |
| selective poly | #6 |
| smoking abstinence rates | #6 |
| background chemotherapy | #6 |
| alliance clinical | #6 |
| placebo arm patients | #6 |
| induced sensory | #6 |
| imidazoles letrozole | #6 |
| intervention lymphedema | #6 |
| active malignancy | #6 |
| cancerrelated fatigue life | #6 |
| versus combination | #6 |
| paclitaxel peripheral neuropathy | #6 |
| fatigue pilot study | #6 |
| bf qol | #6 |
| nonanthracycline chemotherapy | #6 |
| sadenosyllmethionine treatment | #6 |
| placebo hot flashes | #6 |
| 5fubased chemotherapy | #6 |
| severity data | #6 |
| participants sham acupuncture | #6 |
| olanzapine prevention | #6 |
| 5fu folfox | #6 |
| highly emetogenic chemotherapy | #6 |
| sensory scale | #6 |
| citalopram cyclohexanols | #7 |
| throat discomfort | #7 |
| scheduled receive | #7 |
| 20 percent placebo | #7 |
| illness antimetabolites | #7 |
| rs10509681 | #7 |
| 5fu based chemotherapy | #7 |
| 1week baseline period | #7 |
| study arms difference | #7 |
| cmt genes | #7 |
| outcomes primary outcomes | #7 |
| venlafaxine versus | #7 |
| toxic polyneuropathy | #7 |
| uniscale | #7 |
| venlafaxine therapy | #7 |
| mucositis placebo | #7 |
| appetites | #7 |
| symptom subscale | #7 |
| odx score | #7 |
| cancer patients anorexia | #7 |
| induced rash | #7 |
| vte recurrence doac | #7 |
| serum concentrations cytokines | #7 |
| cream versus | #7 |
| smoking 3 | #7 |
| study drug trial | #7 |
| cryotherapy arm | #7 |
| induced neuropathy | #7 |
| prevalence moderatetosevere | #7 |
| bupropion relapse | #7 |
| intermediate odx | #7 |
| pain cipn | #7 |
| patients product | #7 |
| hemoquant | #7 |
| menopause hot | #7 |
| accru | #7 |
| uniscale qol | #7 |
| incidence rbc transfusion | #7 |
| blind study | #7 |
| patients oral cryotherapy | #7 |
| cyclophosphamidedoxorubicin | #7 |
| venlafaxine day | #7 |
| patients hb response | #7 |
| fluoxetine clinical trials | #7 |
| paclitaxel peripheral | #7 |
| neuropathy oxaliplatin | #7 |
| patient anthracycline | #7 |
| lymphedema education | #7 |
| transdermal clonidine | #7 |
| weight concerns smokers | #7 |
| chronic postmastectomy pain | #7 |
| stage nodal status | #7 |
| placebocontrolled trial | #7 |
| adjuvant interferon patients | #7 |
| lower extremity symptoms | #7 |
| week followup | #7 |
| fuinduced | #7 |
| model estimates survival | #7 |
| follow year | #7 |
| intervention lymphedema status | #7 |
| letrozole differences | #7 |
| nutrition score | #7 |
| hemoccult hemoquant | #7 |
| weekly epoetin alfa | #7 |
| mpa arm | #7 |
| minority smokers | #7 |
| sensitivity fecal | #7 |
| nausea cancer patients | #7 |
| pregabalin prevention | #7 |
| skindex16 | #7 |
| 12 treatment arms | #7 |
| neuropathy scale | #8 |
| administered systemically | #8 |
| evidence pharmacologic interventions | #8 |
| greater toxicity | #8 |
| topic antineoplastic | #8 |
| venlafaxine hot flashes | #8 |
| oral placebo | #8 |
| 18 months symptoms | #8 |
| symptoms neuropathy | #8 |
| sdt1 | #8 |
| mouth sores | #8 |
| agents newer | #8 |
| progestational | #8 |
| severe hot flashes | #8 |
| paclitaxel severity | #8 |
| oxaliplatin paclitaxel | #8 |
| treatment cinv | #8 |
| pros aes | #8 |
| neuropathy pain | #8 |
| odx risk | #8 |
| paclitaxel pain | #8 |
| epa survival | #8 |
| flutamide placebo | #8 |
| nonhormonal treatments | #8 |
| raw data trials | #8 |
| life antibodies | #8 |
| chronic neurotoxicity | #8 |
| folfox dfs | #8 |
| venous toxicity | #8 |
| fecal blood | #8 |
| cycle capecitabine | #8 |
| placebo pilot study | #8 |
| efficacy newer antidepressants | #8 |
| prior chemotherapy exposure | #8 |
| neuropathic symptoms | #8 |
| opioids moderate pain | #8 |
| cpmp | #8 |
| cancer survivors cipn | #8 |
| smokers weight concerns | #8 |
| oxaliplatin neuropathy | #8 |
| libido women | #8 |
| antidepressant patients | #8 |
| tamoxifeninduced hot flashes | #8 |
| 70305 | #8 |
| anecdotal | #8 |
| 1355 | #8 |
| recurrence colon cancer | #8 |
| placebo suggestion | #8 |
| factors cipn | #8 |
| series clinical trials | #8 |
| direct oral factor | #8 |
| induced painful | #8 |
| stomatitis patients | #8 |
| oral iron placebo | #8 |
| women hfs | #8 |
| lamotrigine pain | #9 |
| follow tests | #9 |
| study treatment arm | #9 |
| prevention vomiting | #9 |
| baseline week week | #9 |
| cutaneous aged anesthetics | #9 |
| lmwh injections | #9 |
| 5 nausea | #9 |
| antiemetic properties | #9 |
| questionnaires syndrome | #9 |
| disease receive | #9 |
| cipn patients | #9 |
| cancer patients cipn | #9 |
| sensory axonopathy | #9 |
| relapse relapse prevention | #9 |
| lymphedema hrqol | #9 |
| hot flashes tamoxifen | #9 |
| vitality subscale | #9 |
| appetite weight | #9 |
| skindex16 scores | #9 |
| patients hot | #9 |
| surgical year | #9 |
| neuropathic symptoms patients | #9 |
| lymphedema prevention | #9 |
| patients provided | #9 |
| fosaprepitant | #9 |
| ambulatory analgesics | #9 |
| dose dfmo | #9 |
| flash control | #9 |
| medications evidence | #9 |
| mometasone furoate placebo | #9 |
| 43 trials | #9 |
| mucositis pain | #9 |
| fatigue methylphenidate | #9 |
| acid amines | #9 |
| flashes hot | #9 |
| incurable disease | #9 |
| letrozole day | #9 |
| aged pilot | #9 |
| trial paroxetine | #9 |
| radiationinduced esophagitis | #9 |
| numbness fingers | #9 |
| genistein tumor growth | #9 |
| topical antimetabolites | #9 |
| disease recurrence recurrence | #9 |
| oxaliplatin placebo | #9 |
| incidence colorectal adenomas | #9 |
| apixaban lower rate | #9 |
| oxaliplatin trpa1 | #10 |
| patients treatment period | #10 |
| chemotherapy‐induced | #10 |
| humans megestrol | #10 |
| trials demonstrated | #10 |
| inhibit cyp2d6 | #10 |
| flash data | #10 |
| qol total | #10 |
| qol anemia | #10 |
| recommendations general population | #10 |
| asco guideline | #10 |
| controlled randomized | #10 |
| sensitivity cancer | #10 |
| antineoplastic agents humans | #10 |
| ctcae grades | #10 |
| cancerassociated anemia | #10 |
| neoplasms neuralgia | #10 |
| venlafaxine arm | #10 |
| scrambler therapy patients | #10 |
| phase iii | #10 |
| shark cartilage | #10 |
| oxaliplatin peripheral | #10 |
| symptomatic malignant ascites | #10 |
| factes | #10 |
| cancerrelated fatigue fatigue | #10 |
| δ − | #10 |
| life topic reproducibility | #10 |
| cognitive chemotherapy | #10 |
| incidence stomatitis | #10 |
| data relatedness | #10 |
| combination therapy relapse | #10 |
| physical consequences | #10 |
| minocycline reduction | #10 |
| life dietary supplements | #10 |
| megestrol acetate quality | #10 |
| ecog kps | #10 |
| folfox 5fu | #10 |
| patients neurotoxic chemotherapy | #10 |
| pain medications patients | #10 |
| nonhormonal therapies | #10 |
| anorexia cachexia | #10 |
| gabapentin | #10 |
| vaginal dryness | #10 |
| nonhormonal treatment | #10 |
| randomized placebo | #10 |
| 40 arm | #10 |
| frequency hot flashes | #10 |
| adult cancers | #10 |
| advanced cancer life | #10 |
| differences 5 years | #10 |
| aprepitant treatment | #10 |
| doses citalopram | #10 |
| physicians increased risk | #11 |
| gbu | #11 |
| flashes | #11 |
| prevalence neuropathic pain | #11 |
| difficulty patients | #11 |
| electroanalgesia | #11 |
| anastrozole 10 | #11 |
| ginseng placebo | #11 |
| dalteparin major bleeding | #11 |
| vomiting cancer patients | #11 |
| differences study arms | #11 |
| translational component | #11 |
| reported incidences | #11 |
| hydrazine sulfate | #11 |
| antiemetic guidelines | #11 |
| efficacy black cohosh | #11 |
| sensory neurotoxicity | #11 |
| promising data | #11 |
| olanzapine chemotherapy | #11 |
| diphenhydramine lidocaine | #11 |
| melt curve | #11 |
| cancer undergoing | #11 |
| ativan | #11 |
| erythropoietic response | #11 |
| institutional guideline | #11 |
| curve assay | #11 |
| fsfi female | #11 |
| combination treated | #11 |
| nicotine patch therapy | #11 |
| qol uniscale | #11 |
| toxicity 4 weeks | #12 |
| completed daily | #12 |
| toxicities groups | #12 |
| pilot trial levetiracetam | #12 |
| hot flashes 95 | #12 |
| cachexia clinical trials | #12 |
| neurotoxic chemotherapy | #12 |
| capsaicin cream | #12 |
| venlafaxine women | #12 |
| leptin cck8 | #12 |
| probability prospective studies | #12 |
| valerian placebo | #12 |
| rash quality | #12 |
| oxaliplatin induced | #12 |
| cipn development | #12 |
| gait testing | #12 |
| ctpm | #12 |
| hb response | #12 |
| recurrence comparisons | #12 |
| adjuvant communication decision | #12 |
| patients cipn symptoms | #12 |
| cycles drugs | #12 |
| reported peripheral | #12 |
| breast cancer letrozole | #12 |
| pluronic lecithin organogel | #12 |
| individuals advanced adenomas | #12 |
| −307 | #12 |
| decreased libido | #12 |
| irox folfox | #12 |
| apixaban dalteparin | #12 |
| venlafaxine hydrochloride | #12 |
| initial 3 months | #13 |
| months smoking | #13 |
| rs3213619 | #13 |
| neuropathy outcome | #13 |
| hot flashes baseline | #13 |
| adenomas aspirin | #13 |
| severity hot flashes | #13 |
| valerian sleep | #13 |
| education clinical practice | #13 |
| weight cachexia | #13 |
| troubling | #13 |
| incident exposure | #13 |
| acute treatment vte | #13 |
| bmd 1 year | #13 |
| patients breakthrough cinv | #13 |
| median hb | #13 |
| nausea patients | #13 |
| treatment advanced cancer | #13 |
| anemia life | #13 |
| adjuvant benefit | #13 |
| patients advancedstage cancer | #13 |
| life investigation | #13 |
| abh gel | #13 |
| adjuvant colon cancer | #13 |
| flashes day | #13 |
| improve cancer | #13 |
| 10 range | #13 |
| common toxicity | #13 |
| troublesome symptoms | #13 |
| newer antidepressants placebo | #13 |
| megestrol acetate therapy | #13 |
| andropause | #13 |
| venlafaxine paroxetine | #13 |
| venlafaxine life | #13 |
| therapy benefits | #13 |
| ncctg | #13 |
| life neoplasm recurrence | #13 |
| oral anesthetics | #13 |
| estimates prognosis | #13 |
| paroxetine hot flashes | #13 |
| trial support | #13 |
| 2000 update | #13 |
| patients diphenhydramine | #13 |
| autonomic scale | #13 |
| neuropathic pain surgery | #13 |
| ais women | #13 |
| major bleeding doac | #13 |
| 40 points 95 | #13 |
| based topical | #14 |
| palliate | #14 |
| phase 3 months | #14 |
| genital symptoms | #14 |
| life anemia | #14 |
| provided data | #14 |
| flash activity | #14 |
| patients pain scores | #14 |
| 5fu surgery | #14 |
| benefit toxicity | #14 |
| oral iron | #14 |
| fluoxymesterone | #14 |
| oxaliplatin vivo | #14 |
| smokers placebo | #14 |
| marked toxicity | #14 |
| diagnosis localized disease | #14 |
| prophylactic agent | #14 |
| recurrences patients | #14 |
| biomarkers bone formation | #14 |
| stool dna | #14 |
| aes treatment | #15 |
| triazoles zoledronic | #15 |
| week darbepoetin | #15 |
| monoclonal carcinoma antibodies | #15 |
| duloxetine cipn | #15 |
| therapy nicotine | #15 |
| life life survivors | #15 |
| evidence treatment options | #15 |
| oxaliplatininduced neurotoxicity | #15 |
| agents life | #15 |
| folfox irox | #15 |
| 16–28 | #15 |
| trials gabapentin | #15 |
| syndromes peripheral | #15 |
| suggestion guideline | #15 |
| lidocaine patch | #15 |
| vaginal dryness dyspareunia | #15 |
| advanced cancer methods | #15 |
| acceptability device | #15 |
| highly emetogenic | #15 |
| advanced malignant disease | #15 |
| grade age | #15 |
| persistent incisional pain | #15 |
| mastectomy irradiation | #15 |
| bfq | #15 |
| taste alterations | #15 |
| adjuvant aromatase | #15 |
| academic oncologists | #15 |
| androgen ablation therapy | #15 |
| acute diarrhea patients | #15 |
| week baseline | #15 |
| sternal skin conductance | #15 |
| prognosis quality life | #15 |
| clinician perception | #15 |
| treatment weeks patients | #15 |
| endpoints baseline | #16 |
| premenopausal women chemotherapy | #16 |
| venlafaxine patients | #16 |
| stool dna test | #16 |
| randomized trial aspirin | #16 |
| rash pruritus | #16 |
| induced hot | #16 |
| paclitaxel oxaliplatin | #16 |
| tingling pain | #16 |
| patients venlafaxine | #16 |
| loss appetite | #16 |
| symptoms numbness | #16 |
| patch therapy | #16 |
| female cancer survivors | #16 |
| diarrhoea time | #16 |
| dalteparin 95 | #16 |
| breast gynecologic cancer | #16 |
| mfsi | #16 |
| antiemetic agent | #16 |
| advancedstage cancer patients | #16 |
| vte apixaban | #16 |
| treatment cancer vte | #16 |
| product time | #16 |
| findings education | #16 |
| measurable evaluable disease | #16 |
| leptin concentrations groups | #17 |
| women metastatic | #17 |
| 786 patients | #17 |
| arhgef10 | #17 |
| flashes tamoxifen | #17 |
| device women | #17 |
| oxaliplatin doses | #17 |
| breast cancer oestrogen | #17 |
| institute common | #17 |
| arthralgias | #17 |
| 18 months women | #17 |
| leap study | #17 |
| dfs folfox | #17 |
| inadequate control | #17 |
| reduction fatigue | #17 |
| rs11849538 | #17 |
| recommendation suggestion | #17 |
| adenomas 1 | #17 |
| venlafaxine | #17 |
| oxaliplatin treated | #17 |
| cancer menopause | #17 |
| vaginal symptoms | #17 |
| crc patients patients | #17 |
| fractional co2 | #17 |
| study tetracycline | #17 |
| screen detection | #17 |
| 5 adjuvant | #18 |
| sigmoidoscopy tomography | #18 |
| flash frequencies | #18 |
| mri mastectomy | #18 |
| severity cipn | #18 |
| patients hb | #18 |
| prophylactic antiemetic therapy | #18 |
| oncology providers patients | #18 |
| subsets age | #18 |
| patients overview | #18 |
| standard prognostic | #18 |
| treatment osteopenia | #18 |
| baseline 4 | #18 |
| randomized trials women | #18 |
| receiving head | #18 |
| intervention guidelines | #18 |
| severity hot | #18 |
| postmenopausal women letrozole | #18 |
| patients irox | #18 |
| placebo 04 | #18 |
| menopausal problems | #18 |
| secondary endpoint analysis | #18 |
| symptoms hormone | #18 |
| sternal skin | #18 |
| 120000 | #18 |
| data followup | #18 |
| oral dronabinol | #18 |
| patients informed decisions | #18 |
| neoplasms peripheral | #19 |
| unpleasant taste | #19 |
| physician reported | #19 |
| panax quinquefolius | #19 |
| oxaliplatin carboplatin | #19 |
| ncdf | #19 |
| treatment mastectomy | #19 |
| mastectomy methotrexate | #19 |
| evidence status | #19 |
| acute cancer | #19 |
| rs7349683 | #19 |
| bmd neoplasms chemotherapy | #19 |
| 95 46 | #19 |
| groups infliximab | #19 |
| double blinded | #19 |
| minimal adverse effects | #19 |
| oxaliplatin neurotoxicity | #19 |
| patients based chemotherapy | #19 |
| flash reduction | #19 |
| previous colorectal | #19 |
| induced mucositis | #19 |
| n6 n5 | #19 |
| 7 outcomes | #19 |
| folfox fluorouracil | #19 |
| life gabapentin | #19 |
| cancer cancer therapy | #20 |
| placebo cream | #20 |
| palliating | #20 |
| numbness | #20 |
| surveillance protocol | #20 |
| moderate pain patients | #20 |
| major bleeding treatment | #20 |
| pilot trials | #20 |
| life skindex16 | #20 |
| receiving pelvic | #20 |
| reducing pain | #20 |
| appetite nutritional status | #20 |
| study ginseng | #20 |
| advanced cancer study | #20 |
| therapeutic options treatment | #20 |
| revisitation | #20 |
| progestational agents | #20 |
| emetogenic chemotherapy | #20 |
| placebo smokers | #20 |
| baseline week | #20 |
| diseases randomized | #20 |
| fecal occult | #20 |
| fatigue 4 | #20 |
| studies methylphenidate | #21 |
| substantial problem | #21 |
| treatment options women | #21 |
| female menopause | #21 |
| cancer starting | #21 |
| trial 12 months | #21 |
| management cachexia | #21 |
| radiationinduced dermatitis | #21 |
| cipn symptoms | #21 |
| chemotherapy agents | #21 |
| therapy adverse effects | #21 |
| crossover analysis | #21 |
| acetate patients | #21 |
| routine test | #21 |
| receptorpositive breast cancer | #21 |
| metastatic breast carcinoma | #21 |
| refractory cachexia | #21 |
| oral mucositis pain | #21 |
| scores ≤ | #22 |
| patients testosterone | #22 |
| optumlabs | #22 |
| pharmacokinetics infliximab | #22 |
| asco panel | #22 |
| subcutaneous testosterone | #22 |
| emetogenic | #22 |
| gain patients | #22 |
| crossover phase | #22 |
| severity adverse events | #22 |
| 150 groups | #22 |
| guideline intervention | #22 |
| doc time | #22 |
| median time initiation | #22 |
| candidate single | #22 |
| n9741 | #22 |
| npy leptin | #22 |
| projects quality | #22 |
| location stage | #22 |
| patients 5 weeks | #22 |
| mcf7 cells genistein | #23 |
| potential toxicities | #23 |
| detecting recurrence | #23 |
| aes qol | #23 |
| followup tests | #23 |
| stool dna testing | #23 |
| versus delayed | #23 |
| life ascites | #23 |
| mascc isoo | #23 |
| acetate middle | #23 |
| fsdsr | #23 |
| sucralfate patients | #23 |
| acupuncture hot | #23 |
| 5 pounds | #23 |
| decision adjuvant | #23 |
| randomized 1 | #24 |
| design rcts | #24 |
| pilot clinical | #24 |
| adjuvant decision making | #24 |
| abstract5fluorouracil | #24 |
| topic design severity | #24 |
| aged amines | #24 |
| apixaban treatment | #24 |
| day chemotherapy | #24 |
| n56 | #24 |
| aged anorexia | #24 |
| tamoxifen octreotide | #24 |
| ortho biotech | #24 |
| weeks primary | #24 |
| replacement testosterone | #24 |
| female hot | #24 |
| every3 | #24 |
| mirtazapine patients | #24 |
| prevention chemotherapy | #24 |
| hrt survival | #24 |
| bpisf | #25 |
| trial pilot | #25 |
| qol tools | #25 |
| placebo arm treatment | #25 |
| cancerassociated weight loss | #25 |
| antiepileptic agent | #25 |
| severe nausea vomiting | #25 |
| recommendations basis | #25 |
| mmf placebo | #25 |
| criteria adverse | #25 |
| institutional guidelines | #25 |
| prevention nausea | #25 |
| women adjuvant tamoxifen | #25 |
| vte trial | #25 |
| lymphedema incidence | #25 |
| doses schedules | #25 |
| neoplasia screening | #25 |
| nausea olanzapine | #25 |
| cco guideline | #25 |
| neoplasms estrogens | #26 |
| induced musculoskeletal | #26 |
| syndrome menopause | #26 |
| colorectal adenomas patients | #26 |
| nci ctc | #26 |
| trial evaluate | #26 |
| agents prevention | #26 |
| joints muscles | #26 |
| regional breast | #26 |
| prior week | #26 |
| oncology journals | #26 |
| irradiation mastectomy | #26 |
| undergoing adjuvant | #26 |
| receiving oxaliplatin | #26 |
| mfsisf | #26 |
| dose gabapentin | #26 |
| treatment arms | #26 |
| clinical trials chemotherapy | #26 |
| aiinduced | #26 |
| combination weight loss | #26 |
| cachexia carcinoma | #26 |
| 2005 update | #26 |
| adjuvant 5fu | #27 |
| smoking bupropion | #27 |
| valerian | #27 |
| prophylactic antiemetic | #27 |
| hot flashes hf | #27 |
| antiemetic | #27 |
| lymphedema arm | #27 |
| fubased | #27 |
| events ctcae | #27 |
| neuropathy symptoms | #27 |
| nurse survey | #27 |
| patients short term | #27 |
| series trials | #27 |
| lmwh survival | #27 |
| recommendations trials | #27 |
| newer | #28 |
| gynecologic cancer survivors | #28 |
| prevent colorectal adenomas | #28 |
| primary endpoint proportion | #28 |
| treatment hot flushes | #28 |
| matched general population | #28 |
| describers | #28 |
| fluoxetine citalopram | #28 |
| lidocaine patches | #28 |
| alliance | #28 |
| mastectomy rate | #28 |
| intractable palliative | #28 |
| muscles joints | #28 |
| chest rays | #28 |
| definitively | #28 |
| standard prognostic factors | #28 |
| difluoromethylornithine dfmo | #29 |
| patients paclitaxel | #29 |
| taxanebased chemotherapy | #29 |
| smokers bupropion | #29 |
| mucositis study | #29 |
| efficacy venlafaxine | #29 |
| placebo arm | #29 |
| blood screening | #29 |
| vitamin incidence | #29 |
| pain cancer survivors | #29 |
| citalopram placebo | #29 |
| survival arms | #29 |
| statistical controversies | #29 |
| feet hands | #29 |
| chemotherapy cipn | #29 |
| points study | #29 |
| asco guideline update | #29 |
| paclitaxel cipn | #29 |
| biological predictors | #29 |
| phase iii comparison | #30 |
| management oral mucositis | #30 |
| middle aged postmenopause | #30 |
| alfa darbepoetin | #30 |
| benadryl | #30 |
| cipn pain | #30 |
| diseases peripheral | #30 |
| loss postmenopausal | #30 |
| small pilot | #30 |
| pain oral | #30 |
| twoyear followup | #30 |
| development cipn | #30 |
| month duration | #30 |
| anthrapyrazoles | #30 |
| contralateral axillary | #30 |
| postmenopause predictive | #30 |
| mild nausea | #30 |
| usual oncology | #30 |
| mastectomy mri | #31 |
| prevention oral mucositis | #31 |
| sixtysix patients | #31 |
| pain quality life | #31 |
| treatment acute vte | #31 |
| symptomatic ascites | #31 |
| efficacy methylphenidate | #31 |
| calcium magnesium | #31 |
| patients secondary analysis | #31 |
| treatment paclitaxel | #31 |
| middle aged perimenopause | #31 |
| management menopausal symptoms | #31 |
| ixabepilone patients | #31 |
| benefit dfs | #31 |
| patients races | #31 |
| arms placebo | #31 |
| term rectal | #31 |
| delayed chemotherapy | #32 |
| doubleblind trial | #32 |
| female services | #32 |
| oncologist patients | #32 |
| vera gel | #32 |
| women lymphedema | #32 |
| rash severity | #32 |
| guideline endorsement | #32 |
| breast cancer symptoms | #32 |
| receiving highly | #32 |
| camg | #32 |
| evidencebased guidance | #32 |
| painful cipn | #33 |
| aloe vera gel | #33 |
| fingers hands | #33 |
| dose megestrol | #33 |
| increased difficulty | #33 |
| toxicity breast | #33 |
| week treatment | #33 |
| breast neoplasms life | #33 |
| patients taxol | #33 |
| sensitivity polyps | #33 |
| blind manner | #33 |
| smokers randomized | #33 |
| neoplasms carboplatin | #33 |
| isoo | #33 |
| chemotherapeutic regimens | #33 |
| neuropathy patients | #33 |
| therapy bupropion | #33 |
| patients cinv | #33 |
| hands feet | #33 |
| pursuant | #33 |
| survival advanced cancer | #33 |
| questionnaires total | #33 |
| 4week followup | #33 |
| acupuncture hot flashes | #33 |
| instruments life | #33 |
| continuation study | #34 |
| patients nausea | #34 |
| toxicity fluorouracil | #34 |
| chemotherapy hec | #34 |
| patients acitretin | #34 |
| cancer international society | #35 |
| cipn severity | #35 |
| carcinoembryonic antigen levels | #35 |
| levels week | #35 |
| primary outcomes trials | #35 |
| united states hrqol | #35 |
| major bleeding lmwh | #35 |
| moderatetosevere patients | #35 |
| inhibitors venlafaxine | #35 |
| patients tools | #35 |
| stomatitis | #35 |
| treating cancer | #35 |
| dawley statistics | #35 |
| 4 week | #35 |
| formal consensus process | #35 |
| trial designed | #35 |
| prevention chemotherapyinduced nausea | #35 |
| tnfα study | #36 |
| nk1ras | #36 |
| myalgias | #36 |
| mometasone placebo | #36 |
| lymphedema treatment | #36 |
| cohosh | #36 |
| doxepin | #36 |
| secondary prevention measures | #36 |
| pyrexia patients | #36 |
| stages colorectal cancer | #36 |
| head neck radiotherapy | #36 |
| pain pilot | #36 |
| ctcae | #37 |
| topic humans life | #37 |
| topic stomatitis | #37 |
| symptoms cancer | #37 |
| mc5 | #37 |
| study intravenous | #37 |
| early integrated | #37 |
| survival supportive | #37 |
| p00052 | #37 |
| planned sample size | #37 |
| global impression | #37 |
| alleviation | #37 |
| chronic nausea | #37 |
| nausea neoplasms | #37 |
| cancerrelated fatigue | #37 |
| individual item | #38 |
| relationships populations | #38 |
| 5ht3ras | #38 |
| trial conducted | #38 |
| women metastatic disease | #38 |
| patients taxanes | #38 |
| tests controlled trials | #38 |
| oncology providers | #38 |
| fluorouracil based | #38 |
| illness purpose | #38 |
| patients highdose melphalan | #38 |
| sensitization nociceptors | #38 |
| trials oncology | #39 |
| qol clinical trials | #39 |
| 3 agents | #39 |
| study double | #39 |
| arm placebo | #39 |
| grade 2 toxicity | #39 |
| arm difference | #39 |
| european organisation cancer | #39 |
| treatment breakthrough | #39 |
| chi2 tests | #39 |
| cohort type | #39 |
| crushed ice | #39 |
| menopause gsm | #39 |
| blind crossover | #39 |
| acids drug | #39 |
| difluoromethylornithine | #40 |
| mastectomy chemotherapy | #40 |
| method fatigue | #40 |
| initial mastectomy | #40 |
| single dose placebo | #40 |
| topic reproducibility surveys | #40 |
| prevent colorectal | #40 |
| patients lamotrigine | #40 |
| terminology criteria | #40 |
| cachexia clinical | #40 |
| arthralgia breast | #40 |
| treatment analyses | #40 |
| appetite patients | #40 |
| relapse 3 months | #41 |
| zoledronic acid bmd | #41 |
| bupropion smokers | #41 |
| cure recurrence | #41 |
| symptoms 12 months | #41 |
| undergoing androgen | #41 |
| united states guidelines | #41 |
| trial performed | #41 |
| treatment period | #41 |
| smokers weight | #41 |
| drug evaluation studies | #41 |
| gabapentin placebo | #41 |
| oral gabapentin | #42 |
| location age | #42 |
| neuronal protection | #42 |
| transdermal gel | #42 |
| patients incurable | #42 |
| nortriptyline placebo | #42 |
| patients completed | #42 |
| randomized doubleblind trial | #42 |
| appetite body | #42 |
| treating institution | #42 |
| chemotherapy day | #42 |
| placebo venlafaxine | #42 |
| baseline fatigue | #43 |
| preliminary insights | #43 |
| sex location | #43 |
| desipramine patients | #43 |
| dietary supplements life | #43 |
| postsurgical | #43 |
| 5 induced | #43 |
| highdose interferon | #43 |
| median weight | #43 |
| nonpain | #44 |
| pain reduction patients | #44 |
| disagreement | #44 |
| outcome gamma | #44 |
| trial benefit | #44 |
| sensory symptoms | #44 |
| collaborative effort | #44 |
| vaginal moisturizer | #44 |
| risk cipn | #44 |
| surveillance united states | #44 |
| bupropion placebo | #44 |
| chemotherapyinduced nausea vomiting | #44 |
| weeks efficacy | #44 |
| acute pain patients | #45 |
| 5 years incidence | #45 |
| conclusion trial | #45 |
| humans peripheral | #45 |
| rash grade | #45 |
| survivors colorectal cancer | #45 |
| objective tumor regression | #45 |
| ginseng panax quinquefolius | #45 |
| piroxantrone | #45 |
| menogaril | #45 |
| fisher tests | #45 |
| genitourinary syndrome menopause | #45 |
| historic controls | #45 |
| longitudinal methods | #46 |
| acute skin toxicity | #46 |
| clinical problem | #46 |
| chemotherapy antineoplastic | #46 |
| radiationinduced oral mucositis | #46 |
| patients advanced adenomas | #46 |
| putative mechanism | #46 |
| iii colon cancer | #46 |
| study gaba | #46 |
| item measures | #46 |
| phase iii life | #46 |
| factor prognostic | #46 |
| vaccines melanoma | #46 |
| randomized comparison | #46 |
| current manuscript | #46 |
| megestrol acetate treatment | #46 |
| cisplatin neuropathy | #46 |
| middle aged patient | #46 |
| adverse symptoms | #46 |
| nonpharmacological therapy | #46 |
| epoetin alfa placebo | #46 |
| radiotherapy randomized | #46 |
| darbepoetin alfa patients | #47 |
| aged mometasone | #47 |
| neoplasms parenteral nutrition | #47 |
| average pain | #47 |
| cachexia female | #47 |
| genetic predictors | #47 |
| screening setting | #47 |
| mascc | #47 |
| twopart | #47 |
| bipn | #47 |
| dose paclitaxel | #47 |
| differences pros | #47 |
| physical examinations | #48 |
| neck radiotherapy | #48 |
| oxybutynin | #48 |
| stratification factor | #48 |
| menopause life | #48 |
| genitourinary symptoms | #48 |
| placebo gabapentin | #48 |
| qol female humans | #48 |
| nausea day | #48 |
| sham arm | #49 |
| patientclinician communication | #49 |
| female cancer | #49 |
| flie | #49 |
| chemotherapy nausea | #49 |
| antiserotonergic | #50 |
| receiving androgen | #50 |
| mastectomy pain | #50 |
| models stage | #50 |
| cachexia | #50 |
| hot flashes hfs | #50 |
| pain numbness | #50 |
| time conclusions | #50 |
| replens | #50 |
| cancer survivors fatigue | #50 |
| placebos randomized | #50 |
| effective treating | #51 |
| blinded placebo | #51 |
| cisplatin humans | #51 |
| transdermal testosterone | #51 |
| vomiting chemotherapy | #51 |
| regional hypothermia | #51 |
| patients cancer pain | #51 |
| genitourinary syndrome | #51 |
| patients 8 weeks | #51 |
| differences treatment arms | #52 |
| management chemotherapy | #52 |
| metaanalysis incidence | #52 |
| treatment adt | #52 |
| 80k | #52 |
| trastuzumab orr | #52 |
| black cohosh | #52 |
| risk bone loss | #52 |
| aged orchiectomy | #52 |
| control nausea | #53 |
| purposepatients | #53 |
| nervous peripheral | #53 |
| cancer venous | #53 |
| receiving radiotherapy | #53 |
| toxicity time | #53 |
| tamoxifen antineoplastic agents | #53 |
| potential adjuvant | #53 |
| standard placebo | #54 |
| severe hot | #54 |
| recurrent disease | #54 |
| double‐blind trial | #54 |
| antiemetics antineoplastic | #54 |
| life topic humans | #54 |
| blood testing | #54 |
| 20 data | #54 |
| levetiracetam treatment | #54 |
| treatment months | #54 |
| pilot trial | #54 |
| fatigue inventory | #55 |
| serial levels | #55 |
| cachexia therapy | #55 |
| symptoms therapy | #55 |
| cancerdirected therapy | #55 |
| scalp cooling | #55 |
| treatment tobacco dependence | #55 |
| acupuncture cancer | #55 |
| bupropion treatment | #55 |
| diseases antineoplastic | #56 |
| time placebo | #56 |
| adjuvant endocrine treatment | #56 |
| undergoing chemotherapy | #56 |
| carboplatin female humans | #56 |
| symptoms hot | #56 |
| xaliproden | #56 |
| 12 courses | #57 |
| adjuvant colon | #57 |
| common terminology | #57 |
| benefit scale | #57 |
| placebo solution | #57 |
| recurrence symptoms | #57 |
| quality life questionnaire | #58 |
| ferric gluconate | #58 |
| pain peripheral | #58 |
| limited degree | #58 |
| points placebo | #58 |
| undergoing treatment | #58 |
| completion adjuvant chemotherapy | #58 |
| major bleeding enoxaparin | #58 |
| topical gel | #58 |
| skin dermatitis | #58 |
| compared oral | #58 |
| cachexia weight loss | #58 |
| data understanding | #59 |
| coprescription | #59 |
| safety rivaroxaban | #59 |
| weight appetite | #59 |
| chemotherapyinduced nausea | #59 |
| ocular irritation | #59 |
| placebo citalopram | #59 |
| chemotherapy cognitive | #59 |
| osteopaenia | #59 |
| patients hec | #59 |
| hb baseline | #60 |
| serotonergic effects | #60 |
| anticonvulsants antidepressive | #60 |
| study medication | #60 |
| colonoscopically | #60 |
| patients mirtazapine | #60 |
| sensitivity individuals | #61 |
| paroxetine fluoxetine | #61 |
| standard dosing | #61 |
| cancer patients study | #61 |
| bleomycin patients | #61 |
| 1 week treatment | #61 |
| tamoxifen metabolism | #61 |
| caregivers pain | #61 |
| doubleblind | #61 |
| 3 randomized | #61 |
| topic surveys life | #61 |
| pipn | #61 |
| lymphedema women | #61 |
| emla cream | #61 |
| alpha weight | #62 |
| efficacy fluoxetine | #62 |
| pain bleeding | #62 |
| dermatological toxicities | #62 |
| ocular toxicity | #62 |
| induced taste | #62 |
| venlafaxine placebo | #62 |
| fluorouracil induced | #62 |
| chemotherapy dose | #62 |
| recurrent disease patients | #62 |
| aged placebos | #63 |
| 105 months | #63 |
| patients disease recurrence | #63 |
| prior chemotherapy regimen | #63 |
| anorexia patients | #63 |
| integrative oncology | #63 |
| lessen | #63 |
| antibodies monoclonal carcinoma | #63 |
| ncictc | #63 |
| cyproheptadine | #64 |
| improvement sexual function | #64 |
| incidence rash | #64 |
| bupropion nicotine | #64 |
| versus placebo | #64 |
| alleviate | #64 |
| painful peripheral neuropathy | #64 |
| rivaroxaban enoxaparin | #64 |
| cyclohexanols | #64 |
| treatment chemotherapy | #64 |
| carboplatin oxaliplatin | #64 |
| patients cancer types | #64 |
| allelic variability | #64 |
| aged nausea | #64 |
| administration paclitaxel | #65 |
| 75 daily | #65 |
| validated patient | #65 |
| dalteparin treatment | #65 |
| agents double | #65 |
| 4 weeks week | #65 |
| patients comparisons | #65 |
| efficacy toxicity | #65 |
| appetite weight loss | #65 |
| survivorship issues | #65 |
| patients minocycline | #65 |
| diseases neoplasms | #66 |
| nicotine nasal | #66 |
| oncology clinical | #66 |
| study gabapentin | #66 |
| acetate therapy | #66 |
| food intake patients | #66 |
| placebo months | #66 |
| qol fatigue | #67 |
| life topic | #67 |
| clinician training | #67 |
| estrogen suppression | #67 |
| target doses | #67 |
| subcutaneous dalteparin | #68 |
| prevention smoking | #68 |
| baseline study | #68 |
| cachexia weight | #68 |
| hec | #68 |
| patients randomized | #68 |
| induced dermatitis | #68 |
| hormonal therapies | #68 |
| pilocarpine treatment | #68 |
| 46 95 | #68 |
| ongoing loss | #69 |
| fsfi score | #69 |
| skin surveys | #69 |
| vasomotor symptoms women | #69 |
| gained weight | #69 |
| debilitating | #69 |
| multifactorial syndrome | #70 |
| item score | #70 |
| women ais | #70 |
| surgery cancer | #70 |
| nonsignificant trends | #70 |
| induced ovarian | #70 |
| development severity | #70 |
| chemotherapy anemia | #70 |
| weight compared | #71 |
| major bleeding apixaban | #71 |
| week percentage | #71 |
| anthrapyrazole | #71 |
| infliximab combination | #71 |
| life referral | #71 |
| incidence severity | #71 |
| effects ginseng | #72 |
| oral drug administration | #72 |
| trials planning | #72 |
| systemic retinoids | #72 |
| placebo patches | #72 |
| cisplatin treated | #72 |
| patients pilot | #72 |
| humans lignans | #72 |
| ginseng treatment | #73 |
| chemotherapy supportive | #73 |
| ergotamines | #73 |
| chemoprevention trial | #73 |
| placebo | #73 |
| prospective pilot trial | #73 |
| weeks placebo | #73 |
| stage primary | #73 |
| rcts systematic reviews | #74 |
| fractional co2 laser | #74 |
| trial evaluating | #74 |
| qli | #74 |
| anemia antineoplastic | #74 |
| dronabinol | #74 |
| rash | #74 |
| women estrogen therapy | #74 |
| receiving chemotherapy | #74 |
| 353 patients | #75 |
| acid supplement | #75 |
| cancerrelated fatigue crf | #75 |
| nervous diseases | #75 |
| prevention | #75 |
| cycles cycle | #76 |
| inhibitors tamoxifen | #76 |
| weekly arm | #76 |
| acute skin | #76 |
| blind clinical | #76 |
| 95 01 | #77 |
| breast cancer paclitaxel | #77 |
| dose 90 | #77 |
| week p005 | #77 |
| alliance patients | #77 |
| hospice staff | #77 |
| anorexia weight loss | #77 |
| anemia darbepoetin | #77 |
| cancer randomized | #77 |
| tamoxifen postmenopausal | #77 |
| tamoxifen postmenopausal women | #78 |
| female humans insurance | #78 |
| 3 arm | #78 |
| patients zoledronic acid | #78 |
| values data | #78 |
| surgery year | #79 |
| efficacy lamotrigine | #79 |
| serum concentrations infliximab | #79 |
| vte recurrence | #79 |
| patients darbepoetin alfa | #79 |
| pain syndrome | #79 |
| week schedule | #79 |
| therapy antineoplastic | #79 |
| symptoms sensitivity | #79 |
| isoflavone supplements | #80 |
| week 4 | #80 |
| vomiting antiemetics | #80 |
| zoledronic acid treatment | #80 |
| life phase iii | #80 |
| time mastectomy | #80 |
| foot syndrome | #80 |
| period crossover | #81 |
| guideline recommendation | #81 |
| patient qol | #81 |
| oral oncology | #81 |
| study march | #81 |
| lowmolecular weight heparin | #81 |
| patients treatment arms | #81 |
| bupropion smoking | #82 |
| greater weight gain | #82 |
| standard clinical | #82 |
| backgroundchemotherapy | #82 |
| paroxetine patients | #82 |
| suggestion | #82 |
| day weeks | #83 |
| trpv1 trpa1 | #83 |
| orbital stability | #83 |
| recommendations article | #83 |
| patients participating | #83 |
| cinv patients | #84 |
| method female | #84 |
| trpm8 trpa1 | #84 |
| zinc sulfate | #84 |
| ice pack | #85 |
| systematic reviews rcts | #85 |
| cancer weight | #85 |
| neoplasm metastasis neoplasms | #85 |
| receiving placebo | #86 |
| ttf survival | #86 |
| cryotherapy patients | #86 |
| treatment nicotine dependence | #86 |
| mayo clinic | #86 |
| life cachexia | #87 |
| frequency severity | #87 |
| incidence osteoporosis | #87 |
| nicotine nasal spray | #87 |
| primary symptom | #87 |
| therapyinduced | #87 |
| baseline arms | #87 |
| pilot study safety | #87 |
| serum hepcidin levels | #87 |
| week 5 | #87 |
| methodspatients | #87 |
| acp documentation | #88 |
| anecdotal reports | #88 |
| integrative therapies | #88 |
| iu daily | #89 |
| treatment fatigue | #89 |
| putative mediator | #89 |
| cancer vte | #89 |
| male chemotherapy | #90 |
| outcome venlafaxine | #90 |
| morphine pharmacokinetics | #90 |
| clinical oncology asco | #90 |
| delayed cinv | #91 |
| tolerated patients | #91 |
| symptoms including | #91 |
| endoxifen concentrations | #91 |
| iii efficacy | #91 |
| ncorp | #91 |
| scores placebo | #91 |
| arm treatment | #91 |
| cisplatin oxaliplatin | #92 |
| trials treatment | #92 |
| nerve pain | #92 |
| completion chemotherapy | #92 |
| patients upfront | #92 |
| patients paroxetine | #92 |
| ameliorating | #93 |
| mometasone | #94 |
| breast cancer survivors | #94 |
| anemic patients | #94 |
| apixaban dose | #94 |
| questionnaires survival | #94 |
| quiet stance | #94 |
| duloxetine hydrochloride | #94 |
| arm 3 | #94 |
| 1 primary | #94 |
| neoplasms quality life | #94 |
| alfa patients | #95 |
| cancerrelated pain | #95 |
| common symptoms | #95 |
| patients appetite | #95 |
| prevention management | #96 |
| ccop | #96 |
| mayo clinic rochester | #96 |
| 0 10 | #96 |
| hlaa2 patients | #96 |
| udi | #96 |
| failure chemotherapy | #96 |
| patients completion | #96 |
| paclitaxel patient | #97 |
| adjuvant therapy survival | #97 |
| oral mucositis patients | #97 |
| acute vte | #97 |
| pyrexia | #97 |
| crnmb | #98 |
| painful area | #98 |
| agents paclitaxel | #98 |
| completed study | #98 |
| alleviating | #98 |
| 15 points | #98 |
| treatment tolerability | #98 |
| identical placebo | #98 |
| preliminary data | #98 |
| text review | #98 |
| fatigue insomnia | #99 |
| patient medical | #99 |
| 5fu leucovorin | #99 |
| induced esophagitis | #99 |
| patient questionnaires | #99 |
| pregnadienediols | #99 |
| 4 weeks baseline | #99 |
| 5fluorouracil oxaliplatin | #99 |
| bcca | #99 |
| topic cyclophosphamide | #99 |
| difference incidence | #99 |
| qlq | #100 |
| oncology outpatients | #100 |
| clinician communication | #100 |
| 10 doses | #100 |
| survival nsclc | #100 |
| male sex factors | #100 |
| antineoplastic agents life | #101 |
| oncology asco | #101 |
| nortriptyline | #101 |
| oncology clinicians | #101 |
| 5 based | #101 |
| 275 patients | #101 |
| humans life | #101 |
| lung cancer chemoprevention | #101 |
| lidocaine lidocaine | #101 |
| postresection | #101 |
| methods trial | #102 |
| placebo 1 year | #102 |
| variance clinical trials | #103 |
| reported effects | #103 |
| patients anorexia | #104 |
| purposeprevious | #104 |
| races ethnicities | #104 |
| quality life data | #104 |
| 3106 | #104 |
| patients 150 | #105 |
| phytogenic clinical trials | #105 |
| chemotherapy cycle | #105 |
| leap | #105 |
| 12 24 months | #105 |
| diseases treatment | #105 |
| stool samples patients | #106 |
| compounds oxaliplatin | #106 |
| nutritional determinants | #106 |
| infusion site | #106 |
| neuropathy | #106 |
| dalteparin patients | #106 |
| dfmo | #106 |
| months relapse | #106 |
| trial studies | #106 |
| pain intensity ratings | #107 |
| humans menopause | #107 |
| cycle cycles | #107 |
| anastrozole letrozole | #107 |
| versus dexamethasone | #107 |
| valeriana officinalis | #107 |
| epoetin alfa patients | #107 |
| urogenital diseases | #107 |
| life topic severity | #108 |
| relapse prevention | #108 |
| week study | #108 |
| women experience | #108 |
| time toxicity | #108 |
| breast cancer tamoxifen | #108 |
| women vasomotor symptoms | #109 |
| strong prognostic factor | #109 |
| patients guideline | #109 |
| female urogenital | #109 |
| levocarnitine | #109 |
| treatment cancer pain | #109 |
| mouthwash | #109 |
| patients cancer treatment | #110 |
| life adverse events | #110 |
| combined paclitaxel | #110 |
| oxaliplatin therapy | #110 |
| clinic rochester | #110 |
| prevention bone loss | #111 |
| vomiting adult | #111 |
| cmf chemotherapy | #111 |
| egfr inhibitor | #111 |
| insomnia pain | #112 |
| function suppression | #112 |
| dosing schedules | #112 |
| adverse events ctcae | #113 |
| visits patient | #113 |
| reassess | #113 |
| –iii | #113 |
| vestibulitis | #113 |
| patients arms | #113 |
| vaginal diseases | #113 |
| colorectal neoplasia | #113 |
| functional iron deficiency | #113 |
| agents hormonal | #113 |
| treatment arms patients | #113 |
| single nucleotide variants | #114 |
| patients olanzapine | #114 |
| months 3 | #114 |
| diseases breast | #114 |
| hfsd | #114 |
| alopecia patients | #114 |
| acitretin | #114 |
| qol patient | #114 |
| therapy induced | #114 |
| cachexia humans | #114 |
| dietary lignans | #114 |
| patients anthracycline | #115 |
| studies randomized | #115 |
| combination nicotine | #115 |
| crci | #115 |
| laser therapy lasers | #115 |
| rivaroxaban venous | #115 |
| letrozole tamoxifen | #115 |
| placebo postmenopausal women | #116 |
| treatment arm | #116 |
| 2007 guidelines | #117 |
| nk1 receptor antagonist | #117 |
| patients peripheral neuropathy | #117 |
| oral factor | #117 |
| induction ornithine decarboxylase | #117 |
| symptoms chemotherapy | #117 |
| recurrence diagnosis | #118 |
| oral antineoplastic agents | #118 |
| appetite stimulant | #118 |
| preventive therapies | #119 |
| trpa1 trpv1 | #119 |
| noradrenaline reuptake | #119 |
| diseases pain | #119 |
| patients weekly paclitaxel | #119 |
| trials conducted | #119 |
| 3915 | #119 |
| 750 day | #120 |
| definition classification | #120 |
| participants arms | #120 |
| original report | #120 |
| resultswhile | #120 |
| clinical histories | #120 |
| treatment weeks | #120 |
| olanzapine placebo | #120 |
| untoward | #121 |
| fullerton | #121 |
| patients cancers | #121 |
| hormonal agents | #121 |
| placebo double | #121 |
| postmenopausal postmenopause | #121 |
| induced ocular | #121 |
| cancer multiple | #122 |
| nervous agents | #122 |
| oxaliplatin folfox | #122 |
| objective review | #123 |
| rolapitant | #123 |
| stable dose | #123 |
| netupitant | #123 |
| acute oral | #123 |
| cancer quality | #123 |
| weeks 4 | #123 |
| surgery analysis | #123 |
| skin pain | #123 |
| patients diploid tumors | #124 |
| survivors breast cancer | #124 |
| pros baseline | #124 |
| treatment letrozole | #124 |
| neuropathic pain patients | #124 |
| isoflavones genistein | #124 |
| rivaroxaban compared | #124 |
| 1 month patients | #125 |
| 90 dose | #125 |
| week dose | #125 |
| neurotoxic agents | #126 |
| resultsfour | #126 |
| factors odds | #126 |
| fsfi | #127 |
| genetic quality | #127 |
| anorexia | #127 |
| promising agents | #127 |
| patients physicians | #127 |
| diagnosis metastatic disease | #127 |
| recurrent adenomas | #127 |
| hormonal breast | #127 |
| alfa erythropoietin | #128 |
| arms patients | #128 |
| weight concerns | #128 |
| belladonna | #128 |
| cancerassociated vte | #128 |
| uncommon variants | #128 |
| postural instability | #129 |
| clinical trial patients | #129 |
| resultsforty | #129 |
| neoplasms quality | #129 |
| 5 leucovorin | #129 |
| vomiting cinv | #129 |
| agents neoplasms | #129 |
| problem patients | #130 |
| patientreported outcome | #130 |
| control arms | #130 |
| serum baseline | #130 |
| function fsfi | #131 |
| cancer fatigue | #131 |
| bmd tscore | #131 |
| prognostic variables | #131 |
| 150 iu | #131 |
| treatment toxicities | #131 |
| neurotoxicity syndromes | #132 |
| onycholysis | #132 |
| pilot data | #132 |
| efficacy vitamin | #132 |
| cancerrelated symptoms | #132 |
| relapse smoking | #132 |
| assessable | #133 |
| cachexia patients | #133 |
| progress report | #133 |
| topical treatment | #133 |
| ganglion block | #134 |
| 5 placebo | #134 |
| endodermal sinus tumor | #134 |
| ginseng panax | #134 |
| symptom control | #134 |
| cancers patients | #135 |
| cold hyperalgesia | #135 |
| common adverse effects | #135 |
| toxt | #135 |
| chemotherapy 5 | #135 |
| agents generation | #135 |
| 150 women | #135 |
| bmd postmenopausal women | #135 |
| painful neuropathy | #136 |
| weekly therapy | #136 |
| npy levels | #136 |
| patientlevel pooled analysis | #136 |
| symptomatic benefit | #136 |
| bothersome | #136 |
| stage cancer | #137 |
| life physical function | #137 |
| substantial benefit | #137 |
| agents bortezomib | #137 |
| study trials | #137 |
| poor qol | #137 |
| intrapatient | #137 |
| severe fatigue | #137 |
| percentage reduction | #137 |
| accrued | #138 |
| grade stage | #138 |
| zoledronic | #138 |
| hfs patients | #138 |
| underwent mastectomy | #139 |
| factbr | #139 |
| therapy breast | #139 |
| chemoprevention studies | #139 |
| advanced lung | #139 |
| incurable cancer | #139 |
| patients advanced cancer | #140 |
| liquid suspension | #140 |
| breast chest wall | #140 |
| oxaliplatin chemotherapy | #141 |
| patients placebo | #141 |
| paclitaxel weekly | #141 |
| tamoxifen placebo | #142 |
| financial concerns | #142 |
| patients levetiracetam | #142 |
| disclose | #142 |
| protocols breast | #143 |
| medicine clinical | #143 |
| fluorouracil 5 | #143 |
| european organisation | #144 |
| preoperative magnetic | #144 |
| allopurinol placebo | #144 |
| snv | #144 |
| fluorouracil humans | #145 |
| agents bone | #145 |
| eortc qlq | #145 |
| debilitating condition | #145 |
| vaginal cytology | #145 |
| evidence loe | #145 |
| eligible women | #146 |
| surgery type | #146 |
| oral olanzapine | #148 |
| dietary counselling | #148 |
| backgroundwomen | #148 |
| volatile plants | #148 |
| numeracy | #149 |
| desipramine treatment | #149 |
| adjuvant systemic | #150 |
| n201 | #150 |
| predict recurrence | #150 |
| venlafaxine treatment | #150 |
| patients receive | #151 |
| multinational association | #151 |
| women estrogen | #151 |
| intravenous access | #151 |
| methodologic | #151 |
| prior chemotherapy regimens | #151 |
| response rate survival | #151 |
| daily diaries | #151 |
| tumor recurrence patients | #152 |
| caa patients | #152 |
| groups symptoms | #152 |
| ovarian function suppression | #152 |
| balance impairments | #152 |
| oral mucositis | #152 |
| 14 week | #152 |
| cramping | #153 |
| 80 dose | #154 |
| carboplatin trastuzumab | #154 |
| cindices | #155 |
| dermatomes | #155 |
| adjuvant systemic therapy | #155 |
| mangafodipir | #156 |
| combination chemotherapy cisplatin | #156 |
| life randomized | #156 |
| integrated palliative | #156 |
| infliximab 5 | #156 |
| vinblastine bleomycin | #156 |
| hyperalimentation | #156 |
| methods randomized | #156 |
| fsds | #156 |
| breast cancer trastuzumab | #157 |
| common terminology criteria | #157 |
| women breast carcinoma | #157 |
| gait stability | #157 |
| racially diverse | #157 |
| arm versus | #158 |
| oncology study | #158 |
| vomiting nausea | #158 |
| study initiation | #158 |
| survivors colorectal | #159 |
| induced nausea | #159 |
| physicians patients | #159 |
| chemotherapy breast cancer | #159 |
| weekly doses | #159 |
| iii clinical | #159 |
| treatment postmenopausal women | #160 |
| chemotherapy quality | #160 |
| stellate ganglion | #160 |
| paclitaxel taxol | #160 |
| major problem | #160 |
| cancer pain patients | #160 |
| european organisation treatment | #160 |
| validity life | #161 |
| women hormone therapy | #161 |
| risk infertility | #161 |
| estrogen depletion | #161 |
| data efficacy | #163 |
| neoplasms pain | #164 |
| efficacy women | #164 |
| mometasone furoate | #165 |
| cisplatin vinblastine | #165 |
| current project | #165 |
| patients 1 month | #166 |
| skeletal events | #166 |
| pharmacokinetic analyses | #166 |
| life topic surveys | #167 |
| illness surveys questionnaires | #167 |
| osteoporosis prevention | #167 |
| chemotherapy‐induced nausea | #168 |
| direct inhibitors | #168 |
| chemotherapy groups | #168 |
| anthracycline | #168 |
| patients data | #169 |
| 432 patients | #169 |
| patients adenomas | #169 |
| menopause symptoms | #169 |
| dosing patients | #169 |
| ixabepilone | #170 |
| management chronic pain | #170 |
| disease cmt | #171 |
| daily placebo | #171 |
| global quality | #171 |
| rochester | #171 |
| prospective clinical trials | #171 |
| chemotherapy completion | #172 |
| prestudy | #172 |
| label pilot | #173 |
| placebos | #173 |
| judicious | #173 |
| hot flushes | #173 |
| lamotrigine placebo | #173 |
| impaired balance | #173 |
| 1 year therapy | #173 |
| pilot feasibility study | #174 |
| prospective evaluation | #174 |
| phase iii trial | #174 |
| diarrhoea patients | #174 |
| methylphenidate placebo | #174 |
| male breast cancer | #175 |
| physician order | #175 |
| cancer cancer treatment | #175 |
| arthralgia | #175 |
| decreased quality | #175 |
| baseline weight | #176 |
| life assessments | #177 |
| weeks women | #177 |
| treatment 14 | #177 |
| bodyweights | #178 |
| thirty percent | #178 |
| life baseline | #179 |
| bolus fluorouracil | #179 |
| expected benefits | #179 |
| bothered | #179 |
| treatmentrelated toxicity | #179 |
| sufferer | #180 |
| phase evaluation | #181 |
| ginseng | #182 |
| oxaliplatin 5fluorouracil | #182 |
| gain weight | #182 |
| escalations | #182 |
| darbepoetin | #182 |
| toxicity criteria | #183 |
| organisation treatment | #183 |
| peri postmenopausal women | #183 |
| biostatisticians | #184 |
| effects chemotherapy | #184 |
| infliximab antibodies | #184 |
| received oral | #184 |
| acute pain | #184 |
| acetyll | #184 |
| white smokers | #184 |
| prognostic criteria | #184 |
| tube primary | #184 |
| additional chemotherapy | #185 |
| outcome measures life | #185 |
| reported sexual | #185 |
| arm volume | #186 |
| delayed nausea | #187 |
| treatment 4 weeks | #187 |
| patients drug | #187 |
| treating | #187 |
| cinv | #187 |
| management breast cancer | #188 |
| reduction therapy | #188 |
| troublesome | #188 |
| tamoxifen letrozole | #188 |
| week follow | #188 |
| strong prognostic | #188 |
| lessened | #188 |
| adjuvant decision | #188 |
| aching | #189 |
| oxaliplatin dose | #189 |
| neoplasia female humans | #189 |
| placebo study | #190 |
| week 1 | #190 |
| aged nitriles | #190 |
| protocol therapy | #190 |
| survivors breast | #190 |
| antiemetic regimens | #190 |
| cancer cancer survivors | #191 |
| twentyfive patients | #191 |
| completed baseline | #191 |
| aches | #192 |
| toxicity patients | #192 |
| aspirin incidence | #192 |
| chronic lymphedema | #192 |
| fortysix patients | #192 |
| patients increases | #192 |
| manuscript | #192 |
| treatment cancer patients | #192 |
| cimicifuga racemosa | #193 |
| assigned receive | #193 |
| humans isoflavones | #193 |
| weekly trastuzumab | #194 |
| effective agents | #194 |
| 25 women | #194 |
| pain breast | #195 |
| weight loss patients | #195 |
| 3 fatty | #195 |
| ornithine decarboxylase activity | #195 |
| acids double | #196 |
| resultsdata | #196 |
| trial designs | #197 |
| palonosetron dexamethasone | #197 |
| pituitaryadrenal axis | #197 |
| postmenopausal patients | #198 |
| resultstwo | #198 |
| surveillance strategy | #198 |
| toxicity profiles | #198 |
| accent | #199 |
| organization treatment | #199 |
| nicotine patch | #199 |
| women menopause | #199 |
| delayed emesis | #199 |
| patients letrozole | #199 |
| culminates | #199 |
| percent reduction | #200 |
| adjuvant interferon | #200 |
| oral glutamine | #201 |
| menopause premature | #201 |
| primary goal | #202 |
| imiquimod | #202 |
| item responses | #202 |
| treatment week | #202 |
| greater 5 | #202 |
| treatment bmd | #202 |
| hormonal treatments | #203 |
| cancer anemia | #203 |
| bmd postmenopausal | #203 |
| pelvic radiation therapy | #204 |
| plo | #204 |
| treated placebo | #204 |
| composition cachexia | #204 |
| induced oral | #205 |
| unwilling | #206 |
| udi6 | #206 |
| dalteparin | #206 |
| chemotherapy drugs | #206 |
| leucovorin patients | #206 |
| placebo 8 | #206 |
| mice cisplatin | #207 |
| pharmacologic interventions | #207 |
| heat hyperalgesia | #207 |
| humans leucovorin | #208 |
| reduced food intake | #208 |
| 4 8 weeks | #208 |
| incurable | #208 |
| 5 daily | #209 |
| chemotherapy | #209 |
| hands patients | #209 |
| controlled evaluation | #210 |
| lamotrigine | #210 |
| methotrexate 5 | #210 |
| estrogen receptor modulators | #210 |
| gel application | #211 |
| initials | #212 |
| vomiting patients | #212 |
| methodsthis | #212 |
| diagnosis recurrence | #212 |
| regionally advanced | #212 |
| charcotmarietooth disease | #213 |
| trial vitamin | #213 |
| docetaxel cyclophosphamide | #213 |
| dexamethasone control | #214 |
| placebo 6 weeks | #214 |
| patient weight | #214 |
| oncology practices | #214 |
| oxaliplatin | #215 |
| olanzapine 5 | #215 |
| 15 minutes | #215 |
| december patients | #215 |
| antiemetic therapy | #215 |
| neoplasms cross | #216 |
| prostate cancer survivors | #216 |
| gabapentin humans | #217 |
| tamoxifen users | #217 |
| women tamoxifen | #217 |
| women breast cancer | #217 |
| patients duloxetine | #217 |
| nonmajor | #218 |
| 10 daily | #218 |
| purposethe purpose | #218 |
| placebo weeks | #218 |
| hot | #218 |
| —reply | #218 |
| aprepitant | #218 |
| current management | #218 |
| palliative oncology | #219 |
| nmscs | #219 |
| transdermal fentanyl | #219 |
| life humans | #219 |
| sexual symptoms | #220 |
| sublingual administration | #220 |
| nonabsorbable | #220 |
| pregabalin patients | #221 |
| society clinical oncology | #221 |
| moderate pain | #221 |
| painful peripheral | #221 |
| ornithine decarboxylase odc | #221 |
| prospective study women | #222 |
| methylphenidate modafinil | #222 |
| primary breast cancer | #222 |
| ginkgo biloba egb | #222 |
| lymphedema patients | #222 |
| treatment postmenopausal | #222 |
| neoplasms palliative | #222 |
| relieving | #222 |
| furoate | #223 |
| randomized doubleblind study | #223 |
| prevention patients | #224 |
| quinquefolius | #225 |
| computerized physician | #225 |
| 99 months | #225 |
| vaginal estrogen | #226 |
| partial mastectomy | #226 |
| agent patients | #226 |
| turmoil | #227 |
| bupropion | #227 |
| pain presence | #227 |
| trial | #228 |
| clinical situation | #228 |
| nondiploid | #229 |
| secondary endpoint | #229 |
| 200 iu | #229 |
| akt inhibitor | #230 |
| physicians quality | #230 |
| antidepressive | #230 |
| editorials | #230 |
| anthracycline cardiotoxicity | #230 |
| cancer recommendations | #230 |
| eating disorders humans | #230 |
| placebo 10 | #230 |
| hospice patients | #230 |
| rashes | #231 |
| based adjuvant | #231 |
| vitamin effects | #231 |
| conclusionsthe | #232 |
| cachexia cytokines | #232 |
| lightheadedness | #232 |
| handfoot syndrome | #232 |
| time study | #232 |
| nonpharmacologic | #233 |
| fluoxetine paroxetine | #233 |
| treatment vte | #234 |
| 4 doses | #234 |
| thirty women | #234 |
| acute symptoms | #234 |
| women hot | #234 |
| sucralfate | #235 |
| 375 day | #235 |
| relieve | #235 |
| tamoxifen neoplasms chemotherapy | #235 |
| arm 95 | #235 |
| day response | #235 |
| effective treatments | #236 |
| placebo gel | #237 |
| premenopausal patients | #237 |
| incidence grade | #238 |
| letrozole patients | #238 |
| antiemetics | #238 |
| flash | #238 |
| postoperative monitoring | #238 |
| survivors treatment | #238 |
| improved bioavailability | #239 |
| nonpharmacologic interventions | #239 |
| adjuvant 5 | #239 |
| chemotherapy placebo | #239 |
| oncology clinic | #239 |
| methodswomen | #239 |
| menopause middle | #239 |
| overexpressing metastatic | #239 |
| oral complications | #240 |
| neoadjuvant therapy surgery | #240 |
| cachexia syndrome | #240 |
| treatment breast cancer | #240 |
| independent tests | #241 |
| participants randomized | #242 |
| stinging | #242 |
| aged paclitaxel | #243 |
| small doses | #243 |
| tetracycline | #244 |
| 3 arms | #245 |
| epoetin alfa | #245 |
| appetite stimulants | #246 |
| common practice | #246 |
| adjuvant oxaliplatin | #246 |
| efficacy placebo | #247 |
| mouthwashes | #248 |
| cachexia cancer | #248 |
| 800 iu | #249 |
| dysgeusia | #249 |
| survivors adult | #250 |
| randomized sham | #250 |
| item scores | #250 |
| loss bmd | #250 |
| major problems | #251 |
| patients physical | #251 |
| 689 | #251 |
| coasting | #252 |
| topic vitamin | #252 |
| menopause women | #252 |
| randomised studies | #253 |
| primary point | #253 |
| armodafinil | #253 |
| average intensity | #254 |
| moderate degree | #254 |
| nasal spray | #254 |
| recurrence registries | #255 |
| chemotherapy breast | #255 |
| longitudinal followup | #256 |
| prospective clinical | #256 |
| therapy women | #257 |
| cancer treatment | #257 |
| antidepressant | #257 |
| neoplasms randomized | #257 |
| dyspareunia | #258 |
| women treated | #258 |
| new therapeutic approaches | #258 |
| pretreatment levels | #258 |
| hydrochloride | #259 |
| rigors | #259 |
| tube cancer | #260 |
| opioid doseresponse relationship | #260 |
| inhibitors treatment | #260 |
| 1 baseline | #261 |
| common problem | #261 |
| repeated measures | #261 |
| patients cancer | #261 |
| chronic post | #262 |
| patients ovarian cancer | #262 |
| citalopram treatment | #262 |
| dosage levels | #263 |
| decision framework | #263 |
| months treatment | #263 |
| management options | #263 |
| hematinics | #264 |
| duloxetine placebo | #264 |
| treatment oxaliplatin | #264 |
| phytogenic | #264 |
| recommendations quality | #265 |
| outcome administration | #265 |
| preoperative mri | #266 |
| treatmentrelated deaths | #266 |
| individual items | #267 |
| placebo 8 weeks | #267 |
| paresthesia | #267 |
| treatment cancer | #267 |
| surgery adjuvant | #267 |
| substantiation | #267 |
| impact quality | #268 |
| adult cancer survivors | #268 |
| 208 patients | #269 |
| patients rash | #270 |
| ginkgo biloba | #270 |
| nausea | #270 |
| signaled | #270 |
| 80 90 | #271 |
| moderate correlations | #271 |
| patients octreotide | #271 |
| estrogen antagonists | #271 |
| bridged ring | #272 |
| distressing | #272 |
| score baseline | #272 |
| weekly | #272 |
| dna test | #272 |
| treatment 95 | #272 |
| performance status patients | #272 |
| control trials | #272 |
| placebo‐controlled trial | #273 |
| abstinence rates | #273 |
| dryness | #274 |
| sham treatment | #274 |
| oncology clinical trials | #274 |
| valeriana | #275 |
| induced cisplatin | #275 |
| gross disease | #275 |
| patients caa | #276 |
| chemoprevention trials | #277 |
| treatment breast | #278 |
| perspiration | #278 |
| prominent | #279 |
| cimicifuga | #279 |
| patients symptoms | #279 |
| patients hospice | #279 |
| therapeutic options | #279 |
| biomarkers disease humans | #279 |
| individual patient | #280 |
| breast cancer outcomes | #280 |
| cartilage patients | #280 |
| cholinergic antagonists | #280 |
| patients frequency | #280 |
| psychometric testing | #281 |
| doxorubicin cyclophosphamide | #281 |
| zoledronic acid patients | #281 |
| antidepressive agents | #282 |
| stage colon | #282 |
| chamomile | #282 |
| greater severity | #284 |
| women effects | #284 |
| completed questionnaires | #284 |
| gabapentin treatment | #285 |
| smoking abstinence | #285 |
| fatigue crf | #286 |
| early discontinuation | #286 |
| symptoms function | #287 |
| colorectal lung | #287 |
| acid adult | #287 |
| weeks patients | #287 |
| function quality | #287 |
| female hormone | #287 |
| paps | #287 |
| aromatase inhibitor therapy | #288 |
| hot flush | #288 |
| life survival | #290 |
| eligible patients | #291 |
| qualitative approach | #292 |
| clinical trial participation | #292 |
| common symptom | #292 |
| treatment target | #292 |
| discouraged | #292 |
| mucositis oral | #293 |
| 1636 | #294 |
| cbdca | #294 |
| pain symptoms | #294 |
| weight gain patients | #294 |
| citalopram | #295 |
| bone loss patients | #295 |
| monographs | #295 |
| vinca alkaloids | #295 |
| testosterone supplementation | #295 |
| toxicity evaluation | #296 |
| primary peritoneal cancer | #297 |
| questionnaires treatment | #298 |
| patients entered | #298 |
| aspirin placebo | #298 |
| peripheral nervous | #299 |
| feet | #299 |
| neoplasms cyclophosphamide | #299 |
| inhibitors ais | #300 |
| radiation dermatitis | #300 |
| hypothetical scenarios | #300 |
| shooting | #301 |
| treated combination | #301 |
| survival trials | #302 |
| nogalamycin | #302 |
| octreotide | #302 |
| stage grade | #303 |
| treatment serum | #303 |
| acute neurotoxicity | #303 |
| nausea vomiting | #304 |
| subscale scores | #304 |
| symptoms pain | #304 |
| prospective clinical trial | #305 |
| schedule female | #305 |
| placebo groups | #305 |
| complementary therapies | #305 |
| prime time | #305 |
| factg | #306 |
| global quality life | #306 |
| shortread | #307 |
| prochlorperazine | #307 |
| inflammatory breast cancer | #307 |
| aromatase inhibitor | #307 |
| placebo treatment | #307 |
| apixaban | #308 |
| drug embryo | #308 |
| aged cancer | #308 |
| neoplasms chemotherapy | #308 |
| darbepoetin alfa | #309 |
| studies double | #310 |
| zoledronic acid | #310 |
| riskstratification | #311 |
| individual subject | #311 |
| lung docetaxel | #311 |
| cancer receiving | #311 |
| advanced cancer | #311 |
| placebo‐controlled | #312 |
| epoetin | #312 |
| testosterone placebo | #312 |
| patients cycle | #313 |
| musculoskeletal symptoms | #313 |
| cancer adjuvant | #314 |
| syndrome aps | #314 |
| or10 | #314 |
| operative chemotherapy | #315 |
| new primary | #315 |
| article evidence | #316 |
| organoplatinum | #316 |
| blinded | #317 |
| symptoms breast | #317 |
| bfi | #317 |
| double‐blind | #317 |
| sesame oil | #317 |
| ambulatory patients | #317 |
| rivaroxaban patients | #318 |
| efficacy treatment | #319 |
| irox | #319 |
| informed decisions | #321 |
| life differences | #322 |
| dietary counseling | #322 |
| thromboembolism anticoagulants | #323 |
| monthly intervals | #324 |
| smokers nicotine | #324 |
| glutamine humans | #324 |
| preventing | #325 |
| breast radiotherapy | #326 |
| nsclc chemotherapy | #326 |
| titrate | #327 |
| patients ductal carcinoma | #327 |
| compared baseline | #327 |
| continuation phase | #328 |
| oral nutritional supplements | #329 |
| vte cancer patients | #329 |
| conducted evaluate | #329 |
| lymphedema | #329 |
| treatment 1 year | #329 |
| antagonists female | #329 |
| patients resected | #329 |
| controlled clinical | #330 |
| patients nasal | #330 |
| arms | #330 |
| potential efficacy | #330 |
| future clinical trials | #330 |
| polymerase inhibitor | #331 |
| lozenge | #332 |
| cancer ontario | #332 |
| diagnosed primary | #332 |
| 80 anemia | #334 |
| placebo patients | #334 |
| patients daily | #334 |
| time disease | #335 |
| paclitaxel therapy | #336 |
| 128 patients | #336 |
| pain scale | #336 |
| ongoing clinical | #336 |
| relative benefits | #336 |
| 5 fluorouracil | #337 |
| sublingual | #337 |
| adjuvant letrozole | #337 |
| surveillance guidelines | #338 |
| survival 5 years | #338 |
| discernible | #339 |
| flutamide | #340 |
| order entry | #340 |
| treatment proportion | #341 |
| patients 4 weeks | #341 |
| mastectomy radiotherapy | #341 |
| eligible participants | #341 |
| osteopenia osteoporosis | #342 |
| fallopian tube cancer | #342 |
| cancer cachexia | #342 |
| diseases quality | #343 |
| society clinical | #343 |
| tooth disease | #343 |
| pilot randomized | #344 |
| epha5 | #345 |
| skeletal neoplasms | #345 |
| clinicians patients | #345 |
| clinical problems | #346 |
| mk2206 | #346 |
| accruing | #346 |
| therapy pain | #347 |
| adverse events groups | #347 |
| coumarin | #347 |
| mucositis patients | #348 |
| antineoplastic therapy | #349 |
| sham acupuncture | #349 |
| baseline quality | #350 |
| adjuvant folfox | #350 |
| vast majority | #350 |
| induced acute | #350 |
| dehydroepiandrosterone dhea | #351 |
| dose schedule | #351 |
| treatment citalopram | #351 |
| study therapy | #352 |
| paclitaxel | #353 |
| patientreported outcomes | #353 |
| endodermal sinus | #353 |
| response letter | #353 |
| letrozole | #355 |
| risedronate | #355 |
| cancer life | #355 |
| pain baseline | #356 |
| vomiting | #359 |
| adjuvant colonic | #359 |
| skin toxicities | #359 |
| ductal situ carcinoma | #360 |
| wellknown | #360 |
| cryotherapy | #360 |
| potential benefit | #360 |
| clin oncol | #360 |
| diaries | #361 |
| began | #361 |
| direct oral | #362 |
| pelvic radiation | #362 |
| ovarian suppression | #363 |
| pain measures | #363 |
| nonpharmacological | #363 |
| calculators | #363 |
| flaxseed | #363 |
| cancer surveillance | #363 |
| docetaxel paclitaxel | #365 |
| ovarian fallopian | #365 |
| cddp | #365 |
| completing | #365 |
| local prognosis receptor | #365 |
| bioavailable testosterone | #366 |
| optimal frequency | #366 |
| patients delayed | #366 |
| pain cancer | #366 |
| management cancer | #366 |
| scalp | #367 |
| weeks study | #368 |
| scale 0 | #368 |
| 5‐year | #368 |
| aged neoplasms | #369 |
| scheduled | #369 |
| hrt risk | #370 |
| skeletalrelated events | #371 |
| cancer received | #371 |
| gamma aminobutyric acid | #372 |
| orally daily | #372 |
| skin toxicity | #373 |
| symptoms patients | #373 |
| 5fluorouracil 5fu | #373 |
| ecogps | #374 |
| resected stage | #374 |
| paclitaxel dose | #374 |
| ovarian failure | #374 |
| irreversible damage | #374 |
| clinical oncology | #374 |
| −005 | #375 |
| decreasing | #376 |
| women breast | #376 |
| therapy based | #376 |
| blood test | #377 |
| medroxyprogesterone acetate | #377 |
| week patients | #378 |
| polyneuropathy | #378 |
| drowsiness | #378 |
| assessable patients | #378 |
| humans specificity | #378 |
| nociceptors | #379 |
| national cancer institute | #380 |
| telerehabilitation | #381 |
| fura | #381 |
| loss skeletal | #381 |
| 4 treatment | #382 |
| unacceptable toxicity | #383 |
| leucovorin | #383 |
| organoplatinum compounds | #383 |
| disputes | #384 |
| target dose | #384 |
| trials involving | #384 |
| function pain | #384 |
| adverse event | #384 |
| 402 | #384 |
| patients capecitabine | #384 |
| 5fluorouracil leucovorin | #385 |
| leptin patients | #385 |
| conservation agents | #385 |
| fourths | #386 |
| density conservation | #386 |
| 2 treatment | #388 |
| androgendeprivation therapy | #389 |
| glutathione gsh | #390 |
| treatment women | #390 |
| advanced adenomas | #391 |
| aromatase inhibitors ais | #392 |
| sexual desire | #392 |
| adjuvant trials | #394 |
| 4 weeks | #394 |
| dying patients | #394 |
| early palliative | #395 |
| life breast | #396 |
| discontinuation rates | #396 |
| olanzapine | #397 |
| cytotoxics | #397 |
| ring compounds | #397 |
| humans mastectomy | #397 |
| performance score | #397 |
| 1280 | #398 |
| patients randomly | #398 |
| paired tests | #398 |
| life data | #399 |
| peripheral neurotoxicity | #400 |
| intramuscular | #400 |
| questionnaires treatment outcome | #400 |
| fatty acid supplementation | #400 |
| chemotherapy colorectal | #400 |
| withdrew | #400 |
| 3 cohorts | #401 |
| estrogen receptors biomarkers | #401 |
| assigned | #401 |
| 8090 | #401 |
| entered | #402 |
| loe | #402 |
| evidencebased | #402 |
| sadenosyllmethionine | #403 |
| female humans life | #403 |
| acid female | #403 |
| 5 weeks | #405 |
| female fluorouracil | #406 |
| baseline demographics | #406 |
| responding patients | #408 |
| cisplatin induced | #409 |
| keratolytic | #410 |
| life aged | #411 |
| patients 5fu | #411 |
| topic neoplasms | #412 |
| female hemorrhage humans | #412 |
| regimens patients | #414 |
| ornithine decarboxylase | #414 |
| based chemotherapy | #415 |
| placebo 2 | #415 |
| pain qol | #415 |
| acetate | #415 |
| oxaliplatin based | #415 |
| patient factors | #416 |
| oncology neoplasms | #416 |
| carboplatin patients | #416 |
| gabapentinoids | #417 |
| platinum agents | #417 |
| prospective pilot | #417 |
| delayed | #417 |
| receiving | #418 |
| nighttime sleep | #419 |
| metastatic breast cancer | #419 |
| 0 4 | #419 |
| adjuvant hormonal therapy | #419 |
| case series patients | #419 |
| antiemetic prophylaxis | #420 |
| tcl1a | #421 |
| study entry | #421 |
| tamoxifen women | #421 |
| controlled pilot | #421 |
| cancer purpose | #421 |
| directed therapy | #422 |
| selfreported symptoms | #422 |
| severities | #422 |
| fourth week | #422 |
| pyridones | #423 |
| adequately | #423 |
| arm 2 | #423 |
| 5 trials | #423 |
| neurophysiologic | #424 |
| anastrozole | #425 |
| androgen ablation | #425 |
| tamoxifen | #425 |
| complementary alternative | #426 |
| ongoing clinical trials | #426 |
| baseline 6 weeks | #427 |
| prevention vte | #427 |
| gain adult | #428 |
| treating patients | #428 |
| primary peritoneal | #428 |
| creatine | #429 |
| greater percentage | #429 |
| adjectives | #430 |
| desipramine | #430 |
| laser therapy | #431 |
| fatigue humans | #431 |
| methodsa | #431 |
| glycitein | #431 |
| contraindicated | #431 |
| detection colorectal | #431 |
| hgb | #431 |
| symptom management | #432 |
| diploid tumors | #432 |
| joint symptoms | #433 |
| sunscreen | #433 |
| antiseizure | #433 |
| resultsone | #434 |
| purpose objectives | #434 |
| 115 patients | #434 |
| cancer tamoxifen | #434 |
| oral calcium | #435 |
| topic treatment | #436 |
| pains | #436 |
| nutrition cancer | #436 |
| olanzapine treatment | #436 |
| 1157 | #436 |
| anthracyclinebased chemotherapy | #438 |
| clinical cancer | #438 |
| absolute terms | #438 |
| nodenegative breast cancer | #439 |
| administration cutaneous | #440 |
| postoperative follow | #440 |
| diminish | #441 |
| neoplasms cancer | #441 |
| expected survival | #441 |
| yoga | #442 |
| vasomotor | #442 |
| baseline 1 month | #444 |
| hgpin | #444 |
| screening colorectal | #445 |
| loss aged | #445 |
| preoperative breast | #445 |
| life efficacy | #445 |
| receive | #445 |
| doxorubicin drug administration | #445 |
| agents antineoplastic | #446 |
| marie | #446 |
| day dexamethasone | #447 |
| acid aged | #447 |
| treatment regimen | #447 |
| patients qol | #448 |
| 2 months | #448 |
| european organization | #448 |
| patients weight | #448 |
| climacteric | #449 |
| estrogen therapy | #449 |
| baseline patient | #450 |
| premature discontinuation | #451 |
| cancer symptoms | #452 |
| baseline 4 weeks | #452 |
| study feasibility | #453 |
| outline | #453 |
| nodepositive breast cancer | #454 |
| arms arm | #454 |
| postmenopause | #455 |
| dhea | #455 |
| 5fu patients | #456 |
| geranium | #456 |
| axillary metastases | #457 |
| diphenhydramine | #458 |
| evaluate efficacy | #459 |
| mucositis | #460 |
| questionnaires terminology | #461 |
| enforced | #461 |
| patients venous thromboembolism | #461 |
| helpful | #462 |
| 6 weeks | #462 |
| cytokines patients | #462 |
| patients baseline | #462 |
| increased weight | #463 |
| potential interventions | #463 |
| therapy stage | #464 |
| cancer institute | #468 |
| clin | #468 |
| asco | #468 |
| radiation enteritis | #469 |
| lung humans | #469 |
| referral centers | #469 |
| sexual distress | #470 |
| consensus guideline | #470 |
| esophagitis patients | #471 |
| purposethis | #471 |
| treatment options patients | #471 |
| chemotherapy regimens | #472 |
| new treatment | #473 |
| pilocarpine | #474 |
| 432 | #474 |
| subscale | #474 |
| symptoms menopause | #475 |
| hormonal replacement therapy | #475 |
| groups 6 months | #475 |
| uncertain | #476 |
| preliminary studies | #477 |
| single item | #477 |
| appears | #477 |
| clinical decision making | #478 |
| placebo 24 weeks | #478 |
| onco | #479 |
| iii colon | #479 |
| doubleblind study | #479 |
| 95 placebo | #479 |
| variables age | #479 |
| enrollment patients | #480 |
| alopecia | #480 |
| vitamin placebo | #480 |
| osteoporosis osteopenia | #481 |
| moderatetosevere | #482 |
| crc 95 | #482 |
| higher dose | #483 |
| reluctance | #484 |
| adjuvant therapy | #484 |
| neurotoxicity patients | #485 |
| endpoints included | #485 |
| locoregional disease | #485 |
| tpn | #485 |
| cure | #486 |
| 655 | #486 |
| blind | #488 |
| taqman pcr | #488 |
| induced neuropathic | #489 |
| doselimiting toxicity | #491 |
| pain scores | #491 |
| estrogen deprivation | #491 |
| cancer cardiovascular disease | #492 |
| plant preparations | #493 |
| combined modality treatment | #493 |
| primary breast | #493 |
| narcotics | #494 |
| patients stage disease | #495 |
| decarboxylase activity | #498 |
| dropout rates | #499 |
| fentanyl humans | #500 |
| patients breast cancer | #500 |
| received placebo | #501 |
| “ ” | #501 |
| kps | #502 |
| placebo‐controlled study | #502 |
| life questionnaires survivors | #502 |
| pilot studies | #502 |
| metastatic cancer | #503 |
| mesonephroma | #504 |
| loss patients | #504 |
| chest ray | #505 |
| awaited | #506 |
| survival chemotherapy | #509 |
| pain inventory | #510 |
| smoking nicotine | #511 |
| placebo trial | #511 |
| preventative | #512 |
| trials data | #513 |
| breast diseases | #513 |
| therapy aged | #513 |
| advance planning acp | #514 |
| nonmetastatic breast cancer | #514 |
| flic | #514 |
| evidencebased interventions | #515 |
| letrozole treatment | #516 |
| premature menopause | #516 |
| women receiving | #516 |
| serum albumin levels | #517 |
| outcome antineoplastic | #517 |
| acute diarrhea | #519 |
| pain medications | #520 |
| achievements | #520 |
| eflornithine | #521 |
| cbcs | #521 |
| gamma aminobutyric | #522 |
| pharmaceutic | #522 |
| poorer quality life | #523 |
| mastectomy middle | #525 |
| chills | #525 |
| symptoms fatigue | #525 |
| resultsto | #527 |
| controlled crossover | #528 |
| prophylactic therapy | #528 |
| adverse events placebo | #528 |
| cmf | #529 |
| phytogenic area | #529 |
| abt888 | #529 |
| patients clinical trial | #529 |
| therapy prostate | #530 |
| oncologists | #531 |
| radiodermatitis | #531 |
| centrally | #531 |
| pregabalin | #531 |
| patients vitamin | #532 |
| iii trial | #533 |
| 30 minutes | #534 |
| genitourinary | #535 |
| medications treatment | #536 |
| patients evaluated | #536 |
| antineoplastic agents | #537 |
| superficial bladder | #538 |
| weeks therapy | #538 |
| agents chemotherapy | #538 |
| study week | #538 |
| patients clinical trials | #539 |
| terminally | #540 |
| patients assigned | #541 |
| pharmacologic | #542 |
| dehydroepiandrosterone | #543 |
| topic severity | #543 |
| pain patients | #543 |
| pain score | #544 |
| week 6 | #544 |
| risedronic | #544 |
| 329 | #545 |
| 592 | #546 |
| peripheral | #548 |
| patients scheduled | #548 |
| unable | #549 |
| bmd baseline | #550 |
| receiving adjuvant | #550 |
| differences study | #551 |
| dabrafenib trametinib | #552 |
| 3 95 | #552 |
| hypesthesia | #553 |
| axonal transport | #553 |
| adenomas patients | #554 |
| leucovorin oxaliplatin | #555 |
| co2 laser | #556 |
| dysplastic lesions | #556 |
| neoplasms drug | #556 |
| regular aspirin | #556 |
| evaluable | #556 |
| 300 day | #557 |
| abh | #557 |
| vasomotor symptoms | #559 |
| reported outcomes | #560 |
| 80000 | #560 |
| emesis | #560 |
| rbc transfusions | #560 |
| methylphenidate | #561 |
| day treatment | #561 |
| moisturizer | #561 |
| mesna | #562 |
| lmwh patients | #564 |
| hands | #564 |
| time detection | #565 |
| method drug | #565 |
| induced cold | #565 |
| treatment periods | #566 |
| trial data | #566 |
| supportive cancer | #567 |
| 4 8 | #567 |
| survival stage | #567 |
| 11 months | #568 |
| therapy primary | #569 |
| calgb | #569 |
| adjuvant clinical trials | #569 |
| scientifically | #569 |
| decarboxylase odc | #571 |
| topic treatment outcome | #571 |
| lower dose | #571 |
| bibliometric analysis | #572 |
| paclitaxel patients | #573 |
| fluorouracil oxaliplatin | #578 |
| topical capsaicin | #578 |
| patients candidates | #580 |
| methods systematic review | #580 |
| refute | #580 |
| hwe | #581 |
| treatment phase | #581 |
| paced | #583 |
| breakthrough pain | #583 |
| life questionnaire | #584 |
| paracentesis | #584 |
| desvenlafaxine | #585 |
| moderate correlation | #585 |
| neoplasms nutritional | #587 |
| drug toxicity | #587 |
| paclitaxel carboplatin | #588 |
| multiple cancers | #589 |
| emotional functioning | #589 |
| muscle cramps | #589 |
| limited efficacy | #589 |
| aged occult | #589 |
| oxaliplatin patients | #589 |
| osteopenia | #590 |
| taxane chemotherapy | #590 |
| aminobutyric | #590 |
| acrin | #591 |
| median time progression | #592 |
| ablation therapy | #592 |
| crossover trial | #592 |
| platinum drugs | #593 |
| chemotherapy benefit | #595 |
| pentoxifylline | #596 |
| compounded | #596 |
| exanthema | #597 |
| fatigue female | #597 |
| radiotherapy breast | #597 |
| sst2 | #597 |
| topic depressive disorder | #598 |
| multisite | #598 |
| patients mastectomy | #599 |
| publication administration | #599 |
| initial surgery | #599 |
| effects breast | #600 |
| thromboembolism vte | #600 |
| patients etanercept | #600 |
| oral solution | #601 |
| statistically differences | #601 |
| discretion | #601 |
| 1093 | #601 |
| patient decision | #601 |
| health providers | #601 |
| prevention measures | #602 |
| vte cancer | #602 |
| cfibers | #603 |
| cancer survivors | #604 |
| anthracycline based | #604 |
| exposed patients | #604 |
| toxicity profile | #605 |
| endoxifen | #607 |
| chemotherapy administration | #608 |
| 16 women | #608 |
| toes | #608 |
| agents antidepressive | #609 |
| iron supplementation | #609 |
| management symptoms | #609 |
| agents tricyclic | #611 |
| topic reproducibility | #612 |
| 2 95 | #613 |
| pilot | #613 |
| updated analysis | #614 |
| montanide | #615 |
| animal data | #616 |
| qol baseline | #616 |
| 118 patients | #617 |
| humans quality | #617 |
| commonly | #618 |
| appetite | #620 |
| antacid | #620 |
| urinary frequency | #621 |
| persistent symptoms | #621 |
| aic | #621 |
| follow median | #622 |
| itching | #625 |
| analyzable | #626 |
| gangliosides humans | #626 |
| cisplatin etoposide | #627 |
| life quality | #630 |
| 1 month | #631 |
| iii patients | #632 |
| authors knowledge | #633 |
| biological targets | #634 |
| mistletoe | #634 |
| month patients | #637 |
| female sexual function | #638 |
| serum hepcidin | #640 |
| dose placebo | #640 |
| assessment cancer | #640 |
| eligible | #641 |
| poorer quality | #642 |
| hormonal aromatase | #643 |
| inhibitors breast | #643 |
| prostatic intraepithelial | #644 |
| placebo time | #645 |
| multiple studies | #646 |
| nasal symptoms | #647 |
| palliative quality | #647 |
| malignant melanomas | #648 |
| 300 patients | #648 |
| symptoms | #649 |
| syndrome acute | #649 |
| sores | #651 |
| method humans | #651 |
| flushes | #651 |
| doses patients | #651 |
| appeared | #652 |
| dose limiting | #653 |
| opioid analgesic | #653 |
| limiting toxicity | #653 |
| patients 16 | #655 |
| poms | #657 |
| prior chemotherapy | #658 |
| complete response patients | #659 |
| grade glioma | #660 |
| twentysix patients | #661 |
| patients chemotherapy | #662 |
| colorectal adenocarcinoma | #662 |
| 62 months | #663 |
| 95 − | #665 |
| cancer prospective | #666 |
| neoplasms patient | #666 |
| active agent | #666 |
| alternative treatments | #666 |
| life radiotherapy | #667 |
| nonparametric surveys | #667 |
| cancer treatments | #668 |
| levetiracetam | #668 |
| treatment trials | #669 |
| women chemotherapy | #670 |
| marie tooth | #671 |
| paclitaxel docetaxel | #671 |
| pain adult | #674 |
| axonopathy | #674 |
| p00004 | #674 |
| 1822 | #674 |
| maintenance disorders | #675 |
| pharmacologic management | #675 |
| racially | #676 |
| induced cognitive | #676 |
| patients standard | #678 |
| 5 consecutive | #678 |
| controlled study | #679 |
| routine follow | #680 |
| reported outcome | #681 |
| diethylstilbestrol | #681 |
| purpose report | #682 |
| study samples | #684 |
| highdose melphalan | #685 |
| popularly | #685 |
| oncology practice | #685 |
| deprivation therapy | #686 |
| fluorouracil leucovorin | #687 |
| therapy cancer | #687 |
| practice settings | #688 |
| charcot marie | #688 |
| sulindac | #688 |
| neurologic injury | #688 |
| life survivors | #692 |
| pharmacological targeting | #692 |
| rescue medication | #693 |
| guideline update | #693 |
| administration schedule | #694 |
| phlebitis | #694 |
| randomized treatment | #695 |
| based testing | #698 |
| potential benefits | #699 |
| desmethyl | #699 |
| descriptive statistics | #700 |
| versa | #701 |
| appearing | #702 |
| postmenopausal | #704 |
| chemopreventive agent | #704 |
| v30 | #705 |
| medical oncologists | #706 |
| effective interventions | #707 |
| tens | #709 |
| locoregionally advanced | #710 |
| capecitabine patients | #711 |
| erythropoiesis stimulating | #712 |
| randomized studies | #712 |
| 160 | #712 |
| newer agents | #714 |
| tube neoplasms | #714 |
| prevention cancer | #715 |
| breast magnetic | #716 |
| inflammatory breast | #717 |
| lowmolecularweight heparin | #717 |
| endorsement | #719 |
| convened | #719 |
| ameliorate | #720 |
| data baseline | #722 |
| erythropoietin female | #722 |
| palliative medicine | #725 |
| humans neoplasms | #725 |
| cyclophosphamide methotrexate | #725 |
| 6 months 95 | #725 |
| therapeutic equivalency | #727 |
| physicians predictive | #728 |
| 4 hours | #728 |
| joint pain | #729 |
| patients radiation therapy | #730 |
| induced human | #731 |
| odc activity | #731 |
| study treatment | #731 |
| charcotmarietooth | #732 |
| women undergoing | #733 |
| nucleotide variants | #734 |
| vinca | #735 |
| medroxyprogesterone | #735 |
| adjuvant clinical | #736 |
| secondary prevention | #737 |
| induced neurotoxicity | #738 |
| chemotherapy women | #738 |
| opd | #739 |
| mirtazapine | #741 |
| locoregional therapy | #742 |
| prescribing practices | #742 |
| 4 weeks patients | #742 |
| fist | #744 |
| baseline 1 year | #745 |
| armamentarium | #745 |
| women placebo | #745 |
| patients breast | #747 |
| bone loss | #748 |
| ecog | #748 |
| trials patients | #749 |
| chemotherapy initiation | #749 |
| superficial bladder cancer | #750 |
| 271 | #750 |
| alfa | #750 |
| psychostimulant | #750 |
| rand | #752 |
| cervical dysplasia | #752 |
| complementary medicine | #753 |
| compared placebo | #753 |
| 4·2 | #754 |
| antigen levels | #754 |
| oct2 | #754 |
| radiation skin | #754 |
| secondary points | #755 |
| 46 | #755 |
| paclitaxel chemotherapy | #755 |
| trouble | #755 |
| patients insomnia | #756 |
| metastatic breast | #757 |
| hepcidin levels | #758 |
| local anesthetics | #759 |
| rifngamma | #759 |
| reduction pain | #759 |
| sulfasalazine | #760 |
| prostate adenocarcinoma | #760 |
| additional data | #762 |
| pain quality | #763 |
| ambulatory setting | #765 |
| seventy patients | #766 |
| 81 patients | #766 |
| occult blood | #766 |
| medroxyprogesterone acetate mpa | #768 |
| neoplasms prospective | #768 |
| acid 4 | #768 |
| humans imidazoles | #769 |
| baseline pain | #769 |
| activity breast | #770 |
| actual | #770 |
| sensory neuropathy | #771 |
| sweating | #772 |
| modified radical mastectomy | #772 |
| relatedness | #772 |
| breast carcinoma ductal | #772 |
| women enrolled | #773 |
| primary endpoint | #773 |
| premenopausal women | #773 |
| keratinocyte growth factor | #773 |
| 10 day | #774 |
| fifty patients | #774 |
| neoplasms breast | #774 |
| emla | #774 |
| patients colon | #774 |
| aged peripheral | #775 |
| acupuncture therapy | #776 |
| octreotide treatment | #776 |
| oral administration | #777 |
| 257 | #777 |
| p00002 | #778 |
| gsm | #778 |
| charcot | #778 |
| 137 patients | #781 |
| severity patients | #782 |
| menopausal symptoms | #783 |
| agents phytogenic | #784 |
| skin conductance | #785 |
| cutaneous administration | #785 |
| benefits patients | #785 |
| prognostic survival | #787 |
| enoxaparin | #788 |
| management | #788 |
| symptom experience | #791 |
| anesthetics local | #792 |
| women reported | #793 |
| subsequent cycles | #793 |
| colon rectal cancer | #796 |
| baseline period | #797 |
| estrogen levels | #798 |
| potential treatments | #798 |
| life outcomes | #801 |
| clinical questions | #801 |
| neuralgia pain | #801 |
| erythropoiesisstimulating agents | #802 |
| osteoporosis women | #802 |
| day 3 | #804 |
| randomized phase trial | #804 |
| lack efficacy | #804 |
| primary points | #805 |
| glutathione | #805 |
| double | #806 |
| effects patients | #806 |
| opioid analgesia | #807 |
| 894 | #807 |
| placebotreated patients | #808 |
| etoposide cisplatin | #808 |
| continue | #808 |
| 80 antineoplastic | #808 |
| 3 day | #808 |
| 0025 | #809 |
| complete response | #811 |
| odc | #812 |
| abrogate | #812 |
| previous reports | #816 |
| mild symptoms | #817 |
| disease genes | #818 |
| lorazepam | #819 |
| agents clinical | #820 |
| eastern cooperative | #820 |
| etoposide patients | #823 |
| randomly | #824 |
| tolerated | #826 |
| statisticians | #826 |
| 148 patients | #827 |
| rasch model | #828 |
| cancer control | #828 |
| placebo 6 months | #830 |
| cancer phase | #830 |
| suggestive | #830 |
| administration oral | #830 |
| neoplasms bone | #832 |
| dabrafenib | #832 |
| humans medical | #833 |
| subset analysis | #833 |
| similarities differences | #835 |
| advanced malignancies | #836 |
| 366 | #836 |
| prognosis quality | #837 |
| mandelic | #837 |
| numeric | #838 |
| eventual | #844 |
| breast neoplasms | #845 |
| adverse events aes | #846 |
| herbal products | #846 |
| p006 | #847 |
| 142 patients | #848 |
| global qol | #848 |
| detection rates | #849 |
| toxicities | #850 |
| eortc | #850 |
| taxol | #851 |
| prostate cancer patients | #852 |
| n55 | #853 |
| oncotype | #853 |
| stage ovarian | #853 |
| palliative services | #855 |
| daily dosing | #858 |
| taxoids | #859 |
| assessment management | #859 |
| vaginal bleeding | #859 |
| published data | #860 |
| stratification patients | #860 |
| strongest | #864 |
| etidronic | #866 |
| patients trial | #868 |
| placebo baseline | #868 |
| unacceptable | #868 |
| jellies | #873 |
| efficacious | #873 |
| peritoneal cancer | #874 |
| treatment completion | #875 |
| timepoints | #878 |
| 5ht3 | #879 |
| symptomatic women | #880 |
| nonpharmacological interventions | #880 |
| phytogenic carcinoma | #880 |
| midlife women | #881 |
| antineoplastic | #883 |
| 450 | #883 |
| study placebo | #883 |
| monoclonal antineoplastic agents | #885 |
| mitigates | #889 |
| neurotoxic | #889 |
| topic female | #890 |
| monoclonal female humans | #891 |
| data article | #892 |
| concomitant chemotherapy | #893 |
| caa | #894 |
| cancer guidelines | #894 |
| control arm | #896 |
| completed | #900 |
| oxy | #901 |
| neoplasms hormone | #901 |
| women hormone | #902 |
| percent | #903 |
| nodal status | #903 |
| inconvenience | #903 |
| nmsc | #904 |
| provided | #905 |
| chemotherapy response | #905 |
| survival surgery | #905 |
| 00006 | #905 |
| hospices | #909 |
| chemotherapeutic | #910 |
| increased risk death | #910 |
| cancer studies | #913 |
| national cancer | #914 |
| weight maintenance | #914 |
| norepinephrine reuptake | #915 |
| life cancer patients | #916 |
| paroxetine | #916 |
| gynecomastia | #918 |
| prospective pilot study | #919 |
| cycle chemotherapy | #920 |
| advanced cancer patients | #921 |
| mouth mucosa | #921 |
| evidence practice | #923 |
| manuscripts | #924 |
| population cohort | #924 |
| illness female humans | #925 |
| primary objectives | #926 |
| chemotherapy study | #927 |
| upper extremities | #929 |
| oral dosing | #929 |
| lasa | #930 |
| oncol | #931 |
| starting | #932 |
| fluoxetine | #933 |
| minocycline | #935 |
| cytotoxic therapy | #937 |
| day placebo | #938 |
| electronic health record | #939 |
| serotonin uptake | #939 |
| treatment symptoms | #940 |
| visual analogue | #940 |
| 138 patients | #942 |
| high‐risk | #943 |
| uptake inhibitors | #943 |
| advanced adenoma | #943 |
| patient population | #944 |
| letter editor | #944 |
| colorectal adenomas | #944 |
| gp100 | #945 |
| beckman | #945 |
| iii topic | #945 |
| 1year survival | #946 |
| fluorouracil | #948 |
| arm patients | #949 |
| natural menopause | #951 |
| recurrence score | #952 |
| compare | #953 |
| orally | #954 |
| jci | #954 |
| participating centers | #955 |
| evaluating | #955 |
| cooperative oncology | #957 |
| hfs | #958 |
| adjuvant therapies | #958 |
| aloe vera | #958 |
| rheumatologic | #958 |
| leukopenia | #959 |
| erythropoietic | #959 |
| moderately | #961 |
| monoclonal carcinoma | #962 |
| pjnk | #963 |
| trpm8 | #963 |
| received adjuvant | #964 |
| serum cytokine | #966 |
| menopause | #968 |
| 1160 | #969 |
| mart1 | #970 |
| table | #972 |
| earlystage disease | #972 |
| randomized pilot | #973 |
| gluconate | #976 |
| restarted | #977 |
| olmsted county | #977 |
| 1 10 | #978 |
| hypercalcemia | #978 |
| mechanical allodynia | #980 |
| 1month | #980 |
| 2700 | #982 |
| 150 | #984 |
| antidotes | #984 |
| 1 week | #984 |
| threequarters | #989 |
| patients venous | #989 |
| adjuvant | #992 |
| pain reduction | #993 |
| multiple logistic regression | #997 |
| analyses data | #998 |
| bother | #1003 |
| mayo | #1003 |
| cancer chemoprevention | #1005 |
| publication analgesics | #1007 |
| 71 | #1010 |
| continued | #1014 |
| patients metastatic disease | #1015 |
| organ systems | #1016 |
| neurocutaneous | #1018 |
| anthraquinones | #1019 |
| patients mri | #1020 |
| reported pain | #1021 |
| life symptoms | #1023 |
| trial participation | #1026 |
| 145 patients | #1027 |
| enteritis | #1028 |
| fatigue patients | #1028 |
| urogenital | #1030 |
| alternative treatment | #1031 |
| delayed treatment | #1031 |
| pill | #1037 |
| evidence treatment | #1037 |
| ” “ | #1038 |
| androgen deprivation therapy | #1042 |
| validity responsiveness | #1043 |
| postural control | #1044 |
| prx | #1044 |
| randomized trial patients | #1046 |
| colorectal tumor | #1047 |
| prevention intervention | #1047 |
| patients safety | #1047 |
| substantial | #1050 |
| frey | #1051 |
| nutritional supplementation | #1051 |
| life | #1053 |
| 30 40 | #1053 |
| postchemotherapy | #1056 |
| doxorubicin female humans | #1056 |
| minority | #1057 |
| primary analysis | #1059 |
| feeding eating | #1059 |
| osteoporosis treatment | #1059 |
| 10 weeks | #1060 |
| day study | #1061 |
| tricyclic | #1061 |
| prospective validation | #1063 |
| oncologist | #1063 |
| fruitful | #1063 |
| 347 | #1064 |
| endocrine resistance | #1064 |
| ongoing studies | #1066 |
| loss weight | #1066 |
| suggested | #1069 |
| therapy | #1069 |
| disappointing | #1069 |
| practical guidance | #1070 |
| metastatic lung | #1070 |
| descriptive | #1073 |
| tobacco dependence | #1075 |
| concurrent chemotherapy | #1078 |
| monoclonal humans | #1078 |
| nccn | #1078 |
| women treatment | #1079 |
| placebo day | #1080 |
| patients bone metastases | #1081 |
| women received | #1083 |
| advance planning | #1084 |
| placebo participants | #1085 |
| breast cancer recurrence | #1089 |
| duloxetine | #1089 |
| prompted | #1089 |
| patients adjuvant therapy | #1090 |
| low intermediate | #1091 |
| prospective multicenter study | #1092 |
| progestogens | #1094 |
| postoperative surveillance | #1095 |
| palonosetron | #1095 |
| adult breast | #1097 |
| 25 day | #1098 |
| intravenous iron | #1099 |
| favor | #1099 |
| agents treatment | #1100 |
| functional ability | #1100 |
| previous chemotherapy | #1100 |
| 54 | #1103 |
| phytoestrogens | #1103 |
| prospective trial | #1106 |
| peripheral neuropathies | #1108 |
| acknowledged | #1110 |
| 3 6 months | #1112 |
| transdermal | #1114 |
| randomized | #1115 |
| 1 year treatment | #1116 |
| prevention trials | #1119 |
| treatment life | #1121 |
| life death | #1122 |
| inhaler | #1124 |
| cancer trials | #1126 |
| interprofessional relations | #1126 |
| unpleasant | #1127 |
| prilocaine | #1127 |
| dmc | #1127 |
| based evidence | #1128 |
| mexiletine | #1129 |
| participants received | #1131 |
| patients versus | #1133 |
| clinician | #1133 |
| sunscreening | #1136 |
| lecithins | #1137 |
| 25 micrograms | #1139 |
| opioid therapy | #1139 |
| hormonal therapy | #1140 |
| practice guideline | #1140 |
| cancer | #1141 |
| inhibit | #1144 |
| purposeto | #1144 |
| cancer pain | #1146 |
| egb | #1146 |
| randomized crossover | #1146 |
| locoregionally | #1147 |
| illness surveys | #1148 |
| taste disorders | #1149 |
| premature ovarian failure | #1150 |
| shark | #1150 |
| purpose determine | #1150 |
| 730 | #1153 |
| nervousness | #1153 |
| hormonal | #1154 |
| detrimental | #1154 |
| smoking prevention | #1154 |
| flecainide | #1157 |
| 325 | #1159 |
| 481 | #1161 |
| rinse | #1162 |
| 22 | #1162 |
| doac | #1163 |
| educate | #1164 |
| toxicity assessment | #1167 |
| purposethis study | #1167 |
| comparative efficacy | #1172 |
| ceramides | #1173 |
| therapy estrogens | #1174 |
| painful | #1174 |
| intervention trials | #1175 |
| receptor modulators | #1176 |
| patients syndrome | #1177 |
| clinical trial | #1178 |
| inadequately | #1179 |
| projects | #1180 |
| lowest risk | #1181 |
| chemotherapy regimen | #1182 |
| chose | #1184 |
| aged prostatic | #1185 |
| growing population | #1186 |
| physician patient | #1187 |
| electrostimulation | #1188 |
| prior treatment | #1189 |
| international consensus | #1189 |
| mastectomy breast | #1190 |
| acetate treatment | #1190 |
| usage | #1193 |
| gained | #1196 |
| olmsted | #1197 |
| diary | #1197 |
| estrogen replacement therapy | #1197 |
| experiencing | #1198 |
| alternative therapies | #1200 |
| caregivers patients | #1202 |
| 552 | #1204 |
| partial responses | #1204 |
| male smokers | #1204 |
| panax | #1205 |
| clinical trials patients | #1207 |
| magnesium | #1208 |
| breast cancer | #1212 |
| satisfied | #1212 |
| induced skin | #1213 |
| patients pts | #1215 |
| 611 | #1215 |
| communication skills | #1215 |
| likert | #1217 |
| adjuvant endocrine | #1218 |
| precludes | #1219 |
| sexuality | #1219 |
| secondary endpoints | #1219 |
| 8 week | #1221 |
| higher numbers | #1223 |
| phase clinical trial | #1223 |
| limiting | #1224 |
| thighs | #1227 |
| editor | #1227 |
| participants reported | #1229 |
| organogel | #1230 |
| 8 weeks | #1232 |
| primary melanomas | #1232 |
| 52 | #1233 |
| n54 | #1234 |
| randomized phase | #1235 |
| discontinue | #1235 |
| tricyclic antidepressants | #1241 |
| clinical syndrome | #1241 |
| baseline values | #1245 |
| day 2 | #1248 |
| review data | #1248 |
| symptoms diagnosis | #1248 |
| decided | #1249 |
| etiologies | #1250 |
| female sexual | #1250 |
| bedtime | #1252 |
| postmenopausal women | #1252 |
| il1β tnfα | #1253 |
| estrogens female | #1255 |
| diarrhea patients | #1257 |
| thromboembolism patients | #1258 |
| combination docetaxel | #1258 |
| diphosphonates | #1258 |
| patients 4 | #1259 |
| trametinib | #1259 |
| hypochromic | #1259 |
| kidney dysfunction | #1260 |
| rasch | #1260 |
| pain medication | #1261 |
| neurologic humans | #1263 |
| doubts | #1263 |
| tumor promotion | #1265 |
| dna ploidy | #1265 |
| esophagitis | #1266 |
| sae | #1266 |
| protocols chemotherapy | #1268 |
| magnesium oxide | #1270 |
| phytotherapy | #1271 |
| qol scores | #1272 |
| drug double | #1272 |
| short form36 | #1273 |
| situ carcinoma ductal | #1273 |
| preoperative chemotherapy | #1274 |
| patients families | #1274 |
| preclude | #1276 |
| cutaneous melanomas | #1278 |
| tamoxifen patients | #1279 |
| taxanes | #1279 |
| median ttp | #1280 |
| dosing interval | #1281 |
| heparin lmwh | #1282 |
| label trial | #1284 |
| male medication adherence | #1285 |
| medical oncology | #1286 |
| adjuvant tamoxifen | #1287 |
| adjuvant therapy patients | #1289 |
| opposed | #1289 |
| cyclophosphamide doxorubicin | #1289 |
| folfox | #1291 |
| 109 patients | #1292 |
| cochran | #1294 |
| acupuncture treatment | #1294 |
| data clinical | #1296 |
| prevalence severity | #1296 |
| antimetabolites antineoplastic | #1297 |
| neurosensory | #1298 |
| neoplasms disease | #1300 |
| emetic | #1301 |
| women cancer | #1303 |
| 8 cycles | #1307 |
| abstinent | #1307 |
| stimulating agents | #1309 |
| survival 5 | #1310 |
| motion rom | #1310 |
| critical review | #1312 |
| sportdiscus | #1313 |
| gynecologic cancers | #1314 |
| gsh | #1315 |
| melanoma antigen | #1315 |
| biotech | #1315 |
| breast biopsy | #1317 |
| contacted | #1318 |
| durations | #1318 |
| etanercept | #1320 |
| health‐related quality | #1320 |
| controlled | #1321 |
| investigative | #1321 |
| chemotherapeutic agents | #1321 |
| oncology patients | #1321 |
| patients quality | #1322 |
| primary outcome measure | #1322 |
| pain interference | #1322 |
| ointments | #1323 |
| nerve damage | #1326 |
| appetite loss | #1327 |
| life scores | #1328 |
| patient physician | #1328 |
| cardiac toxicity | #1329 |
| agents colorectal | #1329 |
| life surveys | #1337 |
| adjuvant breast | #1339 |
| 375 | #1340 |
| published reports | #1341 |
| evenly | #1342 |
| 2 week | #1345 |
| ambulatory monitoring | #1346 |
| platinum compounds | #1347 |
| breast cancer women | #1347 |
| colonoscopic | #1350 |
| experienced | #1350 |
| tibolone | #1351 |
| karnofsky | #1352 |
| benefit patients | #1353 |
| cancer experience | #1353 |
| malignant ascites | #1354 |
| carcinoembryonic | #1356 |
| period patients | #1358 |
| eligibility criteria | #1359 |
| wks | #1360 |
| agents cancer | #1367 |
| effects treatment | #1368 |
| attribution | #1369 |
| postural balance | #1372 |
| continues | #1376 |
| combination female humans | #1377 |
| hopes | #1379 |
| titrated | #1381 |
| patients colon cancer | #1382 |
| n32 | #1382 |
| n29 | #1382 |
| duplicates | #1386 |
| hydrazines | #1387 |
| mastectomy | #1387 |
| snvs | #1388 |
| patients 40 | #1391 |
| femoral neck bmd | #1396 |
| medical literature | #1397 |
| ajcc | #1399 |
| cancer adult | #1400 |
| cancer therapies | #1403 |
| pain neuropathic | #1404 |
| somnolence | #1406 |
| polyneuropathies | #1407 |
| rifn | #1407 |
| replete | #1408 |
| physical activity level | #1410 |
| treats | #1411 |
| integrative medicine | #1412 |
| fisher test | #1415 |
| viscum | #1416 |
| wilcoxon | #1416 |
| combination chemotherapy | #1417 |
| cessation treatment | #1418 |
| quality life | #1420 |
| treatment recommendations | #1423 |
| noncompliance | #1424 |
| subjective symptoms | #1424 |
| sleep initiation | #1424 |
| biloba | #1425 |
| therapy initiation | #1426 |
| methodsdata | #1426 |
| prevent | #1427 |
| cancer quality life | #1427 |
| cytotoxic chemotherapy | #1428 |
| hormonal treatment | #1431 |
| aromatase | #1431 |
| and or | #1432 |
| 5fu | #1433 |
| weight heparin | #1433 |
| radiation injuries | #1434 |
| statistically difference | #1434 |
| daily intake | #1435 |
| primary objective | #1437 |
| caloric intake | #1439 |
| adults cancer | #1440 |
| female humans illness | #1442 |
| goserelin | #1445 |
| proctitis | #1445 |
| aminobutyric acid | #1446 |
| postacute | #1447 |
| ehrs | #1447 |
| cancer clinical trials | #1449 |
| incidences | #1449 |
| assigning | #1450 |
| coulter | #1453 |
| patients ovarian | #1454 |
| nccn guidelines | #1454 |
| treatment pain | #1454 |
| infliximab | #1455 |
| cognitive testing | #1456 |
| bruising | #1457 |
| hrqol | #1458 |
| 63 | #1459 |
| dna testing | #1461 |
| effective management | #1461 |
| individual patients | #1461 |
| adjuvant treatment | #1463 |
| life cancer | #1466 |
| aged quality | #1466 |
| haloperidol humans | #1467 |
| network meta | #1467 |
| discrepancies | #1467 |
| crossover | #1468 |
| nutritional support | #1469 |
| locally advanced head | #1469 |
| physical activity patients | #1470 |
| recurrent vte | #1475 |
| hormone dependent | #1477 |
| life treatment | #1477 |
| substantial proportion | #1479 |
| resultsa | #1479 |
| lower extremities | #1483 |
| oral aged | #1484 |
| tumor promoter | #1484 |
| pik3ca mutation | #1485 |
| aromatase inhibitors | #1492 |
| nrs | #1493 |
| cancer society | #1494 |
| ongoing | #1495 |
| systemic chemotherapy | #1498 |
| mood states | #1499 |
| planned | #1500 |
| paclitaxel cisplatin | #1501 |
| resultsafter | #1501 |
| mpa | #1509 |
| anti anxiety | #1510 |
| colon cancer patients | #1510 |
| perimenopause | #1513 |
| gynecologic cancer | #1513 |
| premalignant | #1514 |
| neuropeptide npy | #1518 |
| bowel function | #1520 |
| hair loss | #1523 |
| efficacy | #1523 |
| biweekly | #1523 |
| diagnosed cancer | #1525 |
| p0024 | #1525 |
| root ganglion | #1526 |
| oncology | #1526 |
| 3 weeks | #1528 |
| interfered | #1530 |
| balanced | #1532 |
| gastrointestinal toxicity | #1533 |
| cytotoxic agents | #1537 |
| cck8 | #1537 |
| survivors | #1538 |
| physical examination | #1542 |
| cycle patients | #1546 |
| warranted | #1548 |
| guideline recommendations | #1549 |
| tamoxifen treatment | #1550 |
| treatment induced | #1556 |
| adult cancer | #1560 |
| male breast | #1562 |
| blind randomized | #1562 |
| pounds | #1567 |
| transfusion requirements | #1568 |
| design considerations | #1569 |
| response rates | #1572 |
| or1 | #1574 |
| pharmacologic treatment | #1576 |
| iii disease | #1576 |
| 5 day | #1579 |
| bibliographies | #1580 |
| patients small | #1583 |
| crushed | #1583 |
| rivaroxaban | #1583 |
| rate survival | #1584 |
| vaginal | #1587 |
| prospective trials | #1588 |
| postmenopausal breast | #1589 |
| updates | #1590 |
| dissent | #1593 |
| image body | #1593 |
| phase iii study | #1595 |
| localized disease | #1599 |
| trpa1 | #1600 |
| stratification | #1600 |
| therapy cyclophosphamide | #1602 |
| completion | #1603 |
| aged cross | #1603 |
| advanced colorectal cancer | #1604 |
| disagreements | #1605 |
| modafinil | #1606 |
| allopurinol | #1608 |
| ≥70 | #1611 |
| bid | #1612 |
| dosing | #1619 |
| aged antineoplastic | #1620 |
| accrual | #1623 |
| oncology nursing | #1624 |
| 970 | #1624 |
| dna markers | #1626 |
| cream | #1627 |
| 176 | #1628 |
| prophylactic treatment | #1629 |
| tumor type | #1633 |
| 227 | #1634 |
| vte | #1636 |
| upfront | #1637 |
| potential channels | #1642 |
| respiratory depression | #1643 |
| combined modality therapy | #1649 |
| cardiovascular toxicity | #1650 |
| 49 | #1651 |
| controlled phase | #1652 |
| 2003 | #1652 |
| monthly | #1656 |
| cancer stage | #1660 |
| current treatment | #1661 |
| limited data | #1663 |
| pelvic radiotherapy | #1664 |
| referencing | #1666 |
| populationbased cohort | #1667 |
| breast cancer patients | #1667 |
| evaluation female | #1670 |
| treated breast | #1676 |
| patient preference | #1679 |
| therapy hrt | #1680 |
| ovid medline | #1682 |
| hb | #1683 |
| agents carcinoma | #1687 |
| blood tests | #1689 |
| publication attitude | #1691 |
| neoplasms practice | #1693 |
| anticancer therapy | #1693 |
| weight patients | #1694 |
| stopping | #1695 |
| percent patients | #1695 |
| ≤2 | #1696 |
| methyldopa | #1696 |
| patients bone | #1698 |
| randomization | #1698 |
| nootropic | #1698 |
| morpholines | #1700 |
| symptom distress | #1701 |
| patients control | #1701 |
| endpoint | #1703 |
| glutamine | #1705 |
| enrolled patients | #1705 |
| reported symptoms | #1706 |
| study groups | #1707 |
| chisquare | #1708 |
| 595 | #1709 |
| chemotherapy patients | #1709 |
| endocrine treatment | #1711 |
| incorrectly | #1714 |
| inhibitor therapy | #1715 |
| crossover study | #1716 |
| hyperalgesia male | #1717 |
| antineoplastic agents carcinoma | #1719 |
| interventions patients | #1720 |
| effects cancer | #1726 |
| human epidermal | #1726 |
| referral consultation | #1728 |
| selective estrogen | #1728 |
| 652 | #1729 |
| testosterone treatment | #1729 |
| nineteen | #1730 |
| orchiectomy | #1731 |
| neuropathic pain | #1731 |
| lmwh | #1738 |
| paucity | #1740 |
| life questionnaires | #1741 |
| p450 cyp2d6 | #1746 |
| topical | #1746 |
| oxcarbazepine | #1749 |
| ≥10 | #1749 |
| scores patients | #1751 |
| fifty | #1752 |
| recommendations patients | #1753 |
| neoplasms early | #1754 |
| unique challenges | #1754 |
| greater reduction | #1762 |
| insufficient evidence | #1762 |
| treatment data | #1762 |
| cramps | #1764 |
| fall risk | #1765 |
| grade 2 | #1766 |
| massage | #1766 |
| progression survival | #1770 |
| anticoagulants doacs | #1772 |
| urinary symptoms | #1775 |
| performance status | #1779 |
| clinical endpoints | #1781 |
| 95 0 | #1781 |
| objective responses | #1784 |
| fingers | #1784 |
| lignans | #1785 |
| behavioral interventions | #1785 |
| pros | #1787 |
| dizziness | #1789 |
| facts | #1790 |
| anorectic | #1791 |
| life assessment | #1791 |
| survival outcomes patients | #1791 |
| drug therapy | #1792 |
| rbc transfusion | #1794 |
| transient receptor | #1795 |
| alternative medicine | #1796 |
| primary therapy | #1796 |
| descriptive analysis | #1798 |
| decision aids | #1800 |
| investigator | #1802 |
| acetylcarnitine | #1803 |
| treatment cycles | #1803 |
| severe toxicity | #1804 |
| median survival time | #1804 |
| supporting | #1805 |
| premenopause | #1807 |
| adjunct | #1808 |
| analgesic efficacy | #1811 |
| topic | #1812 |
| 16 patients | #1813 |
| agents female | #1813 |
| breast surgery | #1816 |
| evidencebased recommendations | #1818 |
| trpm | #1818 |
| ql | #1821 |
| receptor potential | #1822 |
| cancer women | #1823 |
| 327 | #1823 |
| evaluable patients | #1825 |
| effective therapy | #1825 |
| anxiety agents | #1827 |
| humans neoplasm | #1831 |
| ganglion neurons | #1831 |
| neoplasms prognosis | #1835 |
| longterm survival patients | #1835 |
| suffering | #1836 |
| menopausal transition | #1837 |
| administration topical | #1849 |
| active cancer | #1850 |
| comprehensive cancer | #1851 |
| months 12 | #1851 |
| patients prognosis | #1853 |
| 23 months | #1853 |
| dermatological | #1853 |
| neuropathic | #1853 |
| providers patients | #1857 |
| initial dose | #1858 |
| aged postmenopause | #1858 |
| cancer types | #1858 |
| rationale design | #1863 |
| antimitotic | #1864 |
| univariate analyses | #1867 |
| antimetabolites | #1871 |
| humans pain | #1873 |
| europe female humans | #1873 |
| secondary objective | #1876 |
| continuing | #1877 |
| vice | #1878 |
| resultsa total | #1879 |
| induced pain | #1879 |
| antigen colorectal | #1881 |
| musculoskeletal pain | #1881 |
| analysis adult | #1881 |
| leucovorin male | #1886 |
| galvanic | #1887 |
| weeks | #1888 |
| 15 weeks | #1890 |
| schedules | #1891 |
| questionnaires time | #1891 |
| keratinocyte | #1891 |
| mainstay | #1892 |
| sexual functioning | #1893 |
| hospice | #1896 |
| triazoles | #1897 |
| sensory motor | #1898 |
| problematic | #1899 |
| stellate | #1899 |
| psqi | #1903 |
| topic surveys | #1910 |
| treatment modality | #1911 |
| neuropeptide | #1913 |
| evidence recommendations | #1918 |
| serum cortisol | #1922 |
| creams | #1924 |
| unwanted | #1928 |
| symptoms women | #1933 |
| pain | #1940 |
| health personnel attitude | #1946 |
| prematurely | #1946 |
| patients prostate cancer | #1949 |
| 5year followup | #1950 |
| treatment trial | #1951 |
| peritoneal neoplasms | #1952 |
| imidazoles | #1953 |
| cancer survivorship | #1955 |
| diagnosed breast | #1956 |
| cannabidiol | #1964 |
| signed | #1966 |
| nipple | #1969 |
| iii breast | #1971 |
| primary aim | #1971 |
| warrant | #1972 |
| articles | #1974 |
| surveillance colonoscopy | #1974 |
| initiating | #1975 |
| estrogen replacement | #1978 |
| clinical patients | #1978 |
| hand foot | #1979 |
| intravaginal | #1982 |
| collaborative | #1982 |
| dose melphalan | #1983 |
| controlled trial | #1985 |
| wasting syndrome | #1989 |
| androgen antagonists | #1994 |
| cancer patient | #1994 |
| current treatments | #2002 |
| stool samples | #2004 |
| patients dose | #2005 |
| effective therapies | #2011 |
| dose reductions | #2012 |
| gastrointestinal neoplasms | #2017 |
| phytotherapy plant | #2018 |
| form36 | #2018 |
| fallopian tube | #2019 |
| topic clinical trials | #2022 |
| steroidal aspirin | #2023 |
| perimenopausal | #2025 |
| critics | #2025 |
| neuromuscular diseases | #2026 |
| cardiotoxicity | #2029 |
| testing patients | #2031 |
| patients arm | #2032 |
| outpatient visits | #2034 |
| doses | #2036 |
| eortc qlqc30 | #2038 |
| transcutaneous | #2041 |
| exercise interventions | #2042 |
| recurrence survival | #2044 |
| dnr | #2045 |
| functional impairment | #2046 |
| breast cancer treatment | #2047 |
| evidence base | #2056 |
| status patients | #2056 |
| concentration time | #2058 |
| doxorubicin female | #2059 |
| 35 patients | #2063 |
| antibodies monoclonal antibodies | #2064 |
| head neck cancers | #2065 |
| chest | #2066 |
| relaxation therapy | #2069 |
| cancer population | #2069 |
| 120 patients | #2070 |
| contention | #2073 |
| inhibitor treatment | #2074 |
| daily | #2075 |
| safety pharmacokinetics | #2075 |
| hb level | #2075 |
| 50 reduction | #2076 |
| vinblastine | #2076 |
| nk1 | #2077 |
| benefit | #2080 |
| methysergide | #2081 |
| 20 day | #2082 |
| iii | #2087 |
| younger women | #2087 |
| patients caregivers | #2088 |
| advanced cancers | #2090 |
| nursing practice | #2090 |
| antidote | #2090 |
| cco | #2094 |
| major bleeding | #2094 |
| 66 years | #2097 |
| weekly paclitaxel | #2097 |
| anticonvulsants | #2102 |
| density bone | #2103 |
| mcg | #2104 |
| mitomycins | #2107 |
| therapy chemotherapy | #2109 |
| eicosapentaenoic acid | #2110 |
| orally administered | #2111 |
| tmt | #2111 |
| menopausal status | #2113 |
| day 1 | #2114 |
| 65 | #2115 |
| bmd lumbar spine | #2121 |
| ≥2 | #2121 |
| 5fluorouracil | #2122 |
| 96 patients | #2124 |
| treatment study | #2124 |
| journals | #2125 |
| mildly | #2126 |
| hb levels | #2126 |
| ttr | #2127 |
| bpi | #2128 |
| hormone concentrations | #2129 |
| hepcidins | #2130 |
| neoplasms clinical | #2133 |
| osteolytic | #2135 |
| egfr inhibitors | #2136 |
| concerned | #2136 |
| secondary objectives | #2136 |
| 525 | #2136 |
| aggressive disease | #2140 |
| qol | #2142 |
| levamisole | #2150 |
| tolerable | #2153 |
| carcinoembryonic antigen | #2154 |
| regimens | #2157 |
| item | #2158 |
| prt | #2160 |
| preventive strategies | #2161 |
| evidence efficacy | #2166 |
| baseline | #2166 |
| anemic | #2169 |
| treatment acute | #2169 |
| aloe | #2175 |
| women | #2177 |
| album | #2179 |
| pain syndromes | #2179 |
| worst | #2179 |
| tosyl | #2181 |
| physician | #2182 |
| detailed description | #2185 |
| fatigue pain | #2188 |
| 44 patients | #2195 |
| nervous | #2197 |
| severe symptoms | #2204 |
| questionnaires survivors | #2207 |
| 455 | #2208 |
| dose intensity | #2208 |
| female head | #2210 |
| prescription drugs | #2210 |
| age race | #2210 |
| 1 7 | #2212 |
| hypnosis | #2213 |
| ensuing | #2213 |
| weight loss | #2214 |
| 1–4 | #2220 |
| recurrences | #2220 |
| cmt | #2224 |
| adenosyl | #2225 |
| premenopausal | #2226 |
| myalgia | #2233 |
| osteonecrosis jaw | #2235 |
| 9 weeks | #2235 |
| 138 | #2242 |
| 60 minutes | #2243 |
| adrenal axis | #2247 |
| failed | #2247 |
| patient populations | #2251 |
| dermatologic | #2256 |
| life severity | #2257 |
| preliminary evidence | #2262 |
| summarized | #2265 |
| exercise female humans | #2266 |
| clinically meaningful | #2270 |
| patients metastatic melanoma | #2271 |
| 566 | #2272 |
| differences patients | #2273 |
| irritation | #2277 |
| bioelectrical impedance | #2284 |
| oophorectomy | #2285 |
| 1 year patients | #2285 |
| occult | #2288 |
| metastatic melanoma | #2290 |
| osteoporosis postmenopausal | #2291 |
| sloan | #2292 |
| gastrointestinal cancer | #2293 |
| likewise | #2298 |
| 800 | #2299 |
| life illness | #2301 |
| therapy adt | #2301 |
| regular | #2302 |
| dysfunction physiological | #2303 |
| incisional | #2308 |
| future trials | #2309 |
| polymerase inhibitors | #2310 |
| conclusionthe | #2310 |
| patch | #2311 |
| recommendation | #2311 |
| cramp | #2312 |
| genetic variations | #2314 |
| therapeutic strategies | #2320 |
| topic risk | #2326 |
| baclofen | #2327 |
| 74 | #2327 |
| weight breast | #2328 |
| worse | #2329 |
| mastectomy segmental | #2333 |
| burning | #2333 |
| 36 | #2333 |
| toxicity | #2334 |
| modest | #2334 |
| subcutaneously | #2335 |
| receptor positive | #2337 |
| exclusion criteria | #2338 |
| week | #2342 |
| society | #2347 |
| opioid analgesics | #2347 |
| improve quality | #2349 |
| androgen deprivation | #2349 |
| 46 patients | #2352 |
| curve analysis | #2352 |
| endorsed | #2357 |
| adult antineoplastic | #2359 |
| density bmd | #2365 |
| cyp2d6 | #2365 |
| baseline treatment | #2367 |
| increased risks | #2367 |
| nonrandomized | #2371 |
| 669 | #2373 |
| agent | #2374 |
| bibliometric | #2375 |
| rom | #2378 |
| health practice guidelines | #2379 |
| taste | #2389 |
| cancer clinical | #2390 |
| ornithine | #2391 |
| treatment duration | #2393 |
| difference 95 | #2396 |
| justification | #2397 |
| neoplasms survival | #2399 |
| neurological complications | #2400 |
| 266 | #2405 |
| counteract | #2405 |
| titles | #2406 |
| treatment baseline | #2407 |
| inadequate | #2407 |
| remaining patients | #2412 |
| postural | #2418 |
| rectal cancer patients | #2419 |
| poor performance | #2419 |
| ovid | #2420 |
| documenting | #2421 |
| 5 patients | #2425 |
| advanced prostate cancer | #2425 |
| symptom scores | #2426 |
| limited evidence | #2426 |
| debate | #2433 |
| 761 | #2436 |
| 71 patients | #2437 |
| practiced | #2437 |
| estrogen deficiency | #2439 |
| patients crc | #2439 |
| acupuncture | #2442 |
| response evaluation | #2442 |
| outpatient treatment | #2443 |
| phase trials | #2449 |
| 56 years | #2452 |
| chemotherapy adjuvant | #2453 |
| receptor antagonist | #2460 |
| common cancers | #2462 |
| iiic | #2463 |
| common adverse | #2464 |
| factor inhibitors | #2469 |
| assessment scale | #2469 |
| fallopian | #2474 |
| 207 | #2474 |
| patients quality life | #2477 |
| weight gain | #2478 |
| bleomycin | #2480 |
| guidelines patients | #2481 |
| practical approach | #2485 |
| network metaanalysis | #2491 |
| crossed | #2493 |
| approached | #2494 |
| melanomas | #2495 |
| raloxifene | #2496 |
| discontinuing | #2497 |
| 6 patients | #2502 |
| sexual function | #2507 |
| ginkgo | #2510 |
| 61 | #2510 |
| locoregional | #2510 |
| patients colorectal cancer | #2519 |
| children cancer | #2524 |
| topic clinical | #2526 |
| venous thromboembolism | #2527 |
| regimen | #2531 |
| cooperative | #2537 |
| amitriptyline | #2542 |
| asked | #2542 |
| radiation induced | #2544 |
| rescue | #2545 |
| treatment methods | #2556 |
| 12 24 | #2556 |
| carryover | #2557 |
| symptom | #2558 |
| galectin3 | #2562 |
| mandated | #2564 |
| telopeptide | #2567 |
| randomised clinical trial | #2567 |
| nitriles | #2568 |
| treatment selection | #2570 |
| reuptake | #2570 |
| stage small | #2573 |
| earlystage breast cancer | #2573 |
| conjunctivitis | #2574 |
| trials | #2592 |
| secondary analyses | #2592 |
| ideally | #2595 |
| carboplatin | #2597 |
| effects drugs | #2598 |
| 2 cycles | #2602 |
| erbb2 receptors | #2608 |
| parenteral | #2610 |
| arm | #2612 |
| pruritus | #2614 |
| patient education | #2617 |
| outcome united | #2624 |
| antineoplastic combined | #2624 |
| apr | #2626 |
| consented | #2626 |
| suspicious | #2627 |
| dorsal root | #2629 |
| symptoms quality | #2629 |
| life hrqol | #2631 |
| increased likelihood | #2639 |
| managing | #2642 |
| prefer | #2644 |
| remedy | #2648 |
| 55 | #2649 |
| thromboembolism | #2657 |
| 0001 patients | #2657 |
| races | #2657 |
| attenuate | #2662 |
| scores | #2663 |
| total parenteral nutrition | #2663 |
| lasted | #2667 |
| basal cell | #2670 |
| testosterone | #2672 |
| cancer outcomes | #2673 |
| imprecise | #2675 |
| comparable | #2676 |
| poorer survival | #2677 |
| symptoms treatment | #2685 |
| 817 | #2686 |
| prescribed | #2687 |
| prevention interventions | #2692 |
| statistically | #2696 |
| randomized controlled | #2699 |
| direct oral anticoagulants | #2701 |
| prevalence smoking | #2705 |
| impotence | #2707 |
| advanced colorectal | #2711 |
| data synthesis | #2713 |
| primary lung | #2717 |
| myelosuppression | #2724 |
| 1000 | #2735 |
| 01 | #2741 |
| modestly | #2745 |
| chemotherapy protocols | #2745 |
| thermal hyperalgesia | #2748 |
| multiple factors | #2749 |
| acp | #2749 |
| patients pain | #2750 |
| topic drug | #2752 |
| efficacies | #2753 |
| taxane | #2758 |
| advanced breast | #2760 |
| male medical | #2761 |
| ttf | #2762 |
| 250 | #2764 |
| neurotoxicity | #2769 |
| pyrazoles | #2774 |
| male neoplasms | #2775 |
| 1 4 | #2775 |
| 237 | #2776 |
| breast carcinoma | #2777 |
| convenience sample | #2780 |
| selfreport | #2781 |
| syndrome aged | #2788 |
| cryosurgery | #2789 |
| pooled data | #2790 |
| paraneoplastic syndromes | #2790 |
| neoplasia | #2791 |
| undergone | #2792 |
| adverse | #2793 |
| ascites | #2794 |
| isoflavones | #2794 |
| agents | #2797 |
| complete data | #2799 |
| nv | #2801 |
| thrice | #2801 |
| doacs | #2802 |
| acid epa | #2806 |
| cox model | #2812 |
| additional studies | #2813 |
| shortness | #2814 |
| continuous infusion | #2815 |
| preferred | #2817 |
| neurofeedback | #2823 |
| 750 | #2827 |
| breast | #2834 |
| sexual health | #2837 |
| muscle weakness | #2840 |
| 1 3 | #2842 |
| opioids | #2844 |
| meeting | #2844 |
| primary outcomes | #2845 |
| 38 | #2845 |
| cancer aged | #2854 |
| n31 | #2857 |
| cohen | #2857 |
| breakthrough | #2859 |
| linseed | #2859 |
| pharmacogenomic | #2860 |
| neoplasms | #2860 |
| sham | #2861 |
| statistical methods | #2866 |
| breaths | #2867 |
| activity level | #2867 |
| anticipate | #2869 |
| purposethe | #2869 |
| covariate | #2870 |
| fertility preservation | #2875 |
| surveillance patients | #2876 |
| task force | #2886 |
| 5 years patients | #2886 |
| ellipse | #2893 |
| p04 | #2895 |
| survival dose | #2895 |
| decarboxylase | #2912 |
| functional assessment | #2915 |
| endodermal | #2917 |
| packyears | #2918 |
| screening tests | #2920 |
| measurable | #2922 |
| p0002 | #2927 |
| placebo response | #2930 |
| condylomata | #2931 |
| prior | #2931 |
| phase clinical | #2933 |
| p008 | #2941 |
| topic design | #2945 |
| review articles | #2949 |
| identifier | #2949 |
| dosing regimens | #2949 |
| colonoscopy colorectal | #2951 |
| auc | #2954 |
| laser treatment | #2955 |
| utility | #2956 |
| week 12 | #2961 |
| 2 groups | #2962 |
| humans infusions | #2963 |
| hirsutism | #2966 |
| combined chemotherapy | #2969 |
| search terms | #2971 |
| curable | #2974 |
| chest wall | #2975 |
| intraepithelial neoplasia | #2977 |
| prophylactic | #2982 |
| placebo difference | #2983 |
| questionnaires | #2985 |
| eicosapentaenoic | #2986 |
| calculator | #2988 |
| testimony | #2989 |
| stopped | #2990 |
| started | #2991 |
| calories | #2991 |
| severity symptoms | #2995 |
| positive breast | #2998 |
| fatigue | #3000 |
| resected | #3004 |
| long acting | #3010 |
| objective response | #3012 |
| n5 | #3012 |
| topically | #3013 |
| time progression | #3014 |
| discomfort | #3014 |
| pathologic complete response | #3019 |
| patients 5 | #3022 |
| mianserin | #3026 |
| bone fractures | #3029 |
| ifosfamide | #3033 |
| nci | #3034 |
| skeletal muscle mass | #3038 |
| her2 status | #3041 |
| reuptake inhibitors | #3041 |
| dermatoses | #3042 |
| placebo week | #3052 |
| sided | #3053 |
| risk colorectal | #3058 |
| relief | #3058 |
| dukes | #3058 |
| tumor activity | #3066 |
| curve auc | #3067 |
| outcome measure | #3067 |
| 264 | #3068 |
| clonidine | #3069 |
| malignancy | #3071 |
| hyperhidrosis | #3072 |
| ctx | #3074 |
| sternal | #3076 |
| histograms | #3092 |
| sexual dysfunction | #3097 |
| nicotine dependence | #3098 |
| loss adult | #3099 |
| intergroup | #3103 |
| patients day | #3107 |
| tumor grade | #3108 |
| cancer female humans | #3111 |
| bmd | #3111 |
| vera | #3111 |
| 66 | #3116 |
| 26 | #3121 |
| neurokinin1 | #3121 |
| reversing | #3135 |
| cognitive dysfunction | #3139 |
| schedule | #3143 |
| 12 weeks | #3144 |
| treatment oral | #3146 |
| life measures | #3147 |
| clinical stage | #3150 |
| trpv1 | #3154 |
| infusions intravenous | #3155 |
| randomized controlled study | #3161 |
| χ2 | #3165 |
| subsequent development | #3166 |
| strongest association | #3168 |
| lifestyle factors | #3178 |
| phase 3 | #3180 |
| reasonable | #3181 |
| systematic literature search | #3183 |
| current approaches | #3185 |
| supportive | #3185 |
| leuprolide | #3186 |
| relevant articles | #3188 |
| 617 | #3189 |
| intravenous | #3190 |
| wore | #3192 |
| cannabinoids | #3193 |
| 64 | #3196 |
| podophyllotoxin | #3197 |
| abstracted | #3201 |
| menopausal | #3208 |
| case reports | #3210 |
| constellation | #3218 |
| 42 | #3222 |
| joint committee | #3225 |
| intervention trial | #3225 |
| 39 | #3226 |
| nonsmallcell lung cancer | #3226 |
| cochrane central register | #3231 |
| pain perception | #3235 |
| enrolled | #3238 |
| breathing | #3239 |
| medical record | #3240 |
| paraneoplastic | #3245 |
| itch | #3260 |
| therapy combination | #3260 |
| intervention patients | #3263 |
| designed | #3264 |
| oral mucosa | #3264 |
| 236 | #3266 |
| prior studies | #3269 |
| disagree | #3269 |
| treatment efficacy | #3270 |
| n30 | #3271 |
| 5 10 | #3272 |
| skin biopsies | #3278 |
| supplementary | #3279 |
| finished | #3282 |
| expert panel | #3284 |
| 2030 | #3287 |
| root ganglia | #3287 |
| 80 antibodies | #3288 |
| lymphoma patients | #3290 |
| 695 | #3290 |
| 885 | #3290 |
| previous analyses | #3291 |
| 576 | #3294 |
| understudied | #3296 |
| 0026 | #3303 |
| neuralgia | #3313 |
| suffer | #3314 |
| undertook | #3316 |
| resection colorectal | #3319 |
| impression | #3320 |
| treatment placebo | #3320 |
| electronic health | #3321 |
| chlorhexidine | #3322 |
| prostate cancer risk | #3328 |
| 171 | #3334 |
| acuminata | #3334 |
| risk vte | #3339 |
| systemically | #3350 |
| platinum based | #3352 |
| terminology | #3356 |
| erythema | #3358 |
| historic | #3360 |
| female breast | #3365 |
| breast prostate | #3368 |
| bone metastases | #3370 |
| doubt | #3370 |
| thirty | #3374 |
| preclinical studies | #3375 |
| relapse free | #3380 |
| chemoprevention | #3386 |
| acute chronic | #3392 |
| equivalency | #3395 |
| advanced prostate | #3396 |
| iii trials | #3399 |
| answers | #3400 |
| preceding | #3406 |
| oral | #3408 |
| lymph node excision | #3411 |
| prostatic neoplasms | #3415 |
| delaying | #3417 |
| anilides | #3418 |
| severity | #3422 |
| delineated | #3425 |
| axillary lymph | #3426 |
| administering | #3437 |
| npy | #3438 |
| higher scores | #3444 |
| screening methods | #3446 |
| 012 | #3446 |
| subsequent | #3452 |
| aminoquinolines | #3460 |
| utilizing | #3463 |
| 64 patients | #3463 |
| sprays | #3464 |
| pts | #3468 |
| listed | #3468 |
| survival benefits | #3468 |
| anthracyclines | #3471 |
| chemotherapy radiation | #3471 |
| multicenter randomized | #3473 |
| lidocaine | #3475 |
| lower rate | #3477 |
| mailed | #3479 |
| cross validation | #3480 |
| cessation smoking | #3481 |
| 3 6 | #3484 |
| attempt | #3489 |
| antidepressants | #3490 |
| intent | #3495 |
| reviewing | #3499 |
| ctc | #3500 |
| malignant disease | #3501 |
| — | #3505 |
| chemotherapeutic agent | #3512 |
| recommend | #3524 |
| allodynia | #3529 |
| carries | #3539 |
| metastatic disease | #3544 |
| points | #3545 |
| opiates | #3559 |
| stage breast | #3561 |
| 148 | #3565 |
| faced | #3566 |
| patients metastatic | #3574 |
| phase topic | #3583 |
| correlational | #3583 |
| survival women | #3583 |
| 135 | #3586 |
| carboplatin paclitaxel | #3586 |
| oestrogen | #3587 |
| patients experiences | #3588 |
| chemotherapy cycles | #3588 |
| treatment decisions | #3595 |
| 211 | #3596 |
| gold standard | #3607 |
| objective measures | #3608 |
| life qol | #3608 |
| periodically | #3610 |
| thiotepa | #3615 |
| stage iiia | #3618 |
| oral adult | #3619 |
| survival cancer | #3620 |
| benefits risks | #3620 |
| ≥30 | #3620 |
| therapeutic benefit | #3623 |
| improvement quality | #3629 |
| antacids | #3630 |
| 29 patients | #3631 |
| survivals | #3634 |
| racial differences | #3639 |
| complete responses | #3648 |
| colon cancer | #3650 |
| patients adjuvant chemotherapy | #3650 |
| ordinal | #3650 |
| adjuvant chemotherapy patients | #3652 |
| ≥18 years | #3655 |
| parp inhibitor | #3660 |
| bodymass | #3661 |
| 34 patients | #3666 |
| acid antagonists | #3674 |
| 673 | #3682 |
| sigmoidoscopy | #3682 |
| preceded | #3685 |
| 580 | #3686 |
| proportion | #3686 |
| aps | #3688 |
| thirty patients | #3689 |
| cardio | #3690 |
| chemotherapies | #3695 |
| redness | #3700 |
| moxibustion | #3702 |
| options | #3705 |
| electron rats | #3706 |
| relapsefree survival | #3707 |
| study evidence | #3708 |
| cancer chemotherapy | #3712 |
| annually | #3714 |
| instructed | #3716 |
| adjuvant chemotherapy | #3718 |
| 5000 | #3719 |
| exception | #3721 |
| 911 | #3725 |
| breast tissue | #3731 |
| impressive | #3738 |
| combination female | #3741 |
| randomized clinical trial | #3742 |
| foams | #3742 |
| practicing | #3743 |
| anabolic | #3746 |
| late effects | #3752 |
| lymphatic vessels | #3754 |
| weight status | #3758 |
| longterm survival | #3768 |
| menopausal women | #3774 |
| symptom severity | #3782 |
| vertigo | #3788 |
| adversely | #3789 |
| cancer drugs | #3795 |
| compassionate | #3800 |
| 567 | #3801 |
| hormone replacement therapy | #3804 |
| external beam | #3805 |
| sixth | #3806 |
| 600 | #3807 |
| hormone replacement | #3811 |
| anesthetics | #3811 |
| terminal | #3811 |
| colchicine | #3815 |
| phase trial | #3816 |
| centric | #3817 |
| etoposide | #3822 |
| pain control | #3825 |
| cancer prostate | #3830 |
| ploidies | #3831 |
| intramuscularly | #3834 |
| patients experienced | #3834 |
| 16 weeks | #3839 |
| 136 | #3839 |
| patients moderate | #3843 |
| cutaneous | #3846 |
| contraindications | #3847 |
| trpv | #3847 |
| blinding | #3854 |
| seventy | #3854 |
| patients grade | #3855 |
| sharks | #3855 |
| internally | #3858 |
| 23 | #3861 |
| treatment metastatic | #3861 |
| 04 | #3866 |
| futility | #3867 |
| 786 | #3875 |
| individually | #3880 |
| queried | #3882 |
| flushing | #3886 |
| midwestern | #3888 |
| adenomas | #3895 |
| compelling | #3897 |
| dfs survival | #3905 |
| modulators | #3906 |
| received chemotherapy | #3909 |
| sponsored | #3917 |
| bone turnover | #3919 |
| 24 weeks | #3921 |
| hyperactivation | #3922 |
| keywords | #3927 |
| vte patients | #3928 |
| therapies | #3933 |
| myoclonus | #3940 |
| publication clinical trials | #3940 |
| discontinued | #3942 |
| grade 1 | #3945 |
| 61 patients | #3947 |
| bf | #3950 |
| food drug administration | #3951 |
| difficulty | #3953 |
| colorectal | #3955 |
| inhibitors female | #3956 |
| prostate carcinoma | #3961 |
| capsaicin | #3969 |
| manifested | #3970 |
| study drug | #3973 |
| 25 | #3975 |
| accidental | #3976 |
| pain severity | #3977 |
| adenosine triphosphate | #3980 |
| pluronic | #3983 |
| 20 | #3988 |
| 30 years | #3991 |
| toxic effects | #3993 |
| 449 | #3994 |
| weight | #4002 |
| lasting | #4002 |
| 370 | #4004 |
| gait | #4005 |
| sideeffects | #4006 |
| 692 | #4008 |
| kras mutations | #4014 |
| surgery radiation | #4018 |
| estrogenic | #4023 |
| audio | #4034 |
| patients intervention | #4034 |
| year patients | #4039 |
| lumbar spine | #4044 |
| thirteen patients | #4047 |
| tid | #4052 |
| prostatic | #4062 |
| erythropoietin | #4062 |
| nonusers | #4066 |
| flax | #4068 |
| conjunction | #4069 |
| cancer therapy | #4069 |
| 516 | #4075 |
| intravenously | #4077 |
| extremities | #4084 |
| strong evidence | #4087 |
| meaningful | #4099 |
| revisions | #4102 |
| rose | #4108 |
| 2–4 | #4116 |
| iii study | #4120 |
| bone neoplasms | #4124 |
| dermatitis | #4125 |
| noninfiltrating | #4126 |
| favoring | #4126 |
| sphase | #4131 |
| documentation | #4132 |
| 7 months | #4134 |
| definitions | #4138 |
| topic practice patterns | #4138 |
| tablets | #4138 |
| malignant melanoma | #4139 |
| femoral neck | #4139 |
| 269 | #4143 |
| combination therapy | #4144 |
| mbc | #4157 |
| interleukin6 il6 | #4159 |
| 4 months | #4164 |
| 326 | #4175 |
| effective | #4194 |
| noxious | #4196 |
| 10 months | #4199 |
| calcium vitamin | #4201 |
| cancer bone | #4210 |
| depressants | #4210 |
| undertaken | #4211 |
| 2006 | #4220 |
| treatment option | #4223 |
| twothirds | #4232 |
| 18 months | #4236 |
| platinumbased chemotherapy | #4238 |
| drug response | #4250 |
| quinazolines | #4254 |
| anemia patients | #4256 |
| contraindication | #4258 |
| neoplasms colorectal | #4258 |
| treatment discontinuation | #4268 |
| serially | #4268 |
| cation channels | #4271 |
| 58 patients | #4278 |
| 2 4 | #4283 |
| bone density | #4284 |
| survival quality | #4284 |
| day | #4285 |
| inconsistencies | #4289 |
| utilized | #4289 |
| colorectal neoplasms | #4297 |
| rheumatism | #4301 |
| node negative | #4307 |
| aged breast | #4313 |
| bioavailable | #4314 |
| chemotherapy treatment | #4323 |
| reductions | #4326 |
| prednisolone | #4326 |
| vast | #4327 |
| bone diseases | #4330 |
| primary endpoints | #4331 |
| healthy women | #4331 |
| reply | #4340 |
| firstline chemotherapy | #4343 |
| treatment studies | #4355 |
| equally | #4357 |
| institute | #4359 |
| neoplasms combined | #4359 |
| participated | #4360 |
| detrimental effects | #4367 |
| outcome data | #4368 |
| 3 months | #4373 |
| sleeping | #4376 |
| discontinuation | #4381 |
| preliminary | #4385 |
| carcinoma ductal | #4389 |
| time surgery | #4393 |
| therapies patients | #4394 |
| judgment | #4395 |
| 12 week | #4396 |
| drug combinations | #4402 |
| repeatedly | #4402 |
| hyperalgesia | #4411 |
| grouping | #4414 |
| minnesota | #4415 |
| purpose | #4417 |
| “ | #4424 |
| evaluate | #4425 |
| 1015 | #4427 |
| 14 months | #4429 |
| balance | #4430 |
| studies colorectal | #4431 |
| 80 breast | #4431 |
| low doses | #4436 |
| drg neurons | #4437 |
| pain relief | #4438 |
| documented | #4440 |
| relevant studies | #4445 |
| improve patient | #4446 |
| day patients | #4446 |
| summarize | #4450 |
| clinical predictors | #4455 |
| clinical parameters | #4460 |
| humanized antineoplastic | #4464 |
| pain measurement | #4465 |
| 80 | #4465 |
| fecal | #4466 |
| clinical practice guidelines | #4490 |
| 05 | #4494 |
| risk breast cancer | #4499 |
| humans lymph | #4501 |
| received | #4504 |
| drug administration | #4505 |
| stimulants | #4510 |
| axillary | #4521 |
| 5 | #4523 |
| daily activities | #4523 |
| sedation | #4529 |
| ductal breast | #4530 |
| ganglion | #4530 |
| gynecologic | #4530 |
| disease recurrence | #4531 |
| cancer methods | #4534 |
| hematology | #4535 |
| stimulant | #4536 |
| disabling | #4536 |
| sphingolipids | #4537 |
| natural | #4537 |
| diarrhea | #4540 |
| drug effects | #4540 |
| journal | #4544 |
| impairments | #4546 |
| 3 4 | #4550 |
| ganglia spinal | #4552 |
| continuation | #4558 |
| outcome measures | #4561 |
| financial | #4562 |
| rescue therapy | #4564 |
| clinical | #4564 |
| 376 | #4567 |
| rbc | #4569 |
| reliability validity | #4575 |
| 4 | #4575 |
| successes | #4577 |
| single blind | #4583 |
| tumor regression | #4587 |
| explore | #4588 |
| hydroxytryptamine | #4591 |
| risk bleeding | #4591 |
| mmf | #4592 |
| cumulative | #4604 |
| tenderness | #4606 |
| 115 | #4609 |
| longer duration | #4612 |
| chemopreventive | #4617 |
| emphasizes | #4620 |
| neoplasms dna | #4626 |
| throat | #4633 |
| caf | #4636 |
| patients increase | #4642 |
| 6 12 | #4647 |
| neuropathies | #4647 |
| daily dose | #4647 |
| tumor recurrence | #4653 |
| 1 study | #4661 |
| data studies | #4662 |
| 96 | #4664 |
| dose chemotherapy | #4665 |
| adpribose | #4665 |
| increased incidence | #4669 |
| treatments | #4674 |
| qol patients | #4679 |
| vitality | #4683 |
| peaked | #4684 |
| hazards | #4689 |
| deprivation | #4691 |
| 29 | #4693 |
| secondary analysis | #4699 |
| treatment survival | #4701 |
| dose | #4704 |
| low dose | #4708 |
| dose reduction | #4712 |
| reference lists | #4722 |
| preliminary study | #4733 |
| mediastinum | #4734 |
| ” | #4734 |
| assessment tool | #4740 |
| phase 2 trial | #4741 |
| vigor | #4751 |
| percentage patients | #4752 |
| cgy | #4762 |
| efficacy tolerability | #4773 |
| analysis neoplasm | #4783 |
| recommended | #4785 |
| adt | #4790 |
| invasive breast cancer | #4792 |
| 353 | #4795 |
| proven | #4798 |
| 009 | #4806 |
| corticosteroid | #4806 |
| 538 | #4810 |
| tears | #4810 |
| evaluations | #4813 |
| circulating concentrations | #4817 |
| improved quality | #4818 |
| cancer compared | #4818 |
| acetylcysteine | #4821 |
| capecitabine | #4829 |
| musculoskeletal | #4830 |
| symptom burden | #4836 |
| multicenter | #4836 |
| carcinoma small | #4837 |
| bridged | #4837 |
| tubulin | #4841 |
| seer program | #4841 |
| aes | #4846 |
| 60 | #4848 |
| 55 patients | #4854 |
| receipt | #4857 |
| 381 | #4861 |
| patients recurrence | #4868 |
| patients prostate | #4870 |
| individual patient data | #4876 |
| amines | #4886 |
| neck neoplasms humans | #4890 |
| 048 | #4901 |
| receptor egfr | #4904 |
| fisher | #4910 |
| crc patients | #4911 |
| lastly | #4917 |
| systemic therapy | #4921 |
| harms | #4922 |
| platinum | #4924 |
| stage iiib | #4925 |
| abstinence | #4926 |
| unfavorable | #4927 |
| existed | #4928 |
| basal cell carcinoma | #4933 |
| ≥1 | #4937 |
| 727 | #4942 |
| coadministration | #4946 |
| sensitization | #4956 |
| screening tool | #4956 |
| 9 months | #4960 |
| plethora | #4970 |
| subsequently | #4974 |
| eligibility | #4975 |
| equivocal | #4980 |
| cancer background | #4981 |
| optimal management | #4983 |
| depot | #4989 |
| deep vein thrombosis | #4992 |
| cumulative dose | #4996 |
| recurrence free | #4997 |
| exercise intervention | #5003 |
| lessons | #5005 |
| metastatic prostate | #5016 |
| situ carcinoma | #5017 |
| based cohort | #5018 |
| combined treatment | #5027 |
| routine clinical | #5028 |
| biphasic | #5029 |
| multicenter trial | #5039 |
| initiate | #5045 |
| sedative | #5055 |
| actively | #5058 |
| missing data | #5060 |
| favorably | #5071 |
| osteoporosis | #5073 |
| physical symptoms | #5075 |
| 3 trials | #5076 |
| methotrexate | #5077 |
| karnofsky performance | #5084 |
| genistein | #5084 |
| study incidence | #5086 |
| phenobarbital | #5091 |
| 100 patients | #5098 |
| 342 | #5099 |
| pyrimidinones | #5104 |
| version | #5104 |
| bortezomib | #5105 |
| cisplatin treatment | #5106 |
| published | #5116 |
| skin neoplasms | #5121 |
| ntprobnp | #5124 |
| conventional chemotherapy | #5126 |
| reducing | #5131 |
| physical therapy | #5131 |
| 120 | #5141 |
| topical application | #5142 |
| indomethacin | #5143 |
| medicine humans | #5149 |
| higher rate | #5154 |
| women early | #5155 |
| lower rates | #5157 |
| bisphosphonates | #5165 |
| resolve | #5169 |
| prognostic | #5176 |
| analysis randomized | #5177 |
| compiled | #5181 |
| cycle | #5186 |
| antiinflammatory agents | #5187 |
| supplement | #5201 |
| thalidomide | #5207 |
| 30 patients | #5214 |
| references | #5218 |
| cisplatin | #5225 |
| april | #5231 |
| medications | #5239 |
| identical | #5243 |
| dying | #5243 |
| randomised controlled trial | #5244 |
| article | #5249 |
| humans lung | #5249 |
| insomnia | #5255 |
| patients time | #5257 |
| conventionally | #5257 |
| mitoxantrone | #5265 |
| progestins | #5266 |
| resectable | #5269 |
| caring | #5270 |
| low molecular | #5270 |
| negative impact | #5277 |
| health disparities | #5278 |
| sed | #5291 |
| undergo | #5306 |
| gynecology | #5309 |
| parenteral nutrition | #5310 |
| vaporizers | #5317 |
| cancer prevention | #5319 |
| conflicting | #5325 |
| pelvic | #5326 |
| ineligible | #5327 |
| 404 | #5333 |
| anticipated | #5335 |
| alkaloids | #5335 |
| administered | #5339 |
| methods design | #5344 |
| patient data | #5349 |
| monophenol | #5351 |
| sensation | #5359 |
| perceived | #5359 |
| current practice | #5361 |
| colorectal cancers | #5362 |
| answered | #5376 |
| neurologists | #5377 |
| 346 | #5385 |
| adenosylmethionine | #5393 |
| isotretinoin | #5394 |
| declining | #5396 |
| judged | #5403 |
| responding | #5412 |
| study women | #5421 |
| officinalis | #5423 |
| stage iii | #5423 |
| 33 | #5425 |
| colonic polyps | #5444 |
| axilla | #5468 |
| 57 | #5470 |
| manner | #5473 |
| p0006 | #5481 |
| minutes | #5482 |
| baseline characteristics | #5486 |
| health records | #5490 |
| pufas | #5492 |
| based interventions | #5496 |
| 167 | #5504 |
| preclinical models | #5506 |
| methylases | #5508 |
| ovary | #5512 |
| thromboembolic events | #5518 |
| patient demographics | #5521 |
| neoplasms humans | #5525 |
| 410 | #5535 |
| pooled | #5548 |
| medical conditions | #5556 |
| 03 | #5571 |
| cancer center | #5573 |
| ready | #5580 |
| acne | #5582 |
| routine clinical practice | #5583 |
| stage patients | #5590 |
| dropped | #5593 |
| 002 | #5594 |
| current literature | #5598 |
| patient quality | #5604 |
| woman | #5605 |
| 41 | #5611 |
| polyps | #5620 |
| carnitine | #5623 |
| enteral | #5633 |
| sensory | #5638 |
| treatment approaches | #5638 |
| lung carcinoma | #5642 |
| new therapies | #5642 |
| 0007 | #5648 |
| concurrent | #5672 |
| treatment regimens | #5676 |
| guideline | #5679 |
| constipation | #5683 |
| sf36 | #5684 |
| n6 | #5687 |
| standard chemotherapy | #5688 |
| neuromodulation | #5689 |
| 50 | #5693 |
| renewed | #5694 |
| dexamethasone | #5694 |
| desire | #5695 |
| preserve | #5696 |
| online | #5699 |
| patients therapy | #5701 |
| nonsignificant | #5703 |
| multiplied | #5704 |
| raise | #5705 |
| cancer type | #5708 |
| androgen | #5716 |
| trials rcts | #5722 |
| complete | #5730 |
| specialist | #5730 |
| dna content | #5733 |
| serial | #5736 |
| provider | #5761 |
| tumor breast | #5762 |
| interruption | #5762 |
| tumor stage | #5762 |
| total score | #5766 |
| impair | #5770 |
| versus | #5773 |
| chance | #5779 |
| mucous | #5783 |
| carcinoma situ | #5783 |
| nicotine | #5783 |
| exploratory study | #5790 |
| node excision | #5795 |
| 345 | #5805 |
| higher doses | #5806 |
| 395 | #5814 |
| vitamin | #5817 |
| systemic effects | #5827 |
| patients aspirin | #5828 |
| patient experience | #5830 |
| 4 5 | #5837 |
| cancer breast | #5842 |
| leukocyte count | #5850 |
| intermediate risk | #5852 |
| selfreported | #5855 |
| patients survival | #5857 |
| stools | #5858 |
| subgroups patients | #5873 |
| 405 | #5877 |
| interfere | #5877 |
| excitatory amino | #5883 |
| enrollment | #5886 |
| neoplasm recurrence | #5887 |
| exercises | #5888 |
| totally | #5898 |
| response relationship | #5899 |
| potential mechanisms | #5909 |
| 3 | #5910 |
| 0 1 | #5917 |
| trastuzumab | #5925 |
| alternating | #5926 |
| gel | #5930 |
| acids omega3 | #5935 |
| humans injections | #5940 |
| pooled analysis | #5946 |
| dysplastic | #5947 |
| questionnaires adult | #5952 |
| treatment toxicity | #5954 |
| previous | #5955 |
| treatment failure | #5964 |
| symptoms depression | #5967 |
| returned | #5979 |
| confounding | #5990 |
| analogue | #5995 |
| devoted | #5996 |
| 239 | #5997 |
| evaluation studies | #5997 |
| icd9 | #6000 |
| sectional survey | #6002 |
| validated | #6007 |
| serum patients | #6010 |
| insulinlike growth factor | #6013 |
| 1977 | #6013 |
| prognostic indicator | #6018 |
| descriptions | #6019 |
| minute | #6019 |
| worsened | #6026 |
| sentinel node | #6028 |
| chemotherapy radiotherapy | #6041 |
| 0013 | #6041 |
| grade 3 | #6042 |
| 243 | #6045 |
| new evidence | #6049 |
| month | #6052 |
| institutional | #6061 |
| syndrome | #6065 |
| protective agents | #6066 |
| caution | #6067 |
| stool | #6070 |
| 480 | #6082 |
| subscales | #6083 |
| approved | #6097 |
| aspect | #6098 |
| 20 years | #6102 |
| 43 | #6104 |
| hormone therapy | #6108 |
| increment | #6109 |
| tests prognosis | #6116 |
| spitzer | #6118 |
| conducted | #6120 |
| randomized controlled trial | #6125 |
| routes | #6128 |
| surviving | #6156 |
| antiepileptic | #6164 |
| kilogram | #6167 |
| endpoints | #6173 |
| inception | #6184 |
| skin diseases | #6188 |
| 241 | #6189 |
| omega3 | #6193 |
| selective serotonin | #6195 |
| boronic | #6199 |
| intraepithelial | #6204 |
| 16 | #6215 |
| 900 | #6218 |
| female | #6221 |
| central venous | #6229 |
| combination treatment | #6232 |
| 62 | #6234 |
| epa | #6239 |
| randomized clinical trials | #6242 |
| invasive breast | #6249 |
| patients colorectal | #6253 |
| treated mice | #6255 |
| exploratory | #6257 |
| 58 | #6258 |
| asymptomatic patients | #6260 |
| metastasis neoplasm | #6261 |
| receptors progesterone | #6265 |
| historically | #6269 |
| palliative | #6270 |
| protocols | #6275 |
| disclosure | #6280 |
| psychotropic drugs | #6280 |
| ease | #6282 |
| 2000 | #6283 |
| xerostomia | #6284 |
| followup patients | #6293 |
| innovations | #6299 |
| scopus | #6300 |
| insignificant | #6302 |
| benzhydryl | #6302 |
| survival female | #6312 |
| 328 | #6314 |
| chi2 | #6320 |
| prospective | #6330 |
| lobular | #6343 |
| counseling | #6344 |
| 59 | #6346 |
| rigorous | #6347 |
| clinically | #6350 |
| endocrine therapy | #6365 |
| aged | #6372 |
| fentanyl | #6372 |
| 2007 | #6385 |
| venous thromboembolism vte | #6385 |
| epidermal growth | #6393 |
| infusions | #6393 |
| breadth | #6395 |
| physicians | #6402 |
| cronbach | #6404 |
| narcotic | #6407 |
| vitro model | #6413 |
| early intervention | #6424 |
| sexes | #6425 |
| initial treatment | #6426 |
| endocrinology | #6432 |
| 2 3 | #6433 |
| psychotropic | #6439 |
| pittsburgh | #6439 |
| multinational | #6440 |
| entire | #6440 |
| 361 | #6445 |
| counts | #6446 |
| soybeans | #6449 |
| sex hormones | #6452 |
| logs | #6453 |
| congeners | #6455 |
| quality | #6458 |
| termed | #6470 |
| intraluminal | #6471 |
| 75 | #6471 |
| life health | #6478 |
| n16 | #6481 |
| treatment guidelines | #6482 |
| patients 2 | #6485 |
| time diagnosis | #6486 |
| mcf7 cells | #6496 |
| records | #6498 |
| abcb1 | #6499 |
| ≥18 | #6501 |
| usual patients | #6512 |
| disease stage | #6515 |
| adenoma | #6520 |
| complementary | #6521 |
| consultation | #6524 |
| guidance | #6531 |
| iu | #6533 |
| ranked | #6536 |
| developments | #6540 |
| transfusions | #6551 |
| 004 | #6552 |
| tumor location | #6554 |
| 86 | #6567 |
| 0004 | #6575 |
| analog | #6576 |
| 53 | #6591 |
| abstracts | #6593 |
| baseline patients | #6598 |
| initiated | #6602 |
| acting | #6604 |
| colonic neoplasms | #6605 |
| pyrazines | #6608 |
| l3 | #6612 |
| hemoglobins | #6612 |
| 287 | #6614 |
| decisions | #6614 |
| fourth | #6615 |
| phase | #6617 |
| 02 | #6618 |
| surveys questionnaires | #6621 |
| hrt | #6622 |
| curative resection | #6623 |
| familiar | #6641 |
| pellet | #6646 |
| guidelines | #6646 |
| crf | #6648 |
| hormone receptor | #6651 |
| patients health | #6651 |
| courses | #6664 |
| randomized controlled trials | #6666 |
| emerging evidence | #6681 |
| osseous | #6682 |
| physical health | #6683 |
| tools | #6685 |
| figure | #6689 |
| dex | #6691 |
| caloric | #6694 |
| erectile dysfunction | #6694 |
| develops | #6696 |
| neoplasm metastasis | #6699 |
| radiotherapy chemotherapy | #6702 |
| hypothesized | #6702 |
| ketamine | #6710 |
| consecutive | #6717 |
| colorectal cancer patients | #6717 |
| interprofessional | #6728 |
| detailed | #6731 |
| testicular cancer | #6743 |
| score | #6745 |
| 295 | #6750 |
| replacement therapy | #6751 |
| quit | #6751 |
| difference | #6763 |
| grade | #6770 |
| lower incidence | #6773 |
| true | #6776 |
| ocular | #6783 |
| prevents | #6784 |
| titration | #6787 |
| pain management | #6793 |
| frequently | #6801 |
| search strategy | #6801 |
| longest | #6801 |
| chart review | #6802 |
| rounds | #6804 |
| 344 | #6806 |
| hepcidin | #6809 |
| controlled studies | #6810 |
| fulfilled | #6810 |
| participating | #6811 |
| mice treated | #6818 |
| detect | #6826 |
| ovarian function | #6841 |
| treatment advanced | #6842 |
| integrative | #6851 |
| early treatment | #6853 |
| exercise therapy | #6861 |
| classification | #6874 |
| inventory | #6877 |
| narrative | #6879 |
| drg | #6883 |
| routinely | #6887 |
| new drugs | #6889 |
| secondary | #6891 |
| concerns | #6896 |
| strength muscle | #6898 |
| differ | #6903 |
| 277 | #6904 |
| serum concentrations | #6912 |
| tumor formation | #6917 |
| 5 ht | #6918 |
| controversial | #6930 |
| summarizes | #6932 |
| mass loss | #6941 |
| factors breast | #6942 |
| cbd | #6942 |
| iiib | #6944 |
| laparotomy | #6953 |
| diarrhoea | #6955 |
| tartrate | #6960 |
| quarter | #6970 |
| skin temperature | #6981 |
| regressions | #6981 |
| ais | #6986 |
| wearing | #6990 |
| calorie | #6990 |
| quiet | #6990 |
| definition | #6994 |
| 35 | #6994 |
| seer | #7001 |
| promise | #7002 |
| patients developed | #7006 |
| 1 year | #7011 |
| initially | #7015 |
| women study | #7019 |
| hemorrhage humans | #7020 |
| breast cancers | #7030 |
| 051 | #7045 |
| metaanalyses | #7049 |
| animal doseresponse relationship | #7050 |
| neoplasms risk | #7063 |
| interested | #7067 |
| patients 1 | #7067 |
| 50 patients | #7068 |
| 31 | #7083 |
| screening middle | #7089 |
| total | #7097 |
| overview | #7098 |
| asian patients | #7111 |
| neu | #7113 |
| approval | #7114 |
| 97 | #7121 |
| neoplasms treatment | #7122 |
| polyadp | #7124 |
| prostate cancer | #7130 |
| neoplasms female | #7130 |
| 261 | #7131 |
| female gastrointestinal | #7143 |
| strengthened | #7144 |
| neuroprotection | #7147 |
| 833 | #7154 |
| therapy humans | #7165 |
| estrogens | #7171 |
| appropriateness | #7179 |
| breast cancer risk | #7187 |
| expect | #7188 |
| pik3ca | #7201 |
| confirm | #7211 |
| uncontrolled | #7220 |
| estrogen | #7228 |
| entity | #7234 |
| discusses | #7238 |
| agents steroidal | #7255 |
| 203 | #7262 |
| questionnaire | #7264 |
| ameliorates | #7264 |
| chosen | #7266 |
| popularity | #7283 |
| additionally | #7295 |
| neoplasms primary | #7296 |
| outpatients | #7296 |
| cinahl | #7333 |
| node biopsy | #7334 |
| increased survival | #7336 |
| 10 | #7340 |
| aged anti | #7343 |
| stages | #7347 |
| superficial | #7353 |
| evaluates | #7353 |
| radiotherapy adjuvant | #7358 |
| prognosis prospective | #7361 |
| firstline therapy | #7376 |
| epo | #7378 |
| eating | #7379 |
| short | #7384 |
| square distribution | #7390 |
| 47 | #7393 |
| noradrenergic | #7407 |
| curative | #7416 |
| rfs | #7416 |
| esr1 | #7417 |
| radiotherapy | #7433 |
| genital | #7435 |
| emphasis | #7436 |
| receptor agonists | #7436 |
| confirmatory | #7436 |
| naphthalenes | #7437 |
| cancer treated | #7438 |
| established | #7449 |
| 25 patients | #7456 |
| clinical evaluation | #7467 |
| 199 | #7478 |
| 1st | #7482 |
| 058 | #7484 |
| wasting | #7488 |
| prognosis proportional | #7488 |
| treatment strategy | #7489 |
| bolus | #7496 |
| genetic factors | #7499 |
| metastatic colorectal | #7501 |
| gonadotropin | #7504 |
| 259 | #7507 |
| november | #7509 |
| dysplasia | #7523 |
| transaminases | #7524 |
| objectively | #7526 |
| melanoma patients | #7528 |
| cancer vaccines | #7531 |
| infertility | #7534 |
| investigators | #7534 |
| october | #7539 |
| tumor colorectal | #7541 |
| local neoplasm | #7543 |
| 315 | #7558 |
| primary treatment | #7559 |
| adequacy | #7564 |
| concurrently | #7578 |
| kaplanmeier method | #7583 |
| intraductal | #7586 |
| 00001 | #7589 |
| patients head | #7594 |
| grades | #7605 |
| single dose | #7607 |
| tretinoin | #7608 |
| discussions | #7609 |
| chronic pain | #7615 |
| coumarins | #7616 |
| gain | #7620 |
| opinions | #7621 |
| interval | #7624 |
| ploidy | #7624 |
| receptor antagonists | #7632 |
| receptor erbb2 | #7633 |
| pharmacists | #7641 |
| local neoplasms | #7642 |
| sequelae | #7645 |
| metastatic colorectal cancer | #7656 |
| clinical benefit | #7666 |
| retinoids | #7678 |
| corticosteroids | #7684 |
| visits | #7691 |
| longterm effects | #7695 |
| evident | #7696 |
| 1 day | #7699 |
| monitored | #7699 |
| 026 | #7710 |
| publication biomarkers | #7713 |
| surveys | #7725 |
| 021 | #7725 |
| recurrence | #7726 |
| risk breast | #7728 |
| thrombophilia | #7734 |
| administration | #7744 |
| washout | #7744 |
| onethird | #7749 |
| nicotinic | #7751 |
| rank | #7758 |
| cancer recurrence | #7763 |
| independent predictors | #7776 |
| omega3 fatty | #7779 |
| treatment time | #7780 |
| serotonergic | #7785 |
| pathophysiology | #7796 |
| negative effects | #7805 |
| 14 | #7807 |
| ovarian neoplasms | #7811 |
| erectile | #7812 |
| clinicians | #7820 |
| gonadal | #7839 |
| 12 months | #7842 |
| swallowing | #7843 |
| subcutaneous | #7855 |
| pain intensity | #7856 |
| patient centered | #7866 |
| thiophenes | #7869 |
| 0 | #7876 |
| hemoglobins humans | #7892 |
| statistic | #7900 |
| physical function | #7917 |
| impacted | #7927 |
| ago | #7927 |
| 40 | #7933 |
| dysfunctions | #7950 |
| androgens | #7955 |
| 5year survival | #7956 |
| comparing | #7956 |
| advanced | #7957 |
| generally | #7963 |
| 305 | #7965 |
| ductal carcinoma | #7968 |
| ≤ | #7972 |
| actuarial | #7973 |
| 055 | #7975 |
| individualized | #7981 |
| collect | #7982 |
| situation | #7983 |
| female genital | #7985 |
| 062 | #8006 |
| 278 | #8020 |
| noninferiority | #8032 |
| powered | #8051 |
| preclinical | #8062 |
| genders | #8063 |
| intractable | #8063 |
| colorectal cancer crc | #8064 |
| 45 | #8065 |
| 208 | #8069 |
| 105 | #8086 |
| sixteen | #8088 |
| humans longitudinal | #8090 |
| relating | #8096 |
| expand | #8099 |
| resultant | #8100 |
| trial background | #8102 |
| occurred | #8107 |
| irrespective | #8127 |
| analgesics opioid | #8128 |
| 5 years | #8132 |
| reduce | #8141 |
| receptors estrogen | #8142 |
| methodswe | #8150 |
| entering | #8154 |
| translational | #8164 |
| facilitating | #8173 |
| dose escalation | #8185 |
| specific antigen | #8189 |
| edetic | #8191 |
| ondansetron | #8204 |
| withdrawal | #8206 |
| tnf alpha | #8213 |
| cancer detection | #8218 |
| popular | #8220 |
| b4 | #8224 |
| mild | #8234 |
| spearman | #8242 |
| patients adult | #8249 |
| regard | #8249 |
| committees | #8252 |
| stage | #8255 |
| parp | #8258 |
| dietary supplements | #8265 |
| treated | #8266 |
| modalities | #8269 |
| tobramycin | #8285 |
| antitumor activity | #8287 |
| neoplasms male | #8289 |
| patient groups | #8315 |
| 201 | #8324 |
| estradiol | #8325 |
| risk cancer | #8327 |
| triazines | #8331 |
| wellbeing | #8341 |
| sertraline | #8344 |
| concern | #8345 |
| cell lung | #8349 |
| pubmed | #8352 |
| patient treatment | #8362 |
| year follow | #8372 |
| pharmacogenetics | #8372 |
| calcium | #8389 |
| clinical activity | #8395 |
| choose | #8397 |
| 6 cycles | #8403 |
| predisposing | #8405 |
| costly | #8417 |
| preparations | #8422 |
| undergoing | #8422 |
| neck neoplasms | #8435 |
| expense | #8447 |
| married | #8448 |
| detecting | #8460 |
| testing | #8465 |
| underestimate | #8466 |
| composition body | #8478 |
| 3 trial | #8482 |
| 37 | #8482 |
| eruptions | #8486 |
| oncologic | #8488 |
| neuromuscular | #8489 |
| clinical experience | #8509 |
| 39 patients | #8527 |
| respond | #8553 |
| cyclophosphamide | #8562 |
| 253 | #8570 |
| average | #8576 |
| 020 | #8587 |
| stratified | #8596 |
| exists | #8598 |
| ttp | #8610 |
| standard therapy | #8620 |
| 81 | #8624 |
| 015 | #8629 |
| estrogen receptors | #8637 |
| morphine | #8637 |
| cancer female | #8639 |
| remain | #8643 |
| fda | #8646 |
| legs | #8657 |
| initial | #8658 |
| relative risks | #8659 |
| practitioners | #8676 |
| functional status | #8679 |
| syndrome patients | #8684 |
| 6 months | #8685 |
| egfr | #8692 |
| grip | #8695 |
| single nucleotide polymorphisms | #8700 |
| notable | #8700 |
| molecular markers | #8705 |
| threatening | #8705 |
| loss | #8714 |
| aged 80 | #8715 |
| selfreports | #8722 |
| leptin | #8728 |
| 32 patients | #8731 |
| colorectal cancer | #8743 |
| drug | #8748 |
| perspectives | #8751 |
| majority | #8756 |
| illustrates | #8757 |
| inhibitors | #8764 |
| repeated | #8765 |
| 123 | #8769 |
| 2001 | #8774 |
| survivorship | #8779 |
| 066 | #8786 |
| aged models | #8792 |
| mouth | #8800 |
| real | #8800 |
| prospective randomized | #8808 |
| providers | #8813 |
| question | #8814 |
| advanced stage | #8823 |
| accumulating | #8842 |
| groups patients | #8847 |
| ferric | #8858 |
| uremic | #8865 |
| concomitant | #8886 |
| highrisk | #8893 |
| enteral nutrition | #8908 |
| publication aged aged | #8919 |
| predefined | #8929 |
| supplemental | #8938 |
| negatively | #8961 |
| 017 | #8966 |
| 145 | #8971 |
| ovaries | #8984 |
| demographics | #8989 |
| ribose | #8990 |
| 28 patients | #8996 |
| 2 study | #9000 |
| acceptability | #9006 |
| dna neoplasm | #9008 |
| 304 | #9013 |
| lung neoplasms | #9014 |
| analyses | #9017 |
| bivariate | #9019 |
| longer | #9020 |
| favored | #9020 |
| 300 | #9035 |
| 18 | #9037 |
| literature | #9043 |
| 223 | #9060 |
| vagina | #9062 |
| analgesics | #9073 |
| women risk | #9074 |
| 116 | #9084 |
| venous | #9089 |
| 275 | #9107 |
| consisted | #9112 |
| medical treatment | #9114 |
| 70 | #9117 |
| instability | #9124 |
| oral anticoagulants | #9131 |
| referred | #9132 |
| 286 | #9133 |
| gene expression profiling | #9135 |
| rated | #9162 |
| 232 | #9167 |
| 1987 | #9170 |
| 103 | #9180 |
| germ cell | #9183 |
| erbb receptors | #9195 |
| feeling | #9196 |
| moderate | #9197 |
| embryonal | #9202 |
| erythropoiesis | #9216 |
| 12 patients | #9228 |
| predict | #9230 |
| approaches | #9232 |
| 320 | #9249 |
| psycinfo | #9250 |
| update | #9253 |
| incidence | #9265 |
| eighteen | #9277 |
| stimulate | #9281 |
| manifestation | #9291 |
| primary | #9292 |
| administrative | #9293 |
| greater risk | #9301 |
| favorable | #9308 |
| hypnotics | #9310 |
| 94 | #9317 |
| systematic literature | #9317 |
| 15 | #9332 |
| possess | #9332 |
| participant | #9336 |
| grip strength | #9341 |
| metastatic | #9361 |
| lives | #9367 |
| cycles | #9371 |
| acceptable | #9383 |
| mechanisms action | #9383 |
| ambulatory | #9385 |
| drug female | #9385 |
| postulated | #9389 |
| 177 | #9431 |
| 82 | #9435 |
| 28 | #9436 |
| consisting | #9437 |
| neurologic | #9443 |
| definitive | #9454 |
| partial response | #9454 |
| abdomen | #9468 |
| 3 groups | #9499 |
| death patients | #9509 |
| ophthalmic | #9514 |
| recurrence patients | #9518 |
| serving | #9539 |
| 500 | #9542 |
| cancer crc | #9542 |
| 006 | #9545 |
| 065 | #9547 |
| jaw | #9565 |
| decisionmaking | #9568 |
| imbalance | #9575 |
| melphalan | #9579 |
| similarities | #9580 |
| add | #9583 |
| sentinel lymph | #9619 |
| 68 | #9624 |
| progesterone receptor | #9627 |
| addressed | #9641 |
| oral cavity | #9657 |
| prednisone | #9662 |
| electroacupuncture | #9668 |
| publications | #9669 |
| referrals | #9677 |
| items | #9695 |
| p0004 | #9696 |
| fell | #9698 |
| 149 | #9702 |
| nerve injury | #9707 |
| adenocarcinoma aged | #9733 |
| logistic regression analysis | #9737 |
| smokers | #9746 |
| cope | #9749 |
| erbb | #9762 |
| experts | #9767 |
| carcinoma patients | #9777 |
| sleep disorders | #9784 |
| food intake | #9785 |
| priority | #9791 |
| monoclonal humanized | #9791 |
| 0002 | #9797 |
| remission induction | #9812 |
| exercise female | #9831 |
| trends | #9835 |
| 7 | #9836 |
| patient age | #9855 |
| saponins | #9856 |
| palliation | #9857 |
| neuroprotective agents | #9871 |
| avoid | #9872 |
| clinical outcomes patients | #9872 |
| 95ci | #9875 |
| goals | #9882 |
| bleeding | #9884 |
| axonal | #9897 |
| illness | #9909 |
| 89 | #9921 |
| injections | #9941 |
| zinc | #9942 |
| mitigate | #9952 |
| provision | #9954 |
| variety | #9963 |
| telephone | #9968 |
| recurrence rates | #9969 |
| education topic | #9980 |
| 88 | #9985 |
| behavioral therapy | #9988 |
| ethics | #9991 |
| 400 | #9997 |
| growing | #9999 |
| square | #10005 |
| reactions female | #10007 |
| prescribing | #10007 |
| advanced disease | #10009 |
| dosedependent manner | #10013 |
| exist | #10016 |
| art | #10020 |
| bone resorption | #10023 |
| progressed | #10053 |
| women health | #10061 |
| autonomic | #10070 |
| ortho | #10071 |
| reason | #10076 |
| percentages | #10095 |
| candidates | #10096 |
| exceptions | #10097 |
| 76 | #10099 |
| node dissection | #10100 |
| il1β | #10101 |
| criterion | #10109 |
| disease adult | #10113 |
| 56 | #10120 |
| predictive factors | #10154 |
| preference | #10168 |
| micronutrients | #10188 |
| categorized | #10215 |
| measures | #10218 |
| monoamine | #10221 |
| 12 | #10224 |
| 40 patients | #10233 |
| demonstrate | #10251 |
| lack | #10261 |
| curve | #10266 |
| guideline adherence | #10267 |
| 256 | #10271 |
| developed | #10274 |
| achieving | #10279 |
| caused | #10317 |
| higher incidence | #10325 |
| sarcomas | #10341 |
| epidermal | #10345 |
| variables | #10354 |
| bone mineral density | #10369 |
| anemia | #10385 |
| cell transplant | #10386 |
| morning | #10392 |
| survival dfs | #10400 |
| changed | #10400 |
| 3 5 | #10407 |
| 142 | #10413 |
| 141 | #10436 |
| smoking cessation | #10437 |
| chart | #10440 |
| 041 | #10450 |
| revised | #10485 |
| 24 hours | #10489 |
| lvef | #10497 |
| masked | #10500 |
| syndromes | #10508 |
| mineral density | #10522 |
| longitudinal studies | #10522 |
| effort | #10550 |
| instruments | #10555 |
| 154 | #10558 |
| define | #10560 |
| 650 | #10565 |
| surveillance | #10571 |
| persisted | #10581 |
| elucidate | #10582 |
| informed | #10584 |
| trend | #10585 |
| months 95 | #10586 |
| encountered | #10600 |
| 667 | #10608 |
| fewer | #10613 |
| counselling | #10617 |
| doxorubicin | #10617 |
| academic | #10623 |
| include | #10636 |
| concert | #10640 |
| european society | #10663 |
| histories | #10672 |
| curative intent | #10673 |
| upper extremity | #10688 |
| vitamins | #10697 |
| examinations | #10703 |
| treatment chronic | #10721 |
| prognostic significance | #10733 |
| median followup | #10743 |
| tests | #10751 |
| edema | #10753 |
| enter | #10757 |
| anticoagulants | #10757 |
| fat mass | #10763 |
| iiia | #10779 |
| median duration | #10779 |
| patients response | #10788 |
| induction chemotherapy | #10795 |
| 60 years | #10802 |
| 182 | #10803 |
| clinic | #10803 |
| columbia | #10805 |
| 73 | #10812 |
| insufficient | #10814 |
| rcts | #10818 |
| internal consistency | #10826 |
| 21 | #10828 |
| advisory | #10839 |
| noradrenaline | #10843 |
| recurrent | #10863 |
| randomised controlled | #10873 |
| determine | #10873 |
| hydroxy | #10874 |
| neck cancer | #10884 |
| clinicaltrialsgov | #10885 |
| nighttime | #10888 |
| felt | #10892 |
| held | #10899 |
| 1 patient | #10911 |
| 9 patients | #10922 |
| limited | #10928 |
| occurring | #10934 |
| supplements | #10937 |
| kits | #10950 |
| head neck cancer | #10956 |
| cognition disorders | #10958 |
| start | #10961 |
| retrospective review | #10966 |
| failure | #10978 |
| needed | #10981 |
| squamous cell carcinoma | #10982 |
| registry | #10999 |
| physiology | #11017 |
| 155 | #11028 |
| 030 | #11031 |
| agents drug | #11051 |
| rationale | #11080 |
| ascertained | #11084 |
| interventions | #11094 |
| soft tissue | #11097 |
| international society | #11105 |
| smoking | #11105 |
| 3 years | #11121 |
| 043 | #11122 |
| editorial | #11123 |
| years diagnosis | #11128 |
| sleep wake | #11133 |
| practice guidelines | #11135 |
| sick | #11135 |
| 091 | #11146 |
| decrease | #11150 |
| extensive | #11160 |
| head neck | #11164 |
| reduces | #11166 |
| 127 | #11168 |
| subclinical | #11185 |
| decreases | #11199 |
| progesterone | #11207 |
| facilitate | #11216 |
| gamma | #11222 |
| 2004 | #11246 |
| secondary outcome | #11250 |
| anticoagulation | #11251 |
| 1983 | #11257 |
| survival | #11259 |
| prostate | #11267 |
| contributed | #11278 |
| cognitive behavioral | #11279 |
| diploid | #11281 |
| therapy neoplasm | #11287 |
| snps | #11295 |
| closer | #11307 |
| reviews | #11329 |
| benzimidazoles | #11334 |
| vincristine | #11361 |
| 168 | #11373 |
| thrombocytopenia | #11377 |
| 129 | #11387 |
| affect | #11397 |
| radiation therapy | #11423 |
| subgroup analyses | #11428 |
| clinical signs | #11439 |
| apparent | #11439 |
| point | #11449 |
| rating scale | #11457 |
| 78 | #11468 |
| 092 | #11469 |
| label | #11482 |
| 2 trial | #11486 |
| patients patient | #11493 |
| multidimensional | #11498 |
| alive | #11501 |
| 235 | #11509 |
| caregivers | #11509 |
| recombinant human | #11530 |
| 6 | #11541 |
| 130 | #11548 |
| lymphatic metastasis | #11549 |
| 040 | #11553 |
| helps | #11582 |
| computerized | #11583 |
| 109 | #11585 |
| enhancing | #11586 |
| 20 patients | #11588 |
| analgesic | #11591 |
| humans mass | #11616 |
| incontinence | #11617 |
| opioid | #11645 |
| benefits | #11651 |
| pulmonary embolism | #11652 |
| minimal | #11660 |
| peritoneal | #11670 |
| 028 | #11674 |
| gefitinib | #11675 |
| adenocarcinoma adult | #11688 |
| camptothecin | #11691 |
| body image | #11717 |
| docetaxel | #11732 |
| sarcopenia | #11745 |
| lumbar | #11751 |
| small cell | #11764 |
| rheumatic | #11765 |
| comparisons | #11767 |
| nerves | #11789 |
| reduction | #11791 |
| oxidative damage | #11822 |
| aged postoperative | #11823 |
| 128 | #11825 |
| resultsthe | #11835 |
| risk recurrence | #11837 |
| definite | #11855 |
| 024 | #11855 |
| neoplasms cell | #11862 |
| interim | #11864 |
| hematologic | #11897 |
| investigation | #11910 |
| testicular | #11913 |
| cured | #11926 |
| haloperidol | #11938 |
| pelvis | #11956 |
| thirteen | #11969 |
| humanized | #11970 |
| ≥3 | #11995 |
| referral | #11997 |
| 1998 | #11997 |
| involving | #11999 |
| 90 patients | #12014 |
| 24 patients | #12015 |
| humans | #12017 |
| negative breast | #12030 |
| effectively | #12047 |
| thirds | #12053 |
| single nucleotide | #12063 |
| muscarinic | #12067 |
| triphosphate | #12068 |
| committee | #12069 |
| rating | #12071 |
| bone mineral | #12074 |
| − | #12078 |
| toxic | #12079 |
| cumulative incidence | #12103 |
| greater | #12144 |
| expectancy | #12147 |
| dosage | #12148 |
| rectal cancer | #12163 |
| 119 | #12183 |
| 104 | #12187 |
| unadjusted | #12191 |
| validity | #12205 |
| aspirin | #12207 |
| deoxycytidine | #12226 |
| alternatively | #12248 |
| believed | #12251 |
| malignant | #12268 |
| sodium channel | #12270 |
| peri | #12270 |
| 2 weeks | #12279 |
| disease specific | #12302 |
| igf | #12308 |
| compliance | #12317 |
| categories | #12322 |
| cognitive | #12338 |
| terms | #12340 |
| grading | #12342 |
| classic | #12345 |
| tolerability | #12360 |
| sexual | #12361 |
| psychometrics | #12376 |
| 27 | #12378 |
| adjuvants | #12396 |
| falls | #12402 |
| searched | #12414 |
| relapse | #12415 |
| qualitative study | #12416 |
| sentinel | #12421 |
| p21ras | #12426 |
| 1 2 | #12446 |
| anticancer drugs | #12449 |
| science | #12462 |
| drug humans | #12482 |
| 90 | #12485 |
| predictive | #12492 |
| 194 | #12495 |
| embase | #12496 |
| transfusion | #12502 |
| consistency | #12511 |
| reasons | #12523 |
| prognostic factor | #12536 |
| mitomycin | #12540 |
| 010 | #12573 |
| predictors | #12577 |
| bladder cancer | #12581 |
| explored | #12591 |
| bioavailability | #12611 |
| sleep | #12615 |
| attempts | #12621 |
| test | #12626 |
| psychometric | #12641 |
| therapeutic approaches | #12642 |
| supports | #12643 |
| fourteen | #12657 |
| rank test | #12657 |
| recommendations | #12691 |
| problem | #12710 |
| 2013 | #12714 |
| patient outcome | #12719 |
| reliability | #12747 |
| translated | #12749 |
| stiffness | #12752 |
| crc | #12777 |
| missed | #12783 |
| develop | #12817 |
| 023 | #12853 |
| segmental | #12865 |
| cancer nsclc | #12868 |
| patients surgery | #12874 |
| statistics | #12876 |
| subject | #12882 |
| ice | #12886 |
| normal tissue | #12931 |
| interviewed | #12944 |
| inform | #12945 |
| irreversible | #12946 |
| poorer | #12947 |
| coded | #12950 |
| 184 | #12952 |
| single agent | #12954 |
| scale | #12961 |
| univariate | #12983 |
| monoclonal antibodies monoclonal | #13009 |
| 193 | #13020 |
| n4 | #13025 |
| defining | #13026 |
| cancers | #13041 |
| ovariectomy | #13045 |
| paired | #13049 |
| humans logistic | #13082 |
| future | #13082 |
| suggests | #13099 |
| longterm followup | #13101 |
| pharmacotherapy | #13121 |
| trial comparing | #13126 |
| gains | #13129 |
| alter | #13132 |
| aged neoadjuvant | #13151 |
| inflammatory cytokines | #13153 |
| demographic | #13159 |
| originally | #13160 |
| cox regression | #13163 |
| responsiveness | #13183 |
| 44 | #13192 |
| tpa | #13230 |
| multiple myeloma | #13238 |
| epidemiologic | #13262 |
| humans lymphatic | #13262 |
| 21 patients | #13267 |
| longitudinal data | #13270 |
| myeloma | #13286 |
| racial | #13299 |
| requiring | #13322 |
| outpatient | #13334 |
| symptomatic | #13346 |
| cognitive function | #13351 |
| hours | #13376 |
| steroidal | #13380 |
| pg | #13393 |
| measure | #13408 |
| formal | #13409 |
| therapeutic potential | #13414 |
| intermediate | #13433 |
| muscle mass | #13492 |
| ductal | #13505 |
| eventually | #13506 |
| randomised trial | #13513 |
| attending | #13528 |
| psychometric properties | #13563 |
| discriminate | #13564 |
| pharmacological | #13578 |
| typically | #13588 |
| diminished | #13609 |
| agonists | #13630 |
| improves | #13630 |
| 196 | #13634 |
| skin cancer | #13649 |
| tended | #13650 |
| frequency | #13652 |
| participants | #13674 |
| infective | #13701 |
| hypothesis | #13703 |
| tested | #13723 |
| attempted | #13739 |
| initiation | #13758 |
| distress | #13778 |
| foods | #13785 |
| severe | #13795 |
| 192 | #13800 |
| clinical manifestations | #13803 |
| 18 years | #13813 |
| marked | #13813 |
| conditional | #13831 |
| 018 | #13858 |
| colonic | #13890 |
| solid tumors | #13891 |
| negative patients | #13900 |
| march | #13918 |
| lymphatic | #13928 |
| sleep quality | #13935 |
| mechanisms underlying | #13938 |
| 102 | #13944 |
| p00001 | #13946 |
| focus | #13988 |
| aged muscle | #13991 |
| conducting | #13996 |
| estimate male | #13999 |
| igf1 | #14032 |
| calcitonin | #14038 |
| head | #14056 |
| eastern | #14057 |
| substances | #14080 |
| lung cancer | #14080 |
| 0001 | #14090 |
| respondents | #14106 |
| skin | #14109 |
| 169 | #14117 |
| breast cancer cells | #14121 |
| physiologic | #14122 |
| antagonist | #14137 |
| led | #14139 |
| risk death | #14180 |
| her2 | #14186 |
| modality | #14195 |
| protective | #14195 |
| risk developing | #14199 |
| etiology | #14201 |
| 189 | #14202 |
| cytotoxic | #14234 |
| demonstrating | #14236 |
| 124 | #14251 |
| life style | #14259 |
| suboptimal | #14279 |
| states aged | #14282 |
| careful | #14282 |
| cetuximab | #14293 |
| hypothesize | #14318 |
| efficacy safety | #14319 |
| 32 | #14329 |
| recurrence risk | #14331 |
| instance | #14341 |
| analysis performed | #14341 |
| virtually | #14371 |
| 188 | #14375 |
| clinical impact | #14379 |
| cessation | #14403 |
| alpha2 | #14412 |
| produces | #14420 |
| 144 | #14420 |
| 4 patients | #14436 |
| extremity | #14440 |
| nodal | #14440 |
| transitional | #14454 |
| stat | #14456 |
| 178 | #14484 |
| 1997 | #14487 |
| distant metastases | #14504 |
| trial registration | #14517 |
| 2008 | #14518 |
| 8 | #14521 |
| univariate multivariate | #14524 |
| nsclc | #14525 |
| erbb2 | #14544 |
| gm | #14553 |
| 035 | #14567 |
| year survival | #14570 |
| heavily | #14577 |
| iron | #14583 |
| 34 | #14587 |
| prospectively | #14607 |
| episodes | #14626 |
| 09 | #14626 |
| 007 | #14634 |
| tumor response | #14639 |
| hypothetical | #14647 |
| additional | #14648 |
| initial diagnosis | #14674 |
| estrogen receptor | #14679 |
| prophylaxis | #14686 |
| 5 year | #14689 |
| dermal | #14710 |
| adult | #14729 |
| 008 | #14729 |
| menstrual | #14740 |
| examine | #14743 |
| practice | #14751 |
| reflecting | #14758 |
| 15 years | #14762 |
| neoplasm | #14762 |
| neoplasm staging | #14774 |
| interferons | #14781 |
| clarify | #14785 |
| health professionals | #14804 |
| erlotinib | #14821 |
| asian | #14838 |
| relevant | #14863 |
| peer | #14921 |
| 1990 | #14930 |
| cancer cases | #14942 |
| incorporate | #14956 |
| emerged | #14959 |
| cancer diagnosis | #14977 |
| median | #15008 |
| colorectal carcinoma | #15030 |
| cognitive decline | #15047 |
| 07 | #15052 |
| premature | #15064 |
| overexpressing | #15067 |
| expected | #15111 |
| september | #15115 |
| proportions | #15119 |
| 011 | #15123 |
| medical | #15125 |
| 2 | #15153 |
| clear | #15163 |
| p004 | #15169 |
| assessments | #15187 |
| colonoscopy | #15187 |
| odds ratios | #15193 |
| replacement | #15198 |
| ganglia | #15220 |
| specific | #15227 |
| portion | #15240 |
| intervals | #15241 |
| acute | #15247 |
| agreed | #15266 |
| subjective | #15290 |
| area | #15293 |
| subgroups | #15325 |
| achieved | #15344 |
| proliferative | #15352 |
| routine | #15362 |
| releasing hormone | #15390 |
| 197 | #15404 |
| 131 | #15404 |
| 072 | #15431 |
| 070 | #15436 |
| december | #15459 |
| investigate | #15464 |
| reports | #15470 |
| 51 | #15487 |
| race | #15509 |
| education | #15510 |
| 1 | #15515 |
| medication | #15554 |
| basis | #15598 |
| standard | #15614 |
| life expectancy | #15626 |
| ranging | #15639 |
| safely | #15648 |
| estimate | #15652 |
| male | #15673 |
| survival benefit | #15674 |
| 24 months | #15681 |
| criteria | #15693 |
| 502 | #15702 |
| measuring | #15712 |
| animals antineoplastic | #15714 |
| individual | #15716 |
| offered | #15728 |
| option | #15749 |
| updated | #15749 |
| colon | #15751 |
| period | #15756 |
| nutrition | #15780 |
| antagonists | #15789 |
| globulin | #15792 |
| quartile | #15810 |
| nonparametric | #15815 |
| kappa | #15831 |
| rate treatment | #15867 |
| societies medical | #15873 |
| glandular | #15882 |
| local | #15882 |
| 87 | #15905 |
| focused | #15931 |
| pharmacokinetics | #15932 |
| longitudinally | #15937 |
| dfs | #15988 |
| usa | #16013 |
| phenomenon | #16013 |
| roughly | #16039 |
| distant metastasis | #16044 |
| squared | #16045 |
| improvement | #16107 |
| 118 | #16114 |
| 079 | #16120 |
| february | #16127 |
| naïve | #16154 |
| decision | #16179 |
| 95 patients | #16188 |
| analysis survival | #16209 |
| 161 | #16209 |
| drug interactions | #16211 |
| lung | #16212 |
| 081 | #16213 |
| neoadjuvant | #16222 |
| supported | #16222 |
| 162 | #16223 |
| serotonin | #16242 |
| cold | #16243 |
| cation | #16245 |
| cochrane library | #16265 |
| 93 | #16278 |
| alternatives | #16284 |
| exceeded | #16313 |
| colleagues | #16319 |
| neurotransmitter | #16320 |
| detection cancer | #16320 |
| channel blockers | #16348 |
| supplemented | #16355 |
| papillomavirus | #16362 |
| 14 patients | #16380 |
| excision | #16385 |
| releasing | #16393 |
| kras | #16396 |
| neoplasm grading | #16407 |
| progressively | #16413 |
| 0006 | #16416 |
| improvements | #16418 |
| diagnostic imaging | #16418 |
| osteonecrosis | #16452 |
| scales | #16460 |
| 30 | #16525 |
| protect | #16536 |
| declined | #16537 |
| ranged | #16562 |
| black | #16565 |
| support | #16576 |
| population surveillance | #16580 |
| improving | #16587 |
| 13 patients | #16588 |
| condition | #16625 |
| systematic review metaanalysis | #16649 |
| radiation | #16657 |
| understand | #16705 |
| male neoplasm | #16705 |
| tumor size | #16709 |
| treat | #16715 |
| mucosa | #16717 |
| broader | #16719 |
| broadly | #16748 |
| 082 | #16750 |
| 106 | #16760 |
| 10 years | #16780 |
| post operative | #16791 |
| mimic | #16818 |
| studying | #16832 |
| demonstrated | #16842 |
| bayes | #16878 |
| safety | #16885 |
| major | #16886 |
| rarely | #16886 |
| maintained | #16890 |
| inpatient | #16921 |
| aware | #16924 |
| drugs | #16939 |
| 67 | #16962 |
| depletion | #16977 |
| sex | #16982 |
| hormone | #16988 |
| confer | #16998 |
| hemoglobin | #17005 |
| 125 | #17019 |
| maximum | #17031 |
| muscles | #17039 |
| investigating | #17045 |
| issues | #17053 |
| neoadjuvant therapy | #17063 |
| genotype humans | #17068 |
| publication adaptation | #17073 |
| 84 | #17091 |
| directed | #17099 |
| diseasefree survival | #17162 |
| iron deficiency | #17162 |
| disseminated | #17164 |
| utilize | #17166 |
| feasible | #17197 |
| energy intake | #17217 |
| inconsistent | #17247 |
| mineral | #17315 |
| 088 | #17335 |
| valid | #17344 |
| tnfα | #17364 |
| percentage | #17396 |
| interleukin6 | #17416 |
| raf | #17421 |
| describing | #17520 |
| centered | #17529 |
| neck | #17557 |
| functioning | #17582 |
| locally | #17585 |
| physical activity | #17586 |
| survival outcomes | #17596 |
| traditional | #17602 |
| fact | #17609 |
| original | #17648 |
| 080 | #17655 |
| 2019 | #17720 |
| current evidence | #17735 |
| log | #17761 |
| adding | #17766 |
| unrelated | #17776 |
| carcinogenesis | #17789 |
| lactic | #17816 |
| impairment | #17825 |
| assayed | #17837 |
| decreased | #17874 |
| confirms | #17879 |
| 094 | #17886 |
| examination | #17892 |
| graded | #17909 |
| meta | #17936 |
| monoclonal antibodies | #17955 |
| 200 | #17981 |
| minimum | #18048 |
| clinical presentation | #18052 |
| structured | #18083 |
| primary prevention | #18124 |
| 48 | #18131 |
| primary tumors | #18132 |
| formulated | #18148 |
| il6 | #18159 |
| metastasis male | #18162 |
| bone | #18174 |
| medline | #18185 |
| uncommon | #18193 |
| mass screening | #18244 |
| 80 biomarkers | #18256 |
| critically | #18295 |
| assessing | #18322 |
| retinoic | #18359 |
| hazards models | #18394 |
| reporting | #18396 |
| healthrelated quality | #18416 |
| relationships | #18418 |
| respective | #18423 |
| carry | #18439 |
| humans intestinal | #18447 |
| 096 | #18450 |
| 83 | #18485 |
| staging prognosis | #18489 |
| consistently | #18499 |
| akt | #18504 |
| adjustment | #18519 |
| equal | #18526 |
| 2 years | #18534 |
| maintain | #18583 |
| negligible | #18617 |
| nutritional | #18643 |
| 003 | #18655 |
| address | #18711 |
| raised | #18739 |
| 3 patients | #18741 |
| meier estimate | #18762 |
| kaplan meier | #18769 |
| mucosal | #18825 |
| promising | #18832 |
| highlighted | #18856 |
| includes | #18858 |
| 098 | #18862 |
| chronic diseases | #18875 |
| poor | #18878 |
| hormones | #18887 |
| tailored | #18923 |
| status | #18942 |
| united states | #18948 |
| pyridines | #18950 |
| serum | #18956 |
| orr | #18990 |
| histologic | #19009 |
| stimulating | #19056 |
| dysfunction | #19111 |
| meier | #19125 |
| cohort | #19137 |
| inhibitor | #19177 |
| mood | #19177 |
| ≥ | #19195 |
| excessive | #19215 |
| irinotecan | #19250 |
| agents apoptosis | #19258 |
| consensus | #19281 |
| accepted | #19282 |
| candidate | #19292 |
| recombinant proteins | #19298 |
| recorded | #19302 |
| ovarian | #19337 |
| metaanalysis | #19377 |
| newly | #19381 |
| staging | #19391 |
| global | #19431 |
| evidenced | #19433 |
| fats | #19483 |
| inflammatory agents | #19496 |
| proportional hazards | #19507 |
| prone | #19520 |
| asymptomatic | #19544 |
| surgically | #19614 |
| hospitalized | #19617 |
| pretreated | #19680 |
| degree | #19687 |
| predicted | #19728 |
| adaptation psychological | #19769 |
| emotional | #19779 |
| making | #19782 |
| humans kaplan | #19803 |
| scored | #19840 |
| kaplan | #19866 |
| neoplasms carcinoma | #19874 |
| 3 year | #19944 |
| 1995 | #19991 |
| procedures | #20019 |
| 2002 | #20057 |
| cervical | #20082 |
| tumor necrosis factor | #20104 |
| observational studies | #20128 |
| randomised | #20168 |
| mediator | #20189 |
| beneficial | #20254 |
| 24 | #20258 |
| patients risk | #20262 |
| maximal | #20273 |
| log rank | #20282 |
| small | #20300 |
| endocrine | #20301 |
| rates | #20333 |
| involves | #20398 |
| allcause mortality | #20422 |
| exploring | #20500 |
| assess | #20503 |
| adjusting | #20553 |
| successful | #20677 |
| usual | #20690 |
| women aged | #20722 |
| 95 confidence interval | #20729 |
| invasiveness neoplasm | #20747 |
| addressing | #20782 |
| 19 | #20821 |
| concluded | #20831 |
| july | #20847 |
| node | #20854 |
| finding | #21019 |
| remaining | #21031 |
| relationship | #21070 |
| collected | #21085 |
| male mass | #21107 |
| reliable | #21137 |
| year | #21139 |
| january | #21202 |
| statistical | #21265 |
| 1999 | #21287 |
| absence | #21319 |
| mri | #21400 |
| comparison | #21403 |
| extended | #21420 |
| proportional | #21490 |
| feasibility | #21521 |
| rectal | #21541 |
| prognosis | #21551 |
| gradually | #21576 |
| implementing | #21589 |
| models male | #21936 |
| improved | #21939 |
| death | #21941 |
| apply | #21969 |
| morbidity | #22004 |
| intervention | #22038 |
| insulin growth | #22054 |
| verbal | #22139 |
| 10 patients | #22157 |
| urinary | #22186 |
| combination | #22213 |
| authors | #22223 |
| 2005 | #22223 |
| alterations | #22302 |
| aimed | #22386 |
| predictive tests | #22416 |
| event | #22426 |
| fibroblast | #22446 |
| reviewed | #22573 |
| status humans | #22597 |
| elevated | #22633 |
| frequent | #22673 |
| setting | #22759 |
| cox proportional | #22797 |
| malignancies | #22798 |
| allocated | #22808 |
| 95 | #22862 |
| imaging mri | #23033 |
| diverse | #23033 |
| superior | #23111 |
| post | #23144 |
| selected | #23153 |
| june | #23240 |
| surgical resection | #23266 |
| aged neoplasm | #23452 |
| persistent | #23460 |
| term | #23463 |
| represent | #23526 |
| antibodies monoclonal | #23543 |
| comprehensive | #23553 |
| continuously | #23560 |
| remained | #23674 |
| classified | #23739 |
| body | #23757 |
| strong | #23813 |
| monoclonal | #23861 |
| physical | #23883 |
| gastrointestinal | #23900 |
| exclude | #23924 |
| 2011 | #23997 |
| 2017 | #23997 |
| severely | #24141 |
| median follow | #24342 |
| partial | #24353 |
| abnormal | #24383 |
| systemic | #24466 |
| recruited | #24477 |
| general | #24560 |
| dietary | #24683 |
| 1996 | #24713 |
| carcinoma | #24787 |
| susceptible | #24878 |
| providing | #25068 |
| acids | #25078 |
| consistent | #25119 |
| implemented | #25293 |
| attributed | #25373 |
| 17 | #25476 |
| early | #25506 |
| markedly | #25526 |
| inhibition | #25536 |
| free | #25571 |
| lymph | #25627 |
| international | #25729 |
| regional | #25737 |
| sought | #25746 |
| selective | #25748 |
| 0003 | #25751 |
| single | #25859 |
| mechanism | #26084 |
| unclear | #26339 |
| putative | #26419 |
| surgery | #26438 |
| 13 | #26589 |
| unknown | #26785 |
| electronic | #26810 |
| predisposition disease | #26997 |
| accompanied | #26998 |
| multiple | #27050 |
| follow studies | #27065 |
| polymorphism single | #27142 |
| united | #27151 |
| histologically | #27323 |
| inherited | #27404 |
| neoplasm proteins | #27717 |
| prognosis retrospective | #27768 |
| systematic | #27775 |
| functional | #27808 |
| 0005 | #28001 |
| predisposition | #28007 |
| preoperative | #28036 |
| skeletal | #28185 |
| longitudinal | #28189 |
| estimated | #28229 |
| leads | #28238 |
| missing | #28264 |
| acid | #28356 |
| anti inflammatory | #28360 |
| correlate | #28365 |
| larger | #28581 |
| sex factors | #28629 |
| causing | #28688 |
| sensitivity | #28740 |
| vary | #28851 |
| 11 | #28869 |
| matched | #28979 |
| represents | #29258 |
| detection | #29343 |
| active | #29413 |
| differentiate | #29510 |
| objectives | #29543 |
| completely | #29721 |
| factual | #29750 |
| databases factual | #29793 |
| varied | #30036 |
| excluded | #30077 |
| quantified | #30091 |
| occurs | #30143 |
| adjusted | #30189 |
| logistic | #30241 |
| underlying | #30508 |
| allowed | #30520 |
| national | #30765 |
| odds | #30909 |
| 001 | #30996 |
| regression | #31005 |
| unchanged | #31053 |
| separately | #31068 |
| characterize | #31283 |
| recombinant | #31415 |
| adolescent | #31473 |
| dose dependent | #31787 |
| age | #31875 |
| lacking | #31939 |
| attenuated | #31971 |
| lower | #32078 |
| correlated | #32273 |
| postoperative | #32309 |
| negative | #32666 |
| growth factor | #33089 |
| positive | #33861 |
| understood | #33957 |
| confirmed | #33982 |
| reduced | #34048 |
| implicated | #34054 |
| confidence | #34153 |
| defined | #34517 |
| occur | #34659 |
| requires | #35112 |
| directly | #35347 |
| followup | #36532 |
| diagnosed | #36787 |
| suggesting | #37604 |
| remains | #37899 |
| multivariate | #38132 |
| independent | #38886 |
| measured | #38991 |
| proto oncogene | #39186 |
| proto | #39814 |
| biomarkers tumor | #39899 |
| examined | #40295 |
| retrospective studies | #42973 |
| underwent | #43365 |
| 95 confidence | #44196 |
Open the FULL List in Excel | |
Prominent publications by Charles L Loprinzi
KOL-Index: 16482
Importance: Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain.
Objective: To determine whether zoledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 weeks.
Design, Setting, Participants: Randomized, open-label clinical trial conducted at 269 academic and community sites in the United ...
| Known for Zoledronic Acid | Bone Metastases | 2 Years | Patients Breast Cancer | Skeletal Events |
KOL-Index: 16399
Postmenopausal women with breast cancer (BC) are at increased risk for bone loss. Bisphosphonates improve bone mineral density (BMD) in normal postmenopausal women. The purpose of this study was to determine if immediate treatment with zoledronic acid preserves BMD in postmenopausal women with BC starting letrozole after tamoxifen. Postmenopausal women with BC completing tamoxifen were treated with daily letrozole 2.5 mg/vitamin D 400 I.U., calcium 500 mg twice daily and were randomized ...
| Known for Postmenopausal Women | Bone Loss | Zoledronic Acid | Breast Cancer | Versus Delayed |
KOL-Index: 13693
PURPOSE: Risedronate prevents bone loss in postmenopausal women. The purpose of this study was to determine whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast cancer.
PATIENTS AND METHODS: Premenopausal women undergoing chemotherapy for breast cancer were treated with oral calcium 600 mg and vitamin D 400 U daily and randomly assigned to receive oral risedronate 35 mg weekly or placebo, with all these therapies beginning within a month of the ...
| Known for Bone Loss | Premenopausal Women | Breast Cancer | 1 Year | Bmd Baseline |
Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice
[ PUBLICATION ]
BACKGROUND: Cisplatin is primarily used for treatment of ovarian and testicular cancer. Oxaliplatin is the only effective treatment for metastatic colorectal cancer. Both are known to cause dose related, cumulative toxic effects on the peripheral nervous system and thirty to forty percent of cancer patients receiving these agents experience painful peripheral neuropathy. The mechanisms underlying painful platinum-induced neuropathy remain poorly understood. Previous studies have ...
| Known for Trpv1 Trpa1 | Transient Receptor | Cisplatin Oxaliplatin | Mechanical Allodynia | Treated Mice |
KOL-Index: 13187
PURPOSE: Functional iron deficiency may impair response to erythropoiesis-stimulating agents (ESAs) in iron-replete patients with chemotherapy-associated anemia (CAA). This study evaluated whether coadministration of parenteral iron improves ESA efficacy in patients with CAA.
PATIENTS AND METHODS: This prospective, multicenter, randomized trial enrolled 502 patients with hemoglobin (Hb) less than 11 g/dL who were undergoing chemotherapy for nonmyeloid malignancies. All patients received ...
| Known for Oral Iron | Darbepoetin Alfa | Erythropoietic Response | Phase Iii | Ferric Gluconate |
KOL-Index: 12870
To develop a framework for the definition and classification of cancer cachexia a panel of experts participated in a formal consensus process, including focus groups and two Delphi rounds. Cancer cachexia was defined as a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Its pathophysiology is characterised by a ...
| Known for Cancer Cachexia | International Consensus | Definition Classification | Weight Loss | Reduced Food Intake |
Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?
[ PUBLICATION ]
PURPOSE: Although it is well-established that fluorouracil- (FU-) based adjuvant therapy improves survival for patients with resected high-risk colon cancer, the magnitude of adjuvant therapy benefit across specific subgroups and for individual patients has been uncertain.
PATIENTS AND METHODS: Using a pooled data set of 3,302 patients with stage II and III colon cancer from seven randomized trials comparing FU + leucovorin or FU + levamisole to surgery alone, we performed an analysis ...
| Known for Adjuvant Therapy | Nodal Status | Colon Cancer | Survival Stage | Pooled Analysis |
Randomized Comparison of a Nicotine Inhaler and Bupropion for Smoking Cessation and Relapse Prevention
[ PUBLICATION ]
OBJECTIVE: To compare the combination of a nicotine inhaler and bupropion to either treatment alone for initiating smoking abstinence and relapse prevention.
METHODS: Smokers were randomized to receive a nicotine inhaler, bupropion, or both for 3 months. At 3 months, smoking-abstinent study participants were randomized to their initial medications or placebo. Participants who were smoking at 3 months were randomized to an alternative treatment regimen or placebo. This study was conducted ...
| Known for Relapse Prevention | Nicotine Inhaler | Bupropion Placebo | Smoking Abstinence | Treatment Phase |
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer
[ PUBLICATION ]
BACKGROUND: Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers.
METHODS: We conducted a randomized, double-blind trial to determine the effect of aspirin on the incidence of colorectal adenomas. We randomly assigned 635 patients with previous colorectal cancer to receive either 325 mg of aspirin per day or placebo. We determined the proportion of ...
| Known for Colorectal Adenomas | Patients Aspirin | Observational Studies | Relative Risks | Cancer Adenoma |
KOL-Index: 12619
BACKGROUND: Stool DNA testing is a new approach to colorectal cancer detection. Few data are available from the screening setting.
OBJECTIVE: To compare stool DNA and fecal blood testing for detection of screen-relevant neoplasia (curable-stage cancer, high-grade dysplasia, or adenomas >1 cm).
DESIGN: Blinded, multicenter, cross-sectional study.
SETTING: Communities surrounding 22 participating academic and regional health care systems in the United States.
PARTICIPANTS: 4482 ...
| Known for Stool Dna | Blood Test | Screen Detection | Colorectal Neoplasia | Humans Specificity |
Trends in Mastectomy Rates at the Mayo Clinic Rochester: Effect of Surgical Year and Preoperative Magnetic Resonance Imaging
[ PUBLICATION ]
PURPOSE: Recent changes have occurred in the presurgical planning for breast cancer, including the introduction of preoperative breast magnetic resonance imaging (MRI). We sought to analyze the trends in mastectomy rates and the relationship to preoperative MRI and surgical year at Mayo Clinic, Rochester, MN.
PATIENTS AND METHODS: We identified 5,405 patients who underwent surgery between 1997 and 2006. Patients undergoing MRI were identified from a prospective database. Trends in ...
| Known for Mastectomy Rates | Magnetic Resonance | Patients Mri | Surgery Type | Surgical Year |
Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia.
[ PUBLICATION ]
PURPOSE: Previous double-blind, placebo-controlled, randomized clinical trials have demonstrated that both corticosteroids and progestational agents do partially alleviate cancer anorexia/cachexia. Pilot information suggested that an anabolic corticosteroid might also improve appetite in patients with cancer anorexia/cachexia. The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer ...
| Known for Cancer Anorexia | Megestrol Acetate | Cachexia Patients | Progestational Agents | Corticosteroid Treatment |
KOL-Index: 12321
BACKGROUND: Vasomotor hot flashes are a common symptom in women during menopause and in men who have undergone androgen-deprivation therapy for prostate cancer. Although treatment with estrogens in women and androgens in men can attenuate these symptoms, these hormones may be contraindicated in women with breast cancer and in men with prostate cancer. Pilot trials have suggested that the progestational agent megestrol acetate can ameliorate hot flashes in both groups of ...
| Known for Megestrol Acetate | Hot Flashes | Women Breast Cancer | Deprivation Therapy | Weeks Placebo |
Key People For Hot Flashes
Top KOLs in the world
Select a search phrase hot flashes , hot flashes women , hot flashes sweats , hot flashes patients , hot flashes hfs
Charles L Loprinzi:Expert Impact
Concepts for whichCharles L Loprinzihas direct influence:Hot flashes, Breast cancer, Megestrol acetate, Peripheral neuropathy, Scrambler therapy, Phase iii, Newer antidepressants, Hot flash.
Charles L Loprinzi:KOL impact
Concepts related to the work of other authors for whichfor which Charles L Loprinzi has influence:Breast cancer, Hot flashes, Adjuvant chemotherapy, Quality life, Weight loss, Oral mucositis, Neuropathic pain.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |